CA2567901A1 - Method and composition for treating angiogenesis and for preventing cancer progression and metastasis comprising a prostate secretory protein (psp94) family member - Google Patents
Method and composition for treating angiogenesis and for preventing cancer progression and metastasis comprising a prostate secretory protein (psp94) family member Download PDFInfo
- Publication number
- CA2567901A1 CA2567901A1 CA002567901A CA2567901A CA2567901A1 CA 2567901 A1 CA2567901 A1 CA 2567901A1 CA 002567901 A CA002567901 A CA 002567901A CA 2567901 A CA2567901 A CA 2567901A CA 2567901 A1 CA2567901 A1 CA 2567901A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- reduce
- vitro assay
- mmp
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 107
- 238000000034 method Methods 0.000 title claims abstract description 97
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 71
- 206010027476 Metastases Diseases 0.000 title claims abstract description 43
- 230000009401 metastasis Effects 0.000 title claims abstract description 42
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 201000011510 cancer Diseases 0.000 title claims abstract description 31
- 102000040739 Secretory proteins Human genes 0.000 title abstract description 4
- 108091058545 Secretory proteins Proteins 0.000 title abstract description 4
- 210000002307 prostate Anatomy 0.000 title description 4
- 206010061218 Inflammation Diseases 0.000 claims abstract description 13
- 230000004054 inflammatory process Effects 0.000 claims abstract description 11
- 238000006366 phosphorylation reaction Methods 0.000 claims description 152
- 230000026731 phosphorylation Effects 0.000 claims description 149
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 118
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 118
- 230000014509 gene expression Effects 0.000 claims description 100
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 93
- 238000000099 in vitro assay Methods 0.000 claims description 93
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 90
- 150000001875 compounds Chemical class 0.000 claims description 87
- 108091008605 VEGF receptors Proteins 0.000 claims description 78
- 239000012634 fragment Substances 0.000 claims description 74
- 230000012292 cell migration Effects 0.000 claims description 60
- 241000124008 Mammalia Species 0.000 claims description 47
- 235000001014 amino acid Nutrition 0.000 claims description 45
- 150000001413 amino acids Chemical group 0.000 claims description 43
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims description 36
- 230000002401 inhibitory effect Effects 0.000 claims description 32
- -1 acetylaminomethyl moiety Chemical group 0.000 claims description 16
- 239000003937 drug carrier Substances 0.000 claims description 16
- 235000018417 cysteine Nutrition 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 12
- 206010029113 Neovascularisation Diseases 0.000 claims description 10
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 125000004434 sulfur atom Chemical group 0.000 claims description 10
- 208000037819 metastatic cancer Diseases 0.000 claims description 7
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 7
- 230000000087 stabilizing effect Effects 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 abstract description 88
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 55
- 201000010099 disease Diseases 0.000 abstract description 54
- 230000015572 biosynthetic process Effects 0.000 abstract description 38
- 210000004204 blood vessel Anatomy 0.000 abstract description 23
- 230000018109 developmental process Effects 0.000 abstract description 12
- 230000004614 tumor growth Effects 0.000 abstract description 7
- 208000022873 Ocular disease Diseases 0.000 abstract description 3
- 230000035790 physiological processes and functions Effects 0.000 abstract description 3
- 230000007170 pathology Effects 0.000 abstract description 2
- PNJSAKBBGRRTHL-RBUYSXEJSA-N tigapotide triflutate Chemical compound OC(=O)C(F)(F)F.C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)[C@H](CSCNC(C)=O)NC(=O)[C@@H](NC(=O)[C@H](CSCNC(C)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CSCNC(C)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCC(O)=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=C(O)C=C1 PNJSAKBBGRRTHL-RBUYSXEJSA-N 0.000 description 149
- 210000004027 cell Anatomy 0.000 description 124
- 108090000765 processed proteins & peptides Proteins 0.000 description 93
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 84
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 84
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 84
- 229920001184 polypeptide Polymers 0.000 description 81
- 102000004196 processed proteins & peptides Human genes 0.000 description 81
- 230000000694 effects Effects 0.000 description 80
- 108091008606 PDGF receptors Proteins 0.000 description 70
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 69
- 108090000623 proteins and genes Proteins 0.000 description 66
- 108010093516 tigapotide Proteins 0.000 description 49
- 102000004169 proteins and genes Human genes 0.000 description 48
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 46
- 235000018102 proteins Nutrition 0.000 description 46
- 239000000758 substrate Substances 0.000 description 45
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 42
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 42
- 238000003556 assay Methods 0.000 description 39
- 229940024606 amino acid Drugs 0.000 description 38
- 210000002889 endothelial cell Anatomy 0.000 description 36
- 238000005755 formation reaction Methods 0.000 description 34
- 230000005764 inhibitory process Effects 0.000 description 33
- 230000028327 secretion Effects 0.000 description 31
- 230000009467 reduction Effects 0.000 description 30
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 27
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 26
- 230000021164 cell adhesion Effects 0.000 description 26
- 238000001262 western blot Methods 0.000 description 24
- 239000000499 gel Substances 0.000 description 21
- 238000006467 substitution reaction Methods 0.000 description 21
- 101150111584 RHOA gene Proteins 0.000 description 19
- 230000004913 activation Effects 0.000 description 19
- 230000004071 biological effect Effects 0.000 description 19
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 108010082117 matrigel Proteins 0.000 description 18
- 230000004048 modification Effects 0.000 description 18
- 238000012986 modification Methods 0.000 description 18
- 229920002674 hyaluronan Polymers 0.000 description 17
- 229960003160 hyaluronic acid Drugs 0.000 description 17
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 16
- 238000009472 formulation Methods 0.000 description 16
- 230000037361 pathway Effects 0.000 description 15
- 230000000638 stimulation Effects 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- 102000006495 integrins Human genes 0.000 description 14
- 108010044426 integrins Proteins 0.000 description 14
- 230000002265 prevention Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 108010035532 Collagen Proteins 0.000 description 13
- 102000008186 Collagen Human genes 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 229920001436 collagen Polymers 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 230000002491 angiogenic effect Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 108700025832 Serum Response Element Proteins 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 230000019491 signal transduction Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 108010010803 Gelatin Proteins 0.000 description 10
- 108091054455 MAP kinase family Proteins 0.000 description 10
- 102000043136 MAP kinase family Human genes 0.000 description 10
- 239000008273 gelatin Substances 0.000 description 10
- 229920000159 gelatin Polymers 0.000 description 10
- 235000019322 gelatine Nutrition 0.000 description 10
- 235000011852 gelatine desserts Nutrition 0.000 description 10
- 230000005012 migration Effects 0.000 description 10
- 238000013508 migration Methods 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 230000029663 wound healing Effects 0.000 description 10
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 9
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 206010060862 Prostate cancer Diseases 0.000 description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 230000033228 biological regulation Effects 0.000 description 9
- 231100000673 dose–response relationship Toxicity 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 238000007805 zymography Methods 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 102100032912 CD44 antigen Human genes 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 8
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 8
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 7
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 210000002469 basement membrane Anatomy 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 6
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 102000005741 Metalloproteases Human genes 0.000 description 6
- 108010006035 Metalloproteases Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 6
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 238000000423 cell based assay Methods 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 229940028334 follicle stimulating hormone Drugs 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- FTTZLFIEUQHLHH-BWBBJGPYSA-N Cys-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CS)N)O FTTZLFIEUQHLHH-BWBBJGPYSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 5
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 210000004087 cornea Anatomy 0.000 description 5
- 108010069495 cysteinyltyrosine Proteins 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000009545 invasion Effects 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000001394 metastastic effect Effects 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 208000005069 pulmonary fibrosis Diseases 0.000 description 5
- 239000012679 serum free medium Substances 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- BDWIZLQVVWQMTB-XKBZYTNZSA-N Cys-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CS)N)O BDWIZLQVVWQMTB-XKBZYTNZSA-N 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 4
- 206010061309 Neoplasm progression Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- MFEBUIFJVPNZLO-OLHMAJIHSA-N Thr-Asp-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O MFEBUIFJVPNZLO-OLHMAJIHSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002870 angiogenesis inducing agent Substances 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 210000003837 chick embryo Anatomy 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000003292 diminished effect Effects 0.000 description 4
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000003668 pericyte Anatomy 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000001323 posttranslational effect Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 108010067415 progelatinase Proteins 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 102000007268 rho GTP-Binding Proteins Human genes 0.000 description 4
- 108010033674 rho GTP-Binding Proteins Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000004017 serum-free culture medium Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000007838 tissue remodeling Effects 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- 230000005751 tumor progression Effects 0.000 description 4
- 210000005166 vasculature Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 150000008574 D-amino acids Chemical class 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000013382 Gelatinases Human genes 0.000 description 3
- 108010026132 Gelatinases Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- KOVXHANYYYMBRF-IRIUXVKKSA-N Tyr-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O KOVXHANYYYMBRF-IRIUXVKKSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001772 anti-angiogenic effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 210000003433 aortic smooth muscle cell Anatomy 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000001174 ascending effect Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 238000001378 electrochemiluminescence detection Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000003779 hair growth Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 235000003642 hunger Nutrition 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 238000010232 migration assay Methods 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000037821 progressive disease Diseases 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 210000004974 shell Anatomy 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- 238000003892 spreading Methods 0.000 description 3
- 230000037351 starvation Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 229950000578 vatalanib Drugs 0.000 description 3
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical group C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000004961 Furin Human genes 0.000 description 2
- 108090001126 Furin Proteins 0.000 description 2
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 2
- 108091006109 GTPases Proteins 0.000 description 2
- 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102100026720 Interferon beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 2
- 108700010340 Leishmanolysins Proteins 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 229940126560 MAPK inhibitor Drugs 0.000 description 2
- 208000024556 Mendelian disease Diseases 0.000 description 2
- 102000036436 Metzincins Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 2
- 229910020700 Na3VO4 Inorganic materials 0.000 description 2
- 108010055723 PDGF receptor tyrosine kinase Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 206010064390 Tumour invasion Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002926 anti-osteoarthritic effect Effects 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 210000002376 aorta thoracic Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000000625 blastula Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000015916 branching morphogenesis of a tube Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 238000000326 densiometry Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 230000001497 fibrovascular Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000007804 gelatin zymography Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000006662 intracellular pathway Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 210000003632 microfilament Anatomy 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 239000012660 pharmacological inhibitor Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000004983 pleiotropic effect Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 210000000717 sertoli cell Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 208000006379 syphilis Diseases 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000003412 trans-golgi network Anatomy 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 description 1
- HOZBSSWDEKVXNO-BXRBKJIMSA-N (2s)-2-azanylbutanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CC(O)=O HOZBSSWDEKVXNO-BXRBKJIMSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 102100028187 ATP-binding cassette sub-family C member 6 Human genes 0.000 description 1
- 208000002618 Aarskog syndrome Diseases 0.000 description 1
- 208000033745 Aarskog-Scott syndrome Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001257 Adenoviral conjunctivitis Diseases 0.000 description 1
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003226 Arteriovenous fistula Diseases 0.000 description 1
- PTNFNTOBUDWHNZ-GUBZILKMSA-N Asn-Arg-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O PTNFNTOBUDWHNZ-GUBZILKMSA-N 0.000 description 1
- LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
- LUVODTFFSXVOAG-ACZMJKKPSA-N Asn-Cys-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)N)N LUVODTFFSXVOAG-ACZMJKKPSA-N 0.000 description 1
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
- FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010044583 Bartonella Infections Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 101150017002 CD44 gene Proteins 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010011017 Corneal graft rejection Diseases 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 101000802964 Dendroaspis angusticeps Muscarinic toxin 1 Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000016974 Eales' disease Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 229920003345 Elvax® Polymers 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- VOUSELYGTNGEPB-NUMRIWBASA-N Gln-Thr-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O VOUSELYGTNGEPB-NUMRIWBASA-N 0.000 description 1
- NUSWUSKZRCGFEX-FXQIFTODSA-N Glu-Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O NUSWUSKZRCGFEX-FXQIFTODSA-N 0.000 description 1
- LLEUXCDZPQOJMY-AAEUAGOBSA-N Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)N)C(O)=O)=CNC2=C1 LLEUXCDZPQOJMY-AAEUAGOBSA-N 0.000 description 1
- RZMXBFUSQNLEQF-QEJZJMRPSA-N Glu-Trp-Asn Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N RZMXBFUSQNLEQF-QEJZJMRPSA-N 0.000 description 1
- ZNOHKCPYDAYYDA-BPUTZDHNSA-N Glu-Trp-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZNOHKCPYDAYYDA-BPUTZDHNSA-N 0.000 description 1
- YSWHPLCDIMUKFE-QWRGUYRKSA-N Glu-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YSWHPLCDIMUKFE-QWRGUYRKSA-N 0.000 description 1
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102100034629 Hemopexin Human genes 0.000 description 1
- 108010026027 Hemopexin Proteins 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101000587539 Homo sapiens Metallothionein-1A Proteins 0.000 description 1
- 101001027956 Homo sapiens Metallothionein-1B Proteins 0.000 description 1
- 101001027945 Homo sapiens Metallothionein-1E Proteins 0.000 description 1
- 101001027943 Homo sapiens Metallothionein-1F Proteins 0.000 description 1
- 101001027938 Homo sapiens Metallothionein-1G Proteins 0.000 description 1
- 101001013794 Homo sapiens Metallothionein-1H Proteins 0.000 description 1
- 101001013797 Homo sapiens Metallothionein-1L Proteins 0.000 description 1
- 101001013796 Homo sapiens Metallothionein-1M Proteins 0.000 description 1
- 101001013799 Homo sapiens Metallothionein-1X Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical group O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010051151 Hyperviscosity syndrome Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- IOVUXUSIGXCREV-DKIMLUQUSA-N Ile-Leu-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IOVUXUSIGXCREV-DKIMLUQUSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
- 206010025412 Macular dystrophy congenital Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 1
- 102100024289 Metalloproteinase inhibitor 4 Human genes 0.000 description 1
- 108050006579 Metalloproteinase inhibitor 4 Proteins 0.000 description 1
- 102100029698 Metallothionein-1A Human genes 0.000 description 1
- 108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 208000024599 Mooren ulcer Diseases 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 208000004788 Pars Planitis Diseases 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- SVXXJYJCRNKDDE-AVGNSLFASA-N Pro-Pro-His Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NCCC1)C1=CN=CN1 SVXXJYJCRNKDDE-AVGNSLFASA-N 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 208000010362 Protozoan Infections Diseases 0.000 description 1
- 201000004613 Pseudoxanthoma elasticum Diseases 0.000 description 1
- 201000002154 Pterygium Diseases 0.000 description 1
- 206010037649 Pyogenic granuloma Diseases 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 208000007135 Retinal Neovascularization Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- GZBKRJVCRMZAST-XKBZYTNZSA-N Ser-Glu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZBKRJVCRMZAST-XKBZYTNZSA-N 0.000 description 1
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
- FZXOPYUEQGDGMS-ACZMJKKPSA-N Ser-Ser-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZXOPYUEQGDGMS-ACZMJKKPSA-N 0.000 description 1
- DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 206010041101 Small intestinal obstruction Diseases 0.000 description 1
- 208000027073 Stargardt disease Diseases 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 208000001163 Tangier disease Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000018656 Terrien marginal degeneration Diseases 0.000 description 1
- IOWJRKAVLALBQB-IWGUZYHVSA-N Thr-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O IOWJRKAVLALBQB-IWGUZYHVSA-N 0.000 description 1
- UZJDBCHMIQXLOQ-HEIBUPTGSA-N Thr-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O UZJDBCHMIQXLOQ-HEIBUPTGSA-N 0.000 description 1
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- MNMYOSZWCKYEDI-JRQIVUDYSA-N Tyr-Asp-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MNMYOSZWCKYEDI-JRQIVUDYSA-N 0.000 description 1
- RMRFSFXLFWWAJZ-HJOGWXRNSA-N Tyr-Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 RMRFSFXLFWWAJZ-HJOGWXRNSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 206010047663 Vitritis Diseases 0.000 description 1
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 230000004009 axon guidance Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 206010004145 bartonellosis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 238000007469 bone scintigraphy Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 210000001775 bruch membrane Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000021235 carbamoylation Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000035289 cell-matrix adhesion Effects 0.000 description 1
- 210000003570 cell-matrix junction Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000003182 dose-response assay Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000000437 effect on angiogenesis Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 208000023965 endometrium neoplasm Diseases 0.000 description 1
- 230000003241 endoproteolytic effect Effects 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 208000021373 epidemic keratoconjunctivitis Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 230000034964 establishment of cell polarity Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 230000000477 gelanolytic effect Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000003731 gingival crevicular fluid Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 210000004524 haematopoietic cell Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 208000013653 hyalitis Diseases 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 230000035984 keratolysis Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000008172 membrane trafficking Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 208000029691 metastatic malignant neoplasm in the lymph nodes Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003705 neurological process Effects 0.000 description 1
- 230000017511 neuron migration Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 201000006790 nonsyndromic deafness Diseases 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 238000011474 orchiectomy Methods 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000006659 positive regulation of apoptotic process Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000009219 proapoptotic pathway Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 208000023558 pseudoxanthoma elasticum (inherited or acquired) Diseases 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000027221 regulation of protein secretion Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 230000004276 retinal vascularization Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009962 secretion pathway Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 201000006476 shipyard eye Diseases 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000006711 vascular endothelial growth factor production Effects 0.000 description 1
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000004865 vascular response Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 229920006163 vinyl copolymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Angiogenesis, the formation of new blood vessels, is an integral part of normal physiological and developmental processes as well as several pathologies, ranging from tumor growth and metastasis to inflammation and ocular disease. Methods and compositions are provided for controlling normal angiogenesis and for treating angiogenesis associated or mediated diseases as well as for preventing cancer progression and metastasis through the use of a prostrate secretory protein (PSP) family member.
Description
DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.
NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME
NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:
Method and composition for treating angiogenesis and for preventing cancer progression and metastasis comprising a prostate secretory protein (PSP94) family member.
FIELD OF THE INVENTION
The present invention relates to methods and compositions for treating or preventing undesirable angiogenesis in a human or animal for preventing cancer progression and metastasis.
BACKGROUND OF THE INVENTION
The present invention relates to methods and compositions for effectively inhibiting angiogenesis and for preventing cancer (tumor) progression and/or metastasis.
More specifically, the invention relates to compositions comprising a PSP94 family member and their use in the inhibition of angiogenesis and treatment of angiogenesis associated diseases as well as for preventing tumor progression and/or metastasis.
Angiogenesis refers to the formation of blood vessels into a tissue or organ.
Under normal physiological conditions, humans or animals only undergo angiogenesis in very specific restricted situations. For example; angiogenesis is normally observed in wound healing, fetal and embryonal development and formation of the corpus luteum, endometrium and placenta.
The control of angiogenesis is a highly regulated system of angiogenic stimulators and ?5 inhibitors. The control of angiogenesis has been found to be altered in certain disease states and, in many cases, the pathological damage associated with the disease is related to the uncontrolled angiogenesis.
Both controlled and uncontrolled angiogenesis are thought to probeed in a similar manner.
Endothelial cells and pericytes which are surrounded by a basement membrane form capillary blood vessels. Angiogenesis begins with the erosion of the basement membrane by enzymes released by endothelial cells and leukocytes. The endothelial cells, which line the lumen of blood vessels, then protrude through the basement membrane.
Angiogenic stimulants induce the endothelial cells to migrate through the eroded basement membrane.
The migrating cells form a "sprout" off the parent blood vessel, where the endothelial cells undergo mitosis and proliferate. The endothelial sprouts merge with each other to form capillary loops, creating the new blood vessel. In the disease state, prevention of angiogenesis could avert the damage caused by the invasion of the new microvascular system.
Maturation and stabilization of the newly formed blood vessel occur via recruitment of pericytes and involve.principally but not exclusively platelet-derived growth factor (PDGF), fibroblast growth factor-2 (FGF-2), transforming growth factor-beta (TGF-beta), vascular endothelial growth factor (VEGF) and angiopoietins (Darland, D.C. and P. A.
D'Amore (1999) Journal of Clinical Investigation, 103:157-58). A number of angiogenic factors have been .0 identified based on the ability to promote the development of new blood vessels in vivo..
Angiogenesis is controlled by the net balance between molecules that have positive and negative regulatory activity. The growth of human tumors and development of metastases depend on the de novo formation of blood vessels. The formation of new blood vessels is tightly regulated by specific growth factors that target receptor tyrosine kinases (RTKs).
Vascular endothelial growth factor (VEGF) is a pivotal stimulator of angiogenesis because its binding to VEGF receptors (RTKs) has been shown to promote endothelial cell migration and proliferation, two key features required for the development of new blood vessels in vivo.
Inhibition of the VEGF tyrosine kinase signaling pathway blocks new blood vessel formation >.0 in growing tumors, leading to stasis or regression of tumor growth.
VEGF is therefore, one of the most potent angiogenic factors affecting endothelial cell (EC) proliferation, motility, and vascular permeability. VEGF binds with high-affinity to the tyrosine kinase receptors Flt-1 (VEGFR-1) and F/k-1/KDR (VEGFR-2) expressed by EC
(Ferrara N., ?5 Am. J. Physiol. Cell Physiol 2001;280:C1358-66). VEGF expression by prostate cancer specimens (Jackson MW, et al., J Urol 1997;157:2323-8) and LNCaP, PC 3, and DU
prostate cancer cell lines (Harper ME, et al., Br J Cancer 1996;74:910-6;
Ferrer FA, et al., J
Urol 1997;157:2329-33; Levine AC, et al., Endocrinology 1998;139:4672-8) is far greater than by stromal cells of the normal prostate. These observations suggest that VEGF plays a 30 role on tumor cell activation (autocrine regulation), in addition to paracrine actions whereby it regulates EC functions and subsequent neovascular development. Upon VEGF-mediated activation, VEGFR-2 undergoes dimerization and ligand-dependent phosphorylation, subsequently inducing the phosphorylation-mediated activation of several intracellular pathways, including Src, P13K, and Raf/MEK/ERK (Matsumoto T, et al., Sci STKE
2001;
35 2001:RE21). VEGFR-2 is considered to be the major mediator of the mitogenic, angiogenic, and permeability-enhancing effects of VEGF, and hence is a major target for antiangiogenic therapies. In addition, the levels of the VEGF receptor are correlated with a poorer grade of tumor differentiation and prognosis in prostate cancer (Huss WJ, et al., Cancer Res 2001;61:2736-43). Overall, these observations have led to the development of several therapeutics for the inhibition of the VEGF signaling pathway such as the humanized anti-VEGF-A monoclonal antibody bevacizumab (Avastin, rhuMAb-VEGF; Genentech, South San Francisco, CA) and endostatin.
In addition to tumor growth, persistent, unregulated angiogenesis occurs in a multiplicity of disease states. The diverse pathological states created due to unregulated angiogenesis have been grouped together as angiogenic dependent or angiogenic associated diseases.
[0 Therapies directed at control of the angiogenic processes could lead to the abrogation or mitigation of these diseases.
One example of a disease mediated by angiogenesis is ocular neovascular disease. This disease is characterized by invasion of new blood vessels into the structures of the eye such as the retina or cornea. It is the most common cause of blindness and is involved in approximately twenty eye diseases. In age-related macular degeneration, the associated visual problems are caused by an ingrowth of chorioidal capillaries through defects in Bruch's membrane with proliferation of fibrovascular tissue beneath the retinal pigment epithelium.
Angiogenic damage is also associated with diabetic retinopathy, retinopathy of prematurity, ?0 corneal graft rejection, neovascular glaucoma and retrolental fibroplasia.
Other diseases associated with corneal neovascularization include, but are not limited to, epidemic keratoconjunctivitis, Vitamin A deficiency, contact lens overwear, atopic keratitis, superior limbic keratitis, pterygium keratitis sicca,-sjogrens, acne rosacea, phylectenulosis, syphilis, Mycobacteria infections, lipid degeneration, chemical burns, bacterial ulcers, fungal ulcers, ?5 Herpes.simplex infections, Herpes zoster infections, protozoan infections, Kaposi's sarcoma, Mooren's ulcer, Terrien's marginal degeneration, mariginal keratolysis, rheumatoid arthritis, systemic lupus, polyarteritis, trauma, Wegener's sarcoidosis, scleritis, Stevens-Johnson disease, pemphigoid, radial keratotomy, and corneal graph rejection.
30 Diseases associated with retinal/choroidal neovascularization include, but are not limited to, diabetic retinopathy, macular degeneration, sickle cell anemia, sarcoid, syphilis, pseudoxanthoma elasticum, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis, mycobacterial infections, Lyme's disease, systemic lupus erythematosis, retinopathy of prematurity, Eales' disease, Behcet's disease, 35 infections causing a retinitis or choroiditis, presumed ocular histoplasmosis, Best's disease, myopia, optic pits, Stargardt's disease, pars planitis, chronic retinal detachment, hyperviscosity syndromes, toxoplasmosis, trauma and post-laser complications.
Other diseases include, but are not limited to, diseases associated with rubeosis (neovasculariation of the angle) and diseases caused by the abnormal proliferation of fibrovascular or fibrous tissue including all forms of proliferative vitreoretinopathy.
Another disease in which angiogenesis is believed to be involved is rheumatoid arthritis. The blood vessels in the synovial lining of the joints undergo angiogenesis. In addition to forming new vascular networks, the endothelial cells release factors and reactive oxygen species that lead to pannus growth and cartilage destruction. The factors involved in angiogenesis may actively contribute to, and help maintain, the chronically inflamed state of rheumatoid arthritis.
Factors associated with angiogenesis may also have a role in osteoarthritis.
The activation of the chondrocytes by angiogenic-related factors contributes to the destruction of the joint. At a later stage, the angiogenic factors would promote new bone formation.
Therapeutic intervention that prevents the bone destruction could halt the progress of the disease and provide relief for persons suffering with arthritis.
Chronic inflammation.may also involve pathological angiogenesis. Such disease states as ulcerative colitis and Crohn's disease show histological changes with the ingrowth of new blood vessels into the inflamed tissues. Bartonellosis, a bacterial infection found in South ?0 America, can result in a chronic stage that is characterized by proliferation of vascular endothelial cells. Another pathological role associated with angiogenesis is found in atherosclerosis. The plaques formed within the lumen of blood vessels have been shown to have angiogenic stimulatory activity.
Angiogenesis is also responsible for damage found in hereditary diseases such as Osler-Weber-Rendu disease, or hereditary hemorrhagic telangiectasia. This is an inherited disease characterized by multiple small angiomas, tumors of blood or lymph vessels.
The angiomas are found in the skin and mucous membranes, often accompanied by epistaxis (nosebleeds) or gastrointestinal bleeding and sometimes with pulmonary or hepatic arteriovenous fistula.
Angiogenesis is prominent in solid tumor formation and metastasis. Angiogenic factors have been found associated with several solid tumors such as rhabdomyosarcomas, retinoblastoma, Ewing sarcoma, neuroblastoma, and osteosarcoma. A tumor cannot expand without a blood supply to provide nutrients and remove cellular wastes. Tumors in which angiogenesis is important include solid tumors, and benign tumors such as acoustic neuroma, neurofibroma, trachoma and pyogenic granulomas. Prevention of angiogenesis could halt the growth of these tumors and the resultant damage to the animal due to the presence of the tumor.
It should be noted that angiogenesis has been associated with blood-born tumors such as leukemias, any of various acute or chronic neoplastic diseases of the bone marrow in which unrestrained proliferation of white blood cells occurs, usually accompanied by anemia, impaired blood clotting, and enlargement of the lymph nodes, liver, and spleen. It is believed that angiogenesis plays a role in the abnormalities in the bone marrow that give rise to leukemia-like tumors.
Angiogenesis is important in two stages of tumor metastasis. The first stage where angiogenesis stimulation is important is in the vascularization of the tumor which allows tumor cells to enter the blood stream and to circulate throughout the body.
After the tumor cells have left the primary site, and have settled into the secondary, metastasis site, angiogenesis must occur before the new tumor can grow and expand. Therefore, prevention of angiogenesis could lead to the prevention of metastasis of tumors and possibly contain the neoplastic growth at the primary site.
Knowledge of the role of angiogenesis in the maintenance and metastasis of tumors has led to a prognostic indicator for breast cancer. The amount of neovascularization found in the ?0 primary tumor was determined by counting the microvessel density in the area of the most intense neovascularization in invasive breast carcinoma. A high level of microvessel density was found to correlate with tumor recurrence. Control of angiogenesis by therapeutic means could possibly lead to cessation of the recurrence of the tumors.
>_5 Angiogenesis is also involved in normal physiological processes such as reproduction and wound healing. Angiogenesis is an important step in ovulation and also in implantation of the blastula after fertilization. Prevention of angiogenesis could be used to induce amenorrhea, to block ovulation or to prevent implantation by the blastula.
30 In wound healing, excessive repair or fibroplasia can be a detrimental side effect of surgical procedures and may be caused or exacerbated by angiogenesis. Adhesions are a frequent complication of surgery and lead to problems such as small bowel obstruction.
Matrix metalloproteinases (MMPs) play an important role in morphogenesis, angiogenesis, 35 wound healing, and in certain disorders such as rheumatoid arthritis, tumor invasion and metastasis (Birkedal-Hansen, 1995, Curr. Opin. Cell Biol. 7:728-735). MMPs are involved, for example, in physiological function where rearrangements of basement membranes occur.
MMP-2 binds specifically to TIMP-2 while MMP-9 binds to TIMP=1.
Evidences show that MMPs are overexpressed in cancer cells. However, in situ hybridization results indicated that stromal fibroblasts found at the proximity of cancer cells as well as vascular cells, inflammatory cells such as macrophages and neutrophils and not only the cancer cells expresses some MMP family members. Thus, there is a significant role of other cells expressing MMP in the contribution to cancer progression.
Five subfamilies of MMPs have been recognized: collagenases, gelatinases, stromelysins, matrilysins, and membrane-type MMPs (MT-MMPs). Most of these enzymes contain propeptide, catalytic and hemopexin domains and are involved in the degradation of collagens, proteoglycans and various glycoproteins. MMPs are secreted as inactive zymogens (pro-MMPs) and their activation seems to be a prerequisite for their function. In vivo activation of pro-MMPs involves the removal of the propeptide by serine proteases (e.g., trypsin, plasmin, etc.). Stimulation or repression of most pro-MMP synthesis is regulated at the transcriptional level by growth factors and cytokines.
Post-translational regulation of MMP activity, on the other hand, is controlled by tissue 20. inhibitors of MMPs ("TIMPs"), four of which have been characterized and designated as TIMP-1, TIMP-2, TIMP-3, and TIMP-4 (Gomez et al., 1997, Eur. J. Cell. Biol.
74:111-122).
TIMP-1 is involved in the activation of MMP-9, while TIMP-2 is involved in the activation of MMP-2.
MMP-2 (gelatinase A) and MMP-9 (gelatinase B) hydrolyze basement membrane (extracellular matrix (ECM) protein and non-ECM protein (including collagen)) and have therefore been incriminated in the mechanism of tumor invasion and metastasis.
MMP-9 is also involved in inflammation, atheroscelerotic plaque rupture, tissue remodeling, wound healing, mobilization of matrix-bound growth factors, processing of cytokines, pulmonary fibrosis, osteoarthritis (Fujisawa et al., J.Biochem. 125:966, 1999), asthma (Oshita, Y. Thorax 2003;58:757-760) multiple sclerosis (Opdenakker, G, et al, The Lancet Neurology, 2:747-756, 2000). Its expression correlates, for example, with the desmoplasia (abnormal collagen deposition) that accompanies pancreatic cancer, with the metastasis to lymph nodes by human breast carcinoma cells and with the invasion of regional vessels in giant cell tumors of bones. MMP-9 expression is associated with multiple sclerosis and autoimmune inflammation (e.g., autoimmune encephalomyelitis). MMP-9 may be elevated in gingival crevicular fluid and saliva in patients with gingivitis and periodontal diseases. Determination of MMP-9 activity and/or level has been found useful in the follow-up and in the assessment of prognosis in breast and lung cancer patients (Ranunculo, Int. J. Cancer;
lizasa, Clinical Cancer Research) suggesting a good correlation between MMP-9 with the tumor burden and the clinical status.
MMP=2 plasma levels and activity are elevated in patients with acute myocardial infarction (MI) and may be involved in post-MI complications. Injury of the vascular wall during coronary interventions (PCI) has been shown to increase MMP-2. The expression of MMP-2 is also increased in the brain of individual with multiple sclerosis.
MT1-MMP (MMP-14) can be activated intracellularly. MT1-MMP contains a motif of basic amino acids upstream of the catalytic domain that are thought to act as endoproteolytic processing signals to furin via the trans-golgi network. MT1 -MMP is processed to an activated proteinase through a process involving post-translational endoproteolysis, further processed by furin via the trans-Golgi network and then secreted in an .active form. The main mechanism of pro-MMP-2 activation involves the zymogen forming a complex at the cell surface with MT1 -MMP and TIMP-2. Cleavage of pro-MMP-2 is also thought to involve binding to integrins. MMP-2 also activates. MMP-9:
?0 Failed human hearts examined at autopsy or explantation exhibit alterations of the extracellular matrix (e.g. due to changes in collagen). Modulation of the balance between matrix synthesis and degradation is important in the process of ventricular remodelling and in the pathophysiology of heart failure. Support for the importance of the ECM
and activity of matrix metalloproteinases in the development of chronic heart failure has been demonstrated ?5 both in animal models of heart diseases and in humans.
Pharmaceutical application of compounds which inhibit the expression of MMPs offers a new approach to cancer treatment as well as treatment for nerve healing, degenerative cartilagenous diseases, decubitus ulcers, arthritis, Alzheimer's disease, wound healing, 30 proliferative retinopathy, proliferative renal diseases, multiple sclerosis, corneal ulcers, uncontrolled tissue remodelling and fertility problems.
Follicle stimulating hormone seems to be involved in the regulation of some MMPs andTlMPs, at least in Sertoli cells (see for example; Mol. Cell. Endocrinol.
118:37-46, 1996;
35 Biol. Reprod. 62:1040-1046, 2000; Mol. Cell. Endocrinol. 189: 25-35, 2002).
In testis, follicle stimulating hormone (FSH) has been shown to induce the expression and secretion of MMP-2, MMP-9, TIMP-1 and TIMP-2 from Sertoli cells in vitro. In addition to its role in normal testicular and ovarian functions, FSH is also involved in stimulation of ovarian, endometrial and prostate tumor cell proliferation and is therefore implicated in tumor progression.
Cell adhesion is a process by which cells associate with each other, migrate towards a specific target or localize within the extra-cellular matrix. As such, cell adhesion constitutes one of the fundamental mechanisms underlying numerous biological phenomena.
For example, cell adhesion is responsible for the adhesion of hematopoietic cells to endothelial cells and the subsequent migration of those hemopoietic cells out of blood vessels and to the site of injury. As such, cell adhesion plays a role in pathologies such as inflammation and immune reactions in mammals.
Investigations into the molecular basis for cell adhesion have revealed that various cell-surface macromolecules; collectively known as cell adhesion molecules or receptors, mediate cell-cell and cell-matrix interactions. For example, proteins of the superfamily called [5 "integrins" are key mediators in adhesive interactions between hematopoietic cells and their microenvironment (M. E. Hemler, Ann. Rev. Immunol., 8, p. 365 (1990)).
Rho GTPase (e.g. RhoA) play a role in several cellular processes, by activating downstream targets that regulates; cell polarization, cell-cell adhesion, cell-matrix adhesion, cell ?0 morphology, cell motility, membrane trafficking, cytoskeletal microfilaments reorganization, focal adhesion formation, migration, differentiation, apoptosis, smooth muscle contraction and cell proliferation. Some of these targets lead, for example, to activation of serum response factors.
?5 Rho GTPases have been linked with several neurological processes including neuronal migration and polarization, axon guidance and dendrite formation, as well as synaptic organization and plasticity (Luo L., Nat. Rev. Neuroseci. 1, 173-180, 2000).
Rho GTPase as therefore been found associated with neurodegenerative disorders (e.g., X-chromosome linked forms of mental retardation, amyotropic lateral sclerosis) and other diseases, such as, 30 faciogenital dysplasia, Wiskott-Aldrich syndrome, diaphanous (non-syndromic deafness), Tangier disease, etc.
Prostate secretory protein (PSP94) constitutes one of the three predominant proteins found in human seminal fluid along with prostate specific antigen (PSA) and prostatic acid 35 phosphatase (PAP). PSP94 has a molecular weight of 10.7kDa and contains 10 cysteine residues. The cDNA and the gene coding for PSP94 have been cloned and characterized.
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.
NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME
NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:
Method and composition for treating angiogenesis and for preventing cancer progression and metastasis comprising a prostate secretory protein (PSP94) family member.
FIELD OF THE INVENTION
The present invention relates to methods and compositions for treating or preventing undesirable angiogenesis in a human or animal for preventing cancer progression and metastasis.
BACKGROUND OF THE INVENTION
The present invention relates to methods and compositions for effectively inhibiting angiogenesis and for preventing cancer (tumor) progression and/or metastasis.
More specifically, the invention relates to compositions comprising a PSP94 family member and their use in the inhibition of angiogenesis and treatment of angiogenesis associated diseases as well as for preventing tumor progression and/or metastasis.
Angiogenesis refers to the formation of blood vessels into a tissue or organ.
Under normal physiological conditions, humans or animals only undergo angiogenesis in very specific restricted situations. For example; angiogenesis is normally observed in wound healing, fetal and embryonal development and formation of the corpus luteum, endometrium and placenta.
The control of angiogenesis is a highly regulated system of angiogenic stimulators and ?5 inhibitors. The control of angiogenesis has been found to be altered in certain disease states and, in many cases, the pathological damage associated with the disease is related to the uncontrolled angiogenesis.
Both controlled and uncontrolled angiogenesis are thought to probeed in a similar manner.
Endothelial cells and pericytes which are surrounded by a basement membrane form capillary blood vessels. Angiogenesis begins with the erosion of the basement membrane by enzymes released by endothelial cells and leukocytes. The endothelial cells, which line the lumen of blood vessels, then protrude through the basement membrane.
Angiogenic stimulants induce the endothelial cells to migrate through the eroded basement membrane.
The migrating cells form a "sprout" off the parent blood vessel, where the endothelial cells undergo mitosis and proliferate. The endothelial sprouts merge with each other to form capillary loops, creating the new blood vessel. In the disease state, prevention of angiogenesis could avert the damage caused by the invasion of the new microvascular system.
Maturation and stabilization of the newly formed blood vessel occur via recruitment of pericytes and involve.principally but not exclusively platelet-derived growth factor (PDGF), fibroblast growth factor-2 (FGF-2), transforming growth factor-beta (TGF-beta), vascular endothelial growth factor (VEGF) and angiopoietins (Darland, D.C. and P. A.
D'Amore (1999) Journal of Clinical Investigation, 103:157-58). A number of angiogenic factors have been .0 identified based on the ability to promote the development of new blood vessels in vivo..
Angiogenesis is controlled by the net balance between molecules that have positive and negative regulatory activity. The growth of human tumors and development of metastases depend on the de novo formation of blood vessels. The formation of new blood vessels is tightly regulated by specific growth factors that target receptor tyrosine kinases (RTKs).
Vascular endothelial growth factor (VEGF) is a pivotal stimulator of angiogenesis because its binding to VEGF receptors (RTKs) has been shown to promote endothelial cell migration and proliferation, two key features required for the development of new blood vessels in vivo.
Inhibition of the VEGF tyrosine kinase signaling pathway blocks new blood vessel formation >.0 in growing tumors, leading to stasis or regression of tumor growth.
VEGF is therefore, one of the most potent angiogenic factors affecting endothelial cell (EC) proliferation, motility, and vascular permeability. VEGF binds with high-affinity to the tyrosine kinase receptors Flt-1 (VEGFR-1) and F/k-1/KDR (VEGFR-2) expressed by EC
(Ferrara N., ?5 Am. J. Physiol. Cell Physiol 2001;280:C1358-66). VEGF expression by prostate cancer specimens (Jackson MW, et al., J Urol 1997;157:2323-8) and LNCaP, PC 3, and DU
prostate cancer cell lines (Harper ME, et al., Br J Cancer 1996;74:910-6;
Ferrer FA, et al., J
Urol 1997;157:2329-33; Levine AC, et al., Endocrinology 1998;139:4672-8) is far greater than by stromal cells of the normal prostate. These observations suggest that VEGF plays a 30 role on tumor cell activation (autocrine regulation), in addition to paracrine actions whereby it regulates EC functions and subsequent neovascular development. Upon VEGF-mediated activation, VEGFR-2 undergoes dimerization and ligand-dependent phosphorylation, subsequently inducing the phosphorylation-mediated activation of several intracellular pathways, including Src, P13K, and Raf/MEK/ERK (Matsumoto T, et al., Sci STKE
2001;
35 2001:RE21). VEGFR-2 is considered to be the major mediator of the mitogenic, angiogenic, and permeability-enhancing effects of VEGF, and hence is a major target for antiangiogenic therapies. In addition, the levels of the VEGF receptor are correlated with a poorer grade of tumor differentiation and prognosis in prostate cancer (Huss WJ, et al., Cancer Res 2001;61:2736-43). Overall, these observations have led to the development of several therapeutics for the inhibition of the VEGF signaling pathway such as the humanized anti-VEGF-A monoclonal antibody bevacizumab (Avastin, rhuMAb-VEGF; Genentech, South San Francisco, CA) and endostatin.
In addition to tumor growth, persistent, unregulated angiogenesis occurs in a multiplicity of disease states. The diverse pathological states created due to unregulated angiogenesis have been grouped together as angiogenic dependent or angiogenic associated diseases.
[0 Therapies directed at control of the angiogenic processes could lead to the abrogation or mitigation of these diseases.
One example of a disease mediated by angiogenesis is ocular neovascular disease. This disease is characterized by invasion of new blood vessels into the structures of the eye such as the retina or cornea. It is the most common cause of blindness and is involved in approximately twenty eye diseases. In age-related macular degeneration, the associated visual problems are caused by an ingrowth of chorioidal capillaries through defects in Bruch's membrane with proliferation of fibrovascular tissue beneath the retinal pigment epithelium.
Angiogenic damage is also associated with diabetic retinopathy, retinopathy of prematurity, ?0 corneal graft rejection, neovascular glaucoma and retrolental fibroplasia.
Other diseases associated with corneal neovascularization include, but are not limited to, epidemic keratoconjunctivitis, Vitamin A deficiency, contact lens overwear, atopic keratitis, superior limbic keratitis, pterygium keratitis sicca,-sjogrens, acne rosacea, phylectenulosis, syphilis, Mycobacteria infections, lipid degeneration, chemical burns, bacterial ulcers, fungal ulcers, ?5 Herpes.simplex infections, Herpes zoster infections, protozoan infections, Kaposi's sarcoma, Mooren's ulcer, Terrien's marginal degeneration, mariginal keratolysis, rheumatoid arthritis, systemic lupus, polyarteritis, trauma, Wegener's sarcoidosis, scleritis, Stevens-Johnson disease, pemphigoid, radial keratotomy, and corneal graph rejection.
30 Diseases associated with retinal/choroidal neovascularization include, but are not limited to, diabetic retinopathy, macular degeneration, sickle cell anemia, sarcoid, syphilis, pseudoxanthoma elasticum, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis, mycobacterial infections, Lyme's disease, systemic lupus erythematosis, retinopathy of prematurity, Eales' disease, Behcet's disease, 35 infections causing a retinitis or choroiditis, presumed ocular histoplasmosis, Best's disease, myopia, optic pits, Stargardt's disease, pars planitis, chronic retinal detachment, hyperviscosity syndromes, toxoplasmosis, trauma and post-laser complications.
Other diseases include, but are not limited to, diseases associated with rubeosis (neovasculariation of the angle) and diseases caused by the abnormal proliferation of fibrovascular or fibrous tissue including all forms of proliferative vitreoretinopathy.
Another disease in which angiogenesis is believed to be involved is rheumatoid arthritis. The blood vessels in the synovial lining of the joints undergo angiogenesis. In addition to forming new vascular networks, the endothelial cells release factors and reactive oxygen species that lead to pannus growth and cartilage destruction. The factors involved in angiogenesis may actively contribute to, and help maintain, the chronically inflamed state of rheumatoid arthritis.
Factors associated with angiogenesis may also have a role in osteoarthritis.
The activation of the chondrocytes by angiogenic-related factors contributes to the destruction of the joint. At a later stage, the angiogenic factors would promote new bone formation.
Therapeutic intervention that prevents the bone destruction could halt the progress of the disease and provide relief for persons suffering with arthritis.
Chronic inflammation.may also involve pathological angiogenesis. Such disease states as ulcerative colitis and Crohn's disease show histological changes with the ingrowth of new blood vessels into the inflamed tissues. Bartonellosis, a bacterial infection found in South ?0 America, can result in a chronic stage that is characterized by proliferation of vascular endothelial cells. Another pathological role associated with angiogenesis is found in atherosclerosis. The plaques formed within the lumen of blood vessels have been shown to have angiogenic stimulatory activity.
Angiogenesis is also responsible for damage found in hereditary diseases such as Osler-Weber-Rendu disease, or hereditary hemorrhagic telangiectasia. This is an inherited disease characterized by multiple small angiomas, tumors of blood or lymph vessels.
The angiomas are found in the skin and mucous membranes, often accompanied by epistaxis (nosebleeds) or gastrointestinal bleeding and sometimes with pulmonary or hepatic arteriovenous fistula.
Angiogenesis is prominent in solid tumor formation and metastasis. Angiogenic factors have been found associated with several solid tumors such as rhabdomyosarcomas, retinoblastoma, Ewing sarcoma, neuroblastoma, and osteosarcoma. A tumor cannot expand without a blood supply to provide nutrients and remove cellular wastes. Tumors in which angiogenesis is important include solid tumors, and benign tumors such as acoustic neuroma, neurofibroma, trachoma and pyogenic granulomas. Prevention of angiogenesis could halt the growth of these tumors and the resultant damage to the animal due to the presence of the tumor.
It should be noted that angiogenesis has been associated with blood-born tumors such as leukemias, any of various acute or chronic neoplastic diseases of the bone marrow in which unrestrained proliferation of white blood cells occurs, usually accompanied by anemia, impaired blood clotting, and enlargement of the lymph nodes, liver, and spleen. It is believed that angiogenesis plays a role in the abnormalities in the bone marrow that give rise to leukemia-like tumors.
Angiogenesis is important in two stages of tumor metastasis. The first stage where angiogenesis stimulation is important is in the vascularization of the tumor which allows tumor cells to enter the blood stream and to circulate throughout the body.
After the tumor cells have left the primary site, and have settled into the secondary, metastasis site, angiogenesis must occur before the new tumor can grow and expand. Therefore, prevention of angiogenesis could lead to the prevention of metastasis of tumors and possibly contain the neoplastic growth at the primary site.
Knowledge of the role of angiogenesis in the maintenance and metastasis of tumors has led to a prognostic indicator for breast cancer. The amount of neovascularization found in the ?0 primary tumor was determined by counting the microvessel density in the area of the most intense neovascularization in invasive breast carcinoma. A high level of microvessel density was found to correlate with tumor recurrence. Control of angiogenesis by therapeutic means could possibly lead to cessation of the recurrence of the tumors.
>_5 Angiogenesis is also involved in normal physiological processes such as reproduction and wound healing. Angiogenesis is an important step in ovulation and also in implantation of the blastula after fertilization. Prevention of angiogenesis could be used to induce amenorrhea, to block ovulation or to prevent implantation by the blastula.
30 In wound healing, excessive repair or fibroplasia can be a detrimental side effect of surgical procedures and may be caused or exacerbated by angiogenesis. Adhesions are a frequent complication of surgery and lead to problems such as small bowel obstruction.
Matrix metalloproteinases (MMPs) play an important role in morphogenesis, angiogenesis, 35 wound healing, and in certain disorders such as rheumatoid arthritis, tumor invasion and metastasis (Birkedal-Hansen, 1995, Curr. Opin. Cell Biol. 7:728-735). MMPs are involved, for example, in physiological function where rearrangements of basement membranes occur.
MMP-2 binds specifically to TIMP-2 while MMP-9 binds to TIMP=1.
Evidences show that MMPs are overexpressed in cancer cells. However, in situ hybridization results indicated that stromal fibroblasts found at the proximity of cancer cells as well as vascular cells, inflammatory cells such as macrophages and neutrophils and not only the cancer cells expresses some MMP family members. Thus, there is a significant role of other cells expressing MMP in the contribution to cancer progression.
Five subfamilies of MMPs have been recognized: collagenases, gelatinases, stromelysins, matrilysins, and membrane-type MMPs (MT-MMPs). Most of these enzymes contain propeptide, catalytic and hemopexin domains and are involved in the degradation of collagens, proteoglycans and various glycoproteins. MMPs are secreted as inactive zymogens (pro-MMPs) and their activation seems to be a prerequisite for their function. In vivo activation of pro-MMPs involves the removal of the propeptide by serine proteases (e.g., trypsin, plasmin, etc.). Stimulation or repression of most pro-MMP synthesis is regulated at the transcriptional level by growth factors and cytokines.
Post-translational regulation of MMP activity, on the other hand, is controlled by tissue 20. inhibitors of MMPs ("TIMPs"), four of which have been characterized and designated as TIMP-1, TIMP-2, TIMP-3, and TIMP-4 (Gomez et al., 1997, Eur. J. Cell. Biol.
74:111-122).
TIMP-1 is involved in the activation of MMP-9, while TIMP-2 is involved in the activation of MMP-2.
MMP-2 (gelatinase A) and MMP-9 (gelatinase B) hydrolyze basement membrane (extracellular matrix (ECM) protein and non-ECM protein (including collagen)) and have therefore been incriminated in the mechanism of tumor invasion and metastasis.
MMP-9 is also involved in inflammation, atheroscelerotic plaque rupture, tissue remodeling, wound healing, mobilization of matrix-bound growth factors, processing of cytokines, pulmonary fibrosis, osteoarthritis (Fujisawa et al., J.Biochem. 125:966, 1999), asthma (Oshita, Y. Thorax 2003;58:757-760) multiple sclerosis (Opdenakker, G, et al, The Lancet Neurology, 2:747-756, 2000). Its expression correlates, for example, with the desmoplasia (abnormal collagen deposition) that accompanies pancreatic cancer, with the metastasis to lymph nodes by human breast carcinoma cells and with the invasion of regional vessels in giant cell tumors of bones. MMP-9 expression is associated with multiple sclerosis and autoimmune inflammation (e.g., autoimmune encephalomyelitis). MMP-9 may be elevated in gingival crevicular fluid and saliva in patients with gingivitis and periodontal diseases. Determination of MMP-9 activity and/or level has been found useful in the follow-up and in the assessment of prognosis in breast and lung cancer patients (Ranunculo, Int. J. Cancer;
lizasa, Clinical Cancer Research) suggesting a good correlation between MMP-9 with the tumor burden and the clinical status.
MMP=2 plasma levels and activity are elevated in patients with acute myocardial infarction (MI) and may be involved in post-MI complications. Injury of the vascular wall during coronary interventions (PCI) has been shown to increase MMP-2. The expression of MMP-2 is also increased in the brain of individual with multiple sclerosis.
MT1-MMP (MMP-14) can be activated intracellularly. MT1-MMP contains a motif of basic amino acids upstream of the catalytic domain that are thought to act as endoproteolytic processing signals to furin via the trans-golgi network. MT1 -MMP is processed to an activated proteinase through a process involving post-translational endoproteolysis, further processed by furin via the trans-Golgi network and then secreted in an .active form. The main mechanism of pro-MMP-2 activation involves the zymogen forming a complex at the cell surface with MT1 -MMP and TIMP-2. Cleavage of pro-MMP-2 is also thought to involve binding to integrins. MMP-2 also activates. MMP-9:
?0 Failed human hearts examined at autopsy or explantation exhibit alterations of the extracellular matrix (e.g. due to changes in collagen). Modulation of the balance between matrix synthesis and degradation is important in the process of ventricular remodelling and in the pathophysiology of heart failure. Support for the importance of the ECM
and activity of matrix metalloproteinases in the development of chronic heart failure has been demonstrated ?5 both in animal models of heart diseases and in humans.
Pharmaceutical application of compounds which inhibit the expression of MMPs offers a new approach to cancer treatment as well as treatment for nerve healing, degenerative cartilagenous diseases, decubitus ulcers, arthritis, Alzheimer's disease, wound healing, 30 proliferative retinopathy, proliferative renal diseases, multiple sclerosis, corneal ulcers, uncontrolled tissue remodelling and fertility problems.
Follicle stimulating hormone seems to be involved in the regulation of some MMPs andTlMPs, at least in Sertoli cells (see for example; Mol. Cell. Endocrinol.
118:37-46, 1996;
35 Biol. Reprod. 62:1040-1046, 2000; Mol. Cell. Endocrinol. 189: 25-35, 2002).
In testis, follicle stimulating hormone (FSH) has been shown to induce the expression and secretion of MMP-2, MMP-9, TIMP-1 and TIMP-2 from Sertoli cells in vitro. In addition to its role in normal testicular and ovarian functions, FSH is also involved in stimulation of ovarian, endometrial and prostate tumor cell proliferation and is therefore implicated in tumor progression.
Cell adhesion is a process by which cells associate with each other, migrate towards a specific target or localize within the extra-cellular matrix. As such, cell adhesion constitutes one of the fundamental mechanisms underlying numerous biological phenomena.
For example, cell adhesion is responsible for the adhesion of hematopoietic cells to endothelial cells and the subsequent migration of those hemopoietic cells out of blood vessels and to the site of injury. As such, cell adhesion plays a role in pathologies such as inflammation and immune reactions in mammals.
Investigations into the molecular basis for cell adhesion have revealed that various cell-surface macromolecules; collectively known as cell adhesion molecules or receptors, mediate cell-cell and cell-matrix interactions. For example, proteins of the superfamily called [5 "integrins" are key mediators in adhesive interactions between hematopoietic cells and their microenvironment (M. E. Hemler, Ann. Rev. Immunol., 8, p. 365 (1990)).
Rho GTPase (e.g. RhoA) play a role in several cellular processes, by activating downstream targets that regulates; cell polarization, cell-cell adhesion, cell-matrix adhesion, cell ?0 morphology, cell motility, membrane trafficking, cytoskeletal microfilaments reorganization, focal adhesion formation, migration, differentiation, apoptosis, smooth muscle contraction and cell proliferation. Some of these targets lead, for example, to activation of serum response factors.
?5 Rho GTPases have been linked with several neurological processes including neuronal migration and polarization, axon guidance and dendrite formation, as well as synaptic organization and plasticity (Luo L., Nat. Rev. Neuroseci. 1, 173-180, 2000).
Rho GTPase as therefore been found associated with neurodegenerative disorders (e.g., X-chromosome linked forms of mental retardation, amyotropic lateral sclerosis) and other diseases, such as, 30 faciogenital dysplasia, Wiskott-Aldrich syndrome, diaphanous (non-syndromic deafness), Tangier disease, etc.
Prostate secretory protein (PSP94) constitutes one of the three predominant proteins found in human seminal fluid along with prostate specific antigen (PSA) and prostatic acid 35 phosphatase (PAP). PSP94 has a molecular weight of 10.7kDa and contains 10 cysteine residues. The cDNA and the gene coding for PSP94 have been cloned and characterized.
It was shown that PSP94 inhibits growth of tumor cells (see U.S. Pat. No.:
5,428,011 to Seth et.al., the entire content of which is incorporated herein by reference).
Tumor growth inhibition by PSP94 fragment, has also been observed in animal models (see International application No. PCT/CA01/01463 to Garde, S. et al., published under No.:
W002/33090, the entire content of which is incorporated herein by reference). PSP94 also reduces the development of skeletal metastasis (see International application No.:
PCT/CA02/01737 to Rabbani, S. et al., published under No.: W003/039576, the entire content of which is incorporated herein by reference). This latter characteristic was observed by a reduction, in calcium levels following administration of PSP94 to animal modeling prostate cancer. PSP94 has also been shown to lower FSH levels (Thakur et al., 1981, Ind. J. Exp.
Biol. Vol. 19:303-313) and also interfere in the binding of FSH to its receptor using testicular membrane preparations (Vijayalakshmi et al., Int. J. Androl. (1981) 691-702).
SUMMARY OF THE INVENTION
The present invention relates to the reduction or inhibition of angiogenesis by a PSP94 family member.
?0 In accordance with the present invention a PSP94 family member is used for treating angiogenesis mediated disease, angiogenesis associated disease or for inhibiting normal angiogenesis.
In accordance with the present invention, compositions and methods are provided that are >_5 effective in inhibiting, for example, unwanted or undesirable angiogenesis. The present invention provides a method of treating or preventing diseases (e.g., in a mammal in need) mediated, for example, by undesired or uncontrolled angiogenesis by administering a composition comprising an anti-angiogenic compound (a PSP94 family member) in a dosage sufficient to inhibit angiogenesis.
In accordance with the present invention, angiogenesis-mediated or associated diseases encompassed by the present invention comprise for example, ocular neovascularization (e.g., cornea, retina), macular degeneration, cancer-associated angiogenesis, metastasis-associated angiogenesis, retrolental fibroplasia, psoriasis, diabetic retinopathy, retrolental fibroplasia, Crohn's disease, or any disease or state in which inhibition of angiogenesis is desired.
5,428,011 to Seth et.al., the entire content of which is incorporated herein by reference).
Tumor growth inhibition by PSP94 fragment, has also been observed in animal models (see International application No. PCT/CA01/01463 to Garde, S. et al., published under No.:
W002/33090, the entire content of which is incorporated herein by reference). PSP94 also reduces the development of skeletal metastasis (see International application No.:
PCT/CA02/01737 to Rabbani, S. et al., published under No.: W003/039576, the entire content of which is incorporated herein by reference). This latter characteristic was observed by a reduction, in calcium levels following administration of PSP94 to animal modeling prostate cancer. PSP94 has also been shown to lower FSH levels (Thakur et al., 1981, Ind. J. Exp.
Biol. Vol. 19:303-313) and also interfere in the binding of FSH to its receptor using testicular membrane preparations (Vijayalakshmi et al., Int. J. Androl. (1981) 691-702).
SUMMARY OF THE INVENTION
The present invention relates to the reduction or inhibition of angiogenesis by a PSP94 family member.
?0 In accordance with the present invention a PSP94 family member is used for treating angiogenesis mediated disease, angiogenesis associated disease or for inhibiting normal angiogenesis.
In accordance with the present invention, compositions and methods are provided that are >_5 effective in inhibiting, for example, unwanted or undesirable angiogenesis. The present invention provides a method of treating or preventing diseases (e.g., in a mammal in need) mediated, for example, by undesired or uncontrolled angiogenesis by administering a composition comprising an anti-angiogenic compound (a PSP94 family member) in a dosage sufficient to inhibit angiogenesis.
In accordance with the present invention, angiogenesis-mediated or associated diseases encompassed by the present invention comprise for example, ocular neovascularization (e.g., cornea, retina), macular degeneration, cancer-associated angiogenesis, metastasis-associated angiogenesis, retrolental fibroplasia, psoriasis, diabetic retinopathy, retrolental fibroplasia, Crohn's disease, or any disease or state in which inhibition of angiogenesis is desired.
Therefore, PSP94, PSP94 derivatives, PCK3145, PCK3145 derivatives, fragments, analogues and homologues thereof may therefore find utility also in cancer treatment or wound healing, for anti-angiogenesis, for anti-inflammation, for anti-osteoarthritis, for inhibition of hair growth, in the reduction of degradation of some cytokine (e.g., IFN-beta) as well as for skin treatment (e.g., prevention of blistering photo-aging, psoriasis), tissue remodeling, pulmonary fibrosis, etc.
In accordance with the present invention a PSP94 family member may be used to inhibit or to reduce normal angiogenesis, for example angiogenesis associated with the menstrual cycle of a woman (endometrial angiogenesis).
Aspects of the present invention relate to the use of a PSP94 family member (in an isolated cell, a cell lyzate, in a tissue, in an individual (a mammal) etc.) for 1) the inhibition or reduction of angiogenesis, 2) the inhibition or reduction of VEGF receptor phosphorylation or activation (e.g., reduction of the tyrosine kinase signal transduction activity) , 3) the inhibition or reduction of PDGF receptor phosphorylation or activation (e.g., reduction of the tyrosine kinase signal transduction activity), 4) inhibition or reduction of the ability of a VEGF receptor to phosphorylate a substrate, 5) inhibition or reduction of the ability of a PDGF receptor to phosphorylate a substrate, 6) inhibition or reduction of VEGF-mediated and/or VEGFR-mediated ERK phosphorylation 7) inhibition or reduction of PDGF-mediated and/or PDGFR-mediated ERK phosphorylation, 8) inhibition or reduction of constitutive secretion, 9) increase or stimulation of protein (RNA) expression from a gene having at least one Serum Response Element (SRE), 10) increase or stimulation of protein (RNA) expression from a gene having at least one NF-KB element; 11) increase or stimulation of ERK
?5 phosphorylation, 12) increase or stimulation of the MAPK/JNK pathway, 13) increase or stimulation of apoptosis 14) inhibition or reduction of VEGF-induced VEGFR
phosphorylation (e.g., in an in vitro assay) 15) inhibition or reduction of PDGF-induced PDGFR
phosphorylation (e.g., in an in vitro assay) and any combinations thereof.
In additional aspect, the present invention relates to the use of a PSP94 family member to treat a condition or disease associated with 1) angiogenesis, 2) VEGF receptor phosphorylation, 3) PDGF receptor phosphorylation, 4) phosphorylation of a substrate mediated by a VEGF receptor, 5) phosphorylation of a substrate mediated by a PDGF
receptor, 6) VEGF-mediated and/or VEGFR-mediated ERK phosphorylation 7) PDGF-5 mediated and/or PDGFR-mediated ERK phosphorylation, 8) insufficient of poor protein (or RNA) expression from a gene having at least one Serum Response Element (SRE), 9) insufficient of poor protein (or RNA) expression from a gene having at least one NF-KB
element; 10) insufficient of poor stimulation of ERK phosphorylation, 11) insufficient or poor stimulation of the MAPK/JNK pathway and any combinations thereof.
It may also be useful to use a PSP94 family member to treat a condition or disease associated with unwanted cell growth by promoting apoptosis in the cell.
More particularly, the present invention relates to the use of a compound which may be selected from the group consisting of SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce tube formation in an angiogenesis assay, a SEQ ID NO.:5 fragment able to reduce l0 tube formation in an angiogenesis assay, a SEQ ID NO.:5 analog able to reduce tube formation in an angiogenesis assay and combination thereof in the treatment of angiogenesis in an individual in need.
Also, more particularly, the present invention relates to the use of a compound selected from the group consisting of SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce at least one of substrate phosphorylation by VEGF receptor, substrate phosphorylation by PDGF receptor and substrate phosphorylation by VEGF receptor and PDGF receptor, a SEQ ID
NO.:5 fragment able to reduce at least one of substrate phosphorylation by VEGF
receptor, substrate phosphorylation by PDGF receptor and substrate phosphorylation by VEGF
In accordance with the present invention a PSP94 family member may be used to inhibit or to reduce normal angiogenesis, for example angiogenesis associated with the menstrual cycle of a woman (endometrial angiogenesis).
Aspects of the present invention relate to the use of a PSP94 family member (in an isolated cell, a cell lyzate, in a tissue, in an individual (a mammal) etc.) for 1) the inhibition or reduction of angiogenesis, 2) the inhibition or reduction of VEGF receptor phosphorylation or activation (e.g., reduction of the tyrosine kinase signal transduction activity) , 3) the inhibition or reduction of PDGF receptor phosphorylation or activation (e.g., reduction of the tyrosine kinase signal transduction activity), 4) inhibition or reduction of the ability of a VEGF receptor to phosphorylate a substrate, 5) inhibition or reduction of the ability of a PDGF receptor to phosphorylate a substrate, 6) inhibition or reduction of VEGF-mediated and/or VEGFR-mediated ERK phosphorylation 7) inhibition or reduction of PDGF-mediated and/or PDGFR-mediated ERK phosphorylation, 8) inhibition or reduction of constitutive secretion, 9) increase or stimulation of protein (RNA) expression from a gene having at least one Serum Response Element (SRE), 10) increase or stimulation of protein (RNA) expression from a gene having at least one NF-KB element; 11) increase or stimulation of ERK
?5 phosphorylation, 12) increase or stimulation of the MAPK/JNK pathway, 13) increase or stimulation of apoptosis 14) inhibition or reduction of VEGF-induced VEGFR
phosphorylation (e.g., in an in vitro assay) 15) inhibition or reduction of PDGF-induced PDGFR
phosphorylation (e.g., in an in vitro assay) and any combinations thereof.
In additional aspect, the present invention relates to the use of a PSP94 family member to treat a condition or disease associated with 1) angiogenesis, 2) VEGF receptor phosphorylation, 3) PDGF receptor phosphorylation, 4) phosphorylation of a substrate mediated by a VEGF receptor, 5) phosphorylation of a substrate mediated by a PDGF
receptor, 6) VEGF-mediated and/or VEGFR-mediated ERK phosphorylation 7) PDGF-5 mediated and/or PDGFR-mediated ERK phosphorylation, 8) insufficient of poor protein (or RNA) expression from a gene having at least one Serum Response Element (SRE), 9) insufficient of poor protein (or RNA) expression from a gene having at least one NF-KB
element; 10) insufficient of poor stimulation of ERK phosphorylation, 11) insufficient or poor stimulation of the MAPK/JNK pathway and any combinations thereof.
It may also be useful to use a PSP94 family member to treat a condition or disease associated with unwanted cell growth by promoting apoptosis in the cell.
More particularly, the present invention relates to the use of a compound which may be selected from the group consisting of SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce tube formation in an angiogenesis assay, a SEQ ID NO.:5 fragment able to reduce l0 tube formation in an angiogenesis assay, a SEQ ID NO.:5 analog able to reduce tube formation in an angiogenesis assay and combination thereof in the treatment of angiogenesis in an individual in need.
Also, more particularly, the present invention relates to the use of a compound selected from the group consisting of SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce at least one of substrate phosphorylation by VEGF receptor, substrate phosphorylation by PDGF receptor and substrate phosphorylation by VEGF receptor and PDGF receptor, a SEQ ID
NO.:5 fragment able to reduce at least one of substrate phosphorylation by VEGF
receptor, substrate phosphorylation by PDGF receptor and substrate phosphorylation by VEGF
10 receptor and PDGF receptor, a SEQ ID NO.:5 analog able to reduce at least one of substrate phosphorylation by VEGF receptor, substrate phosphorylation by PDGF receptor and substrate phosphorylation by VEGF receptor and PDGF receptor and combination thereof, in the treatment of a disease associated with phosphorylation of VEGF receptor, phosphorylation of PDGF receptor, phosphorylation of a substrate mediated by a VEGF
?5 receptor, phosphorylation of a substrate mediated by a PDGF receptor and/or combination thereof.
In an additional aspect, the present invention relates to a compound selected from the group consisting of, SEQ ID NO.:5, a SEQ ID NO.:5 derivative, a SEQ ID NO.:5 fragment, a SEQ ID
30 NO.:5 analog and combination thereof, as well any PSP94 family member for treating a disease selected from diseases associated with (or mediated by); 1) angiogenesis, 2) VEGF
receptor phosphorylation, 3) PDGF receptor phosphorylation, 4) phosphorylation of a substrate mediated by a VEGF receptor, 5) phosphorylation of a substrate mediated by a PDGF receptor, 6) VEGF-mediated and/or VEGFR-mediated ERK phosphorylation 7) 35 PDGF-mediated and/or PDGFR-mediated ERK phosphorylation, 8) insufficient of poor protein (or RNA) expression from a gene having at least one Serum Response Element (SRE), 9) insufficient of poor protein (or RNA) expression from a gene having at least one NF-KB element; 10) insufficient of poor stimulation of ERK phosphorylation, 11) insufficient or poor stimulation of the MAPK/JNK pathway and any combinations thereof, the method may comprise administering a PSP94 family member (e.g., a drug or pharmaceutical composition comprising a PSP94 family member) to a patient in need thereof.
In yet an additional aspect, the present invention relates to a method (of treatment) and pharmaceutical compositions for treating a disease selected from diseases associated with (or mediated by); 1) angiogenesis, 2) VEGF receptor phosphorylation, 3) PDGF
receptor phosphorylation, 4) phosphorylation of a substrate mediated by a VEGF
receptor, 5) phosphorylation of a substrate mediated by a PDGF receptor, 6) VEGF-mediated and/or VEGFR-mediated ERK phosphorylation 7) PDGF-mediated and/or PDGFR-mediated ERK
phosphorylation, 8) ins,ufficient of poor protein (or RNA) expression from a gene having at least one Serum Response Element (SRE), 9) insufficient of poor protein (or RNA) expression from a gene having at least one N F-KB element; 10) insufficient of poor stimulation of ERK phosphorylation, 11) insufficient or poor stimulation of the MAPK/JNK
pathway and any combinations thereof, the method may comprise administering a family member (e.g., a drug or pharmaceutical composition comprising a PSP94 family member) to a patient in need thereof.
More particularly, the present invention provides a method of inhibiting angiogenesis in an individual in need thereof, the method may comprise, for example, administering to the individual a compound which may be selected from the group consisting of, a) SEQ ID NO.:5, b) a SEQ ID NO.:5 derivative able to reduce tube formation in an angiogenesis assay or able to reduce VEGF-mediated and/or VEGFR-mediated ERK
phosphorylation or able to reduce PDGF-mediated and/or PDGFR-mediated ERK
phosphorylation, c) a SEQ ID NO.:5 fragment able to reduce tube formation in an angiogenesis assay, or able to reduce VEGF-mediated and/or VEGFR-mediated ERK
phosphorylation or able to reduce PDGF-mediated and/or PDGFR-mediated ERK
phosphorylation, d) a SEQ ID NO.:5 analog able to reduce tube formation in an angiogenesis assay, or able to reduce VEG F-mediated and/or VEG FR-mediated ERK
phosphorylation or able to reduce PDGF-mediated and/or PDGFR-mediated ERK
phosphorylation, and;
e) combination of any one of a) through d) thereof.
?5 receptor, phosphorylation of a substrate mediated by a PDGF receptor and/or combination thereof.
In an additional aspect, the present invention relates to a compound selected from the group consisting of, SEQ ID NO.:5, a SEQ ID NO.:5 derivative, a SEQ ID NO.:5 fragment, a SEQ ID
30 NO.:5 analog and combination thereof, as well any PSP94 family member for treating a disease selected from diseases associated with (or mediated by); 1) angiogenesis, 2) VEGF
receptor phosphorylation, 3) PDGF receptor phosphorylation, 4) phosphorylation of a substrate mediated by a VEGF receptor, 5) phosphorylation of a substrate mediated by a PDGF receptor, 6) VEGF-mediated and/or VEGFR-mediated ERK phosphorylation 7) 35 PDGF-mediated and/or PDGFR-mediated ERK phosphorylation, 8) insufficient of poor protein (or RNA) expression from a gene having at least one Serum Response Element (SRE), 9) insufficient of poor protein (or RNA) expression from a gene having at least one NF-KB element; 10) insufficient of poor stimulation of ERK phosphorylation, 11) insufficient or poor stimulation of the MAPK/JNK pathway and any combinations thereof, the method may comprise administering a PSP94 family member (e.g., a drug or pharmaceutical composition comprising a PSP94 family member) to a patient in need thereof.
In yet an additional aspect, the present invention relates to a method (of treatment) and pharmaceutical compositions for treating a disease selected from diseases associated with (or mediated by); 1) angiogenesis, 2) VEGF receptor phosphorylation, 3) PDGF
receptor phosphorylation, 4) phosphorylation of a substrate mediated by a VEGF
receptor, 5) phosphorylation of a substrate mediated by a PDGF receptor, 6) VEGF-mediated and/or VEGFR-mediated ERK phosphorylation 7) PDGF-mediated and/or PDGFR-mediated ERK
phosphorylation, 8) ins,ufficient of poor protein (or RNA) expression from a gene having at least one Serum Response Element (SRE), 9) insufficient of poor protein (or RNA) expression from a gene having at least one N F-KB element; 10) insufficient of poor stimulation of ERK phosphorylation, 11) insufficient or poor stimulation of the MAPK/JNK
pathway and any combinations thereof, the method may comprise administering a family member (e.g., a drug or pharmaceutical composition comprising a PSP94 family member) to a patient in need thereof.
More particularly, the present invention provides a method of inhibiting angiogenesis in an individual in need thereof, the method may comprise, for example, administering to the individual a compound which may be selected from the group consisting of, a) SEQ ID NO.:5, b) a SEQ ID NO.:5 derivative able to reduce tube formation in an angiogenesis assay or able to reduce VEGF-mediated and/or VEGFR-mediated ERK
phosphorylation or able to reduce PDGF-mediated and/or PDGFR-mediated ERK
phosphorylation, c) a SEQ ID NO.:5 fragment able to reduce tube formation in an angiogenesis assay, or able to reduce VEGF-mediated and/or VEGFR-mediated ERK
phosphorylation or able to reduce PDGF-mediated and/or PDGFR-mediated ERK
phosphorylation, d) a SEQ ID NO.:5 analog able to reduce tube formation in an angiogenesis assay, or able to reduce VEG F-mediated and/or VEG FR-mediated ERK
phosphorylation or able to reduce PDGF-mediated and/or PDGFR-mediated ERK
phosphorylation, and;
e) combination of any one of a) through d) thereof.
12.
In accordance with the present invention, the compound may further comprise a-grouping for increasing the stability of the compound. Further in accordance with the present invention, the grouping may be, for example, an acetylaminomethyl moiety attached to a sulfur atom of a cysteine. The compound may be, for example, SEQ ID NO.:7.
Also in accordance with the present invention, the method may be used for treating cancer-associated angiogenesis or metastasis-associated angiogenesis.
In a further aspect, the present invention provides a pharmaceutical composition for treating a condition or a disease described herein, the pharmaceutical composition may.comprise;
a PSP94 family member, and;
a pharmaceutically acceptable carrier.
More particularly, the present invention relates to a pharmaceutical composition for treating angiogenesis or an ocular disease, the composition may comprise, for example, a compound selected from the group consisting of, SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce tube formation in an angiogenesis assay or able to reduce VEGF-mediated and/or VEGFR-mediated ERK phosphorylation or able to reduce PDGF-mediated and/or PDGFR-mediated ZO ERK phosphorylation; a SEQ ID NO.:5 fragment able to reduce tube formation in an angiogenesis assay or able to reduce VEGF-mediated and/or VEGFR-mediated ERK phosphorylation or able to reduce PDGF-mediated and/or PDGFR-mediated ERK phosphorylation; a SEQ ID NO.:5 analog able to reduce tube formation in an angiogenesis assay or able to reduce VEGF-mediated and/or ?5 VEGFR-mediated ERK phosphorylation or able to reduce PDGF-mediated and/or PDGFR-mediated ERK phosphorylation and combination thereof, and;
a pharmaceutically acceptable carrier.
The present invention also relates to the use of a PSP94 family member in the manufacture ~0 of a pharmaceutical composition or a drug for the treatment of one or more disease or condition described herein.
More particularly, the present invention relates to the use of a compound which may be selected, for example, from the group consisting of SEQ ID NO.:5, a SEQ ID
NO.:5 derivative 5 able to reduce tube formation in an angiogenesis assay or able to reduce VEGF-mediated and/or VEGFR-mediated ERK phosphorylation or able to reduce PDGF-mediated and/or PDGFR-mediated ERK phosphorylation, a SEQ ID NO.:5 fragment able to reduce tube formation in an angiogenesis assay or able to reduce VEGF-mediated and/or VEGFR-mediated ERK phosphorylation or able to reduce PDGF-mediated and/or PDGFR-mediated ERK phosphorylation, a SEQ ID NO.:5 analog able to reduce tube formation in an angiogenesis assay or able to reduce VEGF-mediated and/or VEGFR-mediated ERK
phosphorylation or able to reduce PDGF-mediated and/or PDGFR-mediated ERK
phosphorylation and combination thereof in the manufacture of a pharmaceutical composition for the treatment of angiogenesis.
Also more particularly the present invention relates to the use of a compound (or a pharmaceutical composition), which may be selected from the group consisting of SEQ ID
NO.:5, a SEQ ID NO.:5 derivative able to reduce at least one of substrate (ERK) phosphorylation by VEGF receptor, substrate (ERK) phosphorylation by PDGF
receptor and substrate phosphorylation by VEGF receptor and PDGF receptor, a SEQ ID NO.:5 fragment able to reduce at least one of substrate phosphorylation by VEGF receptor, substrate phosphorylation by PDGF receptor and substrate phosphorylation by VEGF
receptor and PDGF receptor, a SEQ ID NO.:5 analog able to reduce at least one of substrate phosphorylation by VEGF receptor, substrate phosphorylation by PDGF receptor and substrate phosphorylation by VEGF receptor and PDGF receptor and combination thereof, in the manufacture of a pharmaceutical composition for the treatment of a disease associated with phosphorylation of VEGF receptor, phosphorylation of PDGF receptor, phosphorylation of a substrate mediated by a VEGF receptor, phosphorylation of a substrate mediated by a PDGF receptor and combination thereof.
An example of a disease which may be treated by reducing (blocking) phosphorylation by ?5 VEGF and PDGF receptors is ocular neovascularization (retina) (Ozaki, H., et al., Am. J.
Pathol., 156 (2): 697-707, 2000; the entire content of which is incorporated herein by reference).
The present invention, in a further aspect thereof, relates to a method of treating a disease ;0 associated with substrate-phosphorylation by VEGF receptor, substrate-phosphorylation by PDGF receptor or substrate-phosphorylation by both VEGF and PDGF receptors, the method may comprise administering a compound (in a therapeutically effective amount) which is a PSP94 family member to an individual in need thereof.
6 In accordance with the present invention, the substrate may be a kinase such as Extracellular-signal-Regulated protein Kinases (ERK).
In accordance with the present invention, the compound may further comprise a-grouping for increasing the stability of the compound. Further in accordance with the present invention, the grouping may be, for example, an acetylaminomethyl moiety attached to a sulfur atom of a cysteine. The compound may be, for example, SEQ ID NO.:7.
Also in accordance with the present invention, the method may be used for treating cancer-associated angiogenesis or metastasis-associated angiogenesis.
In a further aspect, the present invention provides a pharmaceutical composition for treating a condition or a disease described herein, the pharmaceutical composition may.comprise;
a PSP94 family member, and;
a pharmaceutically acceptable carrier.
More particularly, the present invention relates to a pharmaceutical composition for treating angiogenesis or an ocular disease, the composition may comprise, for example, a compound selected from the group consisting of, SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce tube formation in an angiogenesis assay or able to reduce VEGF-mediated and/or VEGFR-mediated ERK phosphorylation or able to reduce PDGF-mediated and/or PDGFR-mediated ZO ERK phosphorylation; a SEQ ID NO.:5 fragment able to reduce tube formation in an angiogenesis assay or able to reduce VEGF-mediated and/or VEGFR-mediated ERK phosphorylation or able to reduce PDGF-mediated and/or PDGFR-mediated ERK phosphorylation; a SEQ ID NO.:5 analog able to reduce tube formation in an angiogenesis assay or able to reduce VEGF-mediated and/or ?5 VEGFR-mediated ERK phosphorylation or able to reduce PDGF-mediated and/or PDGFR-mediated ERK phosphorylation and combination thereof, and;
a pharmaceutically acceptable carrier.
The present invention also relates to the use of a PSP94 family member in the manufacture ~0 of a pharmaceutical composition or a drug for the treatment of one or more disease or condition described herein.
More particularly, the present invention relates to the use of a compound which may be selected, for example, from the group consisting of SEQ ID NO.:5, a SEQ ID
NO.:5 derivative 5 able to reduce tube formation in an angiogenesis assay or able to reduce VEGF-mediated and/or VEGFR-mediated ERK phosphorylation or able to reduce PDGF-mediated and/or PDGFR-mediated ERK phosphorylation, a SEQ ID NO.:5 fragment able to reduce tube formation in an angiogenesis assay or able to reduce VEGF-mediated and/or VEGFR-mediated ERK phosphorylation or able to reduce PDGF-mediated and/or PDGFR-mediated ERK phosphorylation, a SEQ ID NO.:5 analog able to reduce tube formation in an angiogenesis assay or able to reduce VEGF-mediated and/or VEGFR-mediated ERK
phosphorylation or able to reduce PDGF-mediated and/or PDGFR-mediated ERK
phosphorylation and combination thereof in the manufacture of a pharmaceutical composition for the treatment of angiogenesis.
Also more particularly the present invention relates to the use of a compound (or a pharmaceutical composition), which may be selected from the group consisting of SEQ ID
NO.:5, a SEQ ID NO.:5 derivative able to reduce at least one of substrate (ERK) phosphorylation by VEGF receptor, substrate (ERK) phosphorylation by PDGF
receptor and substrate phosphorylation by VEGF receptor and PDGF receptor, a SEQ ID NO.:5 fragment able to reduce at least one of substrate phosphorylation by VEGF receptor, substrate phosphorylation by PDGF receptor and substrate phosphorylation by VEGF
receptor and PDGF receptor, a SEQ ID NO.:5 analog able to reduce at least one of substrate phosphorylation by VEGF receptor, substrate phosphorylation by PDGF receptor and substrate phosphorylation by VEGF receptor and PDGF receptor and combination thereof, in the manufacture of a pharmaceutical composition for the treatment of a disease associated with phosphorylation of VEGF receptor, phosphorylation of PDGF receptor, phosphorylation of a substrate mediated by a VEGF receptor, phosphorylation of a substrate mediated by a PDGF receptor and combination thereof.
An example of a disease which may be treated by reducing (blocking) phosphorylation by ?5 VEGF and PDGF receptors is ocular neovascularization (retina) (Ozaki, H., et al., Am. J.
Pathol., 156 (2): 697-707, 2000; the entire content of which is incorporated herein by reference).
The present invention, in a further aspect thereof, relates to a method of treating a disease ;0 associated with substrate-phosphorylation by VEGF receptor, substrate-phosphorylation by PDGF receptor or substrate-phosphorylation by both VEGF and PDGF receptors, the method may comprise administering a compound (in a therapeutically effective amount) which is a PSP94 family member to an individual in need thereof.
6 In accordance with the present invention, the substrate may be a kinase such as Extracellular-signal-Regulated protein Kinases (ERK).
Therefore, the present invention also relates to a method of treating retinal vascularization by inhibiting VEGF receptor tyrosine kinase signal transduction, PDGF receptor tyrosine kinase signal transduction or both VEGF receptor tyrosine kinase signal transduction and PDGF
receptor tyrosine kinase signal transduction, which method comprises administering to a individual in need of such treatment a therapeutically effective amount of a PSP94 family member.
More particularly, the present invention provides a method of treating a disease associated with phosphorylation of VEGF receptor, b) phosphorylation of PDGF receptor, c) phosphorylation of a substrate mediated by a VEGF receptor, d) phosphorylation of a substrate mediated by a PDGF receptor and combination of any of a) through d) thereof, the method may comprise administering to an individual in need thereof, a compound which may be selected from the group consisting of SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce at least one of substrate phosphorylation by VEGF receptor, substrate phosphorylation by PDGF receptor and substrate phosphorylation by VEGF
receptor and PDGF receptor, a SEQ ID NO.:5 fragment able to reduce at least one of substrate phosphorylation by VEGF receptor, substrate phosphorylation by PDGF receptor and substrate phosphorylation by VEGF receptor and PDGF receptor and a SEQ ID
NO.:5 analog able to reduce at least one of substrate phosphorylation by VEGF receptor, substrate ?0 phosphorylation by PDGF receptor and substrate phosphorylation by VEGF
receptor and PDGF receptor.
In accordance with the present invention, the disease may be an ocular disease, such as, for example, ocular neovascularization.
?5 The invention further provides, in an additional aspect, a method of regulating, in a cell (in tissue culture (ex vivo), in a tissue, in a human (body), etc.), an abnormal activation of a molecule selected, for example, from the group of molecules (polypeptides) consisting of a VEGF receptor, a PDGF receptor, a downstream effector activated by a VEGF
receptor and 30 a downstream effector activated by a PDGF receptor, the method comprising contacting the cell with a PSP94 family member.
In accordance with the present invention, the abnormal activation of the VEGF
receptor may be, for example, an increase in the tyrosine kinase signal transduction activity of the VEGF
35 receptor. Further in accordance with the present invention, the abnormal activation of the VEGF receptor or the downstream effector activated by a VEGF receptor, may be promoted, for example by VEGF.
In accordance with the present invention, the abnormal activation of the PDGF
receptor may be, for example, an increase in the tyrosine kinase signal transduction activity of the PDGF
receptor. Further in accordance with the present invention, the abnormal activation of the PDGF receptor or the downstream effector activated by a PDGF receptor may be promoted, for example by PDGF.
Members of the PSP94 family (or PSP94 family member) comprises, for example, (SEQ ID NO.:1), a PSP94 fragment, a PSP94 derivative, a PSP94 analogue, PCK3145 (SEQ
ID NO.:5), a PCK3145 fragment, a PCK3145 derivative and a PCK3145 analogue. A
PCK3145 derivative may be, for example, as defined in SEQ ID NO.:7. PSP94 family members therefore also include, for example, SEQ ID NO.:2, SEQ ID NO.: 3, SEQ
ID NO.:4, SEQ ID NO.:6, as well as SEQ ID NO.: 9 to 98.
In accordance with the present invention, the member of the PSP94 family (PSP94 family member) may be selected, for example, from the group consisting of; a) SEQ ID
NO.:1, b) a SEQ ID NO.:1 derivative, c) a SEQ ID NO.:1 fragment, d) SEQ ID NO.:1 analogue, e) SEQ
ID NO.:5, f) a SEQ ID NO.:5 derivative, g) a SEQ ID NO.:5 fragment, h) a SEQ
ID NO.:5 analogue, i) SEQ ID NO.:7, and j) combination of any one of a) through i) thereof.
It is to be understood herein that peptide derivatives, fragments and analogues of the present invention may be chosen among those which have a desired biological activity.
Derivatives, fragments and analogues encompassed by the present invention are those which have one or more of the following biological activity, for examples, those which 1) inhibit or reduce 15 angiogenesis, 2) inhibit or reduce tubulogenesis, 3) inhibit or reduce phosphorylation of VEGF receptor, 4) inhibit or reduce phosphorylation of PDGF receptor, 5) inhibit or reduce phosphorylation of a substrate (e.g., ERK) mediated by a VEGF receptor (e.g., reduces VEGF-mediated and/or VEGFR-mediated ERK phosphorylation) 6) inhibit or reduce phosphorylation of a substrate (e.g., ERK) mediated by a PDGF receptor (e.g., reduces @ PDGF-mediated and/or PDGFR-mediated ERK phosphorylation), 7) inhibit or reduce VEGF-mediated ERK phosphorylation, 8) inhibit or reduce PDGF-mediated ERK
phosphorylation, 9) increase or stimulate expression from a gene having at least one Serum Response Element (SRE), 10) increase or stimulate expression from a gene having at least one NF-KB element, 11) increase or stimulate the MAPK/JNK pathway or 12) increase or stimulate apoptosis.
receptor tyrosine kinase signal transduction, which method comprises administering to a individual in need of such treatment a therapeutically effective amount of a PSP94 family member.
More particularly, the present invention provides a method of treating a disease associated with phosphorylation of VEGF receptor, b) phosphorylation of PDGF receptor, c) phosphorylation of a substrate mediated by a VEGF receptor, d) phosphorylation of a substrate mediated by a PDGF receptor and combination of any of a) through d) thereof, the method may comprise administering to an individual in need thereof, a compound which may be selected from the group consisting of SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce at least one of substrate phosphorylation by VEGF receptor, substrate phosphorylation by PDGF receptor and substrate phosphorylation by VEGF
receptor and PDGF receptor, a SEQ ID NO.:5 fragment able to reduce at least one of substrate phosphorylation by VEGF receptor, substrate phosphorylation by PDGF receptor and substrate phosphorylation by VEGF receptor and PDGF receptor and a SEQ ID
NO.:5 analog able to reduce at least one of substrate phosphorylation by VEGF receptor, substrate ?0 phosphorylation by PDGF receptor and substrate phosphorylation by VEGF
receptor and PDGF receptor.
In accordance with the present invention, the disease may be an ocular disease, such as, for example, ocular neovascularization.
?5 The invention further provides, in an additional aspect, a method of regulating, in a cell (in tissue culture (ex vivo), in a tissue, in a human (body), etc.), an abnormal activation of a molecule selected, for example, from the group of molecules (polypeptides) consisting of a VEGF receptor, a PDGF receptor, a downstream effector activated by a VEGF
receptor and 30 a downstream effector activated by a PDGF receptor, the method comprising contacting the cell with a PSP94 family member.
In accordance with the present invention, the abnormal activation of the VEGF
receptor may be, for example, an increase in the tyrosine kinase signal transduction activity of the VEGF
35 receptor. Further in accordance with the present invention, the abnormal activation of the VEGF receptor or the downstream effector activated by a VEGF receptor, may be promoted, for example by VEGF.
In accordance with the present invention, the abnormal activation of the PDGF
receptor may be, for example, an increase in the tyrosine kinase signal transduction activity of the PDGF
receptor. Further in accordance with the present invention, the abnormal activation of the PDGF receptor or the downstream effector activated by a PDGF receptor may be promoted, for example by PDGF.
Members of the PSP94 family (or PSP94 family member) comprises, for example, (SEQ ID NO.:1), a PSP94 fragment, a PSP94 derivative, a PSP94 analogue, PCK3145 (SEQ
ID NO.:5), a PCK3145 fragment, a PCK3145 derivative and a PCK3145 analogue. A
PCK3145 derivative may be, for example, as defined in SEQ ID NO.:7. PSP94 family members therefore also include, for example, SEQ ID NO.:2, SEQ ID NO.: 3, SEQ
ID NO.:4, SEQ ID NO.:6, as well as SEQ ID NO.: 9 to 98.
In accordance with the present invention, the member of the PSP94 family (PSP94 family member) may be selected, for example, from the group consisting of; a) SEQ ID
NO.:1, b) a SEQ ID NO.:1 derivative, c) a SEQ ID NO.:1 fragment, d) SEQ ID NO.:1 analogue, e) SEQ
ID NO.:5, f) a SEQ ID NO.:5 derivative, g) a SEQ ID NO.:5 fragment, h) a SEQ
ID NO.:5 analogue, i) SEQ ID NO.:7, and j) combination of any one of a) through i) thereof.
It is to be understood herein that peptide derivatives, fragments and analogues of the present invention may be chosen among those which have a desired biological activity.
Derivatives, fragments and analogues encompassed by the present invention are those which have one or more of the following biological activity, for examples, those which 1) inhibit or reduce 15 angiogenesis, 2) inhibit or reduce tubulogenesis, 3) inhibit or reduce phosphorylation of VEGF receptor, 4) inhibit or reduce phosphorylation of PDGF receptor, 5) inhibit or reduce phosphorylation of a substrate (e.g., ERK) mediated by a VEGF receptor (e.g., reduces VEGF-mediated and/or VEGFR-mediated ERK phosphorylation) 6) inhibit or reduce phosphorylation of a substrate (e.g., ERK) mediated by a PDGF receptor (e.g., reduces @ PDGF-mediated and/or PDGFR-mediated ERK phosphorylation), 7) inhibit or reduce VEGF-mediated ERK phosphorylation, 8) inhibit or reduce PDGF-mediated ERK
phosphorylation, 9) increase or stimulate expression from a gene having at least one Serum Response Element (SRE), 10) increase or stimulate expression from a gene having at least one NF-KB element, 11) increase or stimulate the MAPK/JNK pathway or 12) increase or stimulate apoptosis.
This invention also relates to the regulation (either directly or indirectly) of matrix metalloproteinases (MMPs), (e.g., MMP-9, MMP-2, MT1 -MMP) by PSP94 family members.
More particularly, the present invention relates to the use of a PSP94 family member for the treatment of a condition related to the activity or expression of MMPs or pro-MMPs.
In another aspect, the present invention provides a compound and the use of a compound which is a member of the PSP94 family in the treatment of a condition related, for example, to the activity or to the expression of a polypeptide which may be, for example, selected from the group consisting of matrix metalloproteinases and pro-matrix metal lop rotei nases.
In another aspect, the present invention provides a compound having the biological activity of PCK3145 (SEQ ID NO.:5) which may comprise or consist essentially of the amino acid sequence identified in SEQ ID NO.:5 and may further comprise a stabilizing group (e.g. a group increasing in vivo stability of the compound or polypeptide without affecting l5 deleteriously the biological activity of the compound or polypeptide) covalently attached to an amino acid of the (SEQ ID NO.:5) sequence.
The present invention also relates to prevention of cancer progression (e.g., propagation) and/or metastasis by a PSP94 family member. Prevention of cancer progression and/or ?0 metastasis may be effected by PSP94 by regulating, for example, cellular adhesion.and/or migration.
The present invention further relates to the regulation of protein secretion from a cell by a PSP94 family member. The present invention further provides a mean to control cellular Rho ?5 GTPase levels (e.g. RhoA) and activity by contacting a cell with a PSP94 family member. In accordance with the present invention, the PSP94 family member may further be used to control activation of Rho GTPase downstream effectors.
The present invention, in one aspect thereof, provides a method of preventing, inhibiting or 30 suppressing cell adhesion in a mammal which may comprise the step of administering to the mammal a compound (or pharmaceutical composition comprising a compound) selected from the group consisting of a) SEQ ID NO.:5, b) a SEQ ID NO.:5 derivative able to reduce (i.e., reducing) cell adhesion or able to induce (i.e., inducing) shedding of an integrin from the cell surface, c) a SEQ ID NO.:5 fragment able to reduce cell adhesion or able to induce shedding 35 of an integrin from the cell surface, d) a SEQ ID NO.:5 analog able to reduce cell adhesion or able to induce shedding of an integrin from the cell surface, and e) combination of any one of a) through d) thereof or any other PSP94 family member.
More particularly, the present invention relates to the use of a PSP94 family member for the treatment of a condition related to the activity or expression of MMPs or pro-MMPs.
In another aspect, the present invention provides a compound and the use of a compound which is a member of the PSP94 family in the treatment of a condition related, for example, to the activity or to the expression of a polypeptide which may be, for example, selected from the group consisting of matrix metalloproteinases and pro-matrix metal lop rotei nases.
In another aspect, the present invention provides a compound having the biological activity of PCK3145 (SEQ ID NO.:5) which may comprise or consist essentially of the amino acid sequence identified in SEQ ID NO.:5 and may further comprise a stabilizing group (e.g. a group increasing in vivo stability of the compound or polypeptide without affecting l5 deleteriously the biological activity of the compound or polypeptide) covalently attached to an amino acid of the (SEQ ID NO.:5) sequence.
The present invention also relates to prevention of cancer progression (e.g., propagation) and/or metastasis by a PSP94 family member. Prevention of cancer progression and/or ?0 metastasis may be effected by PSP94 by regulating, for example, cellular adhesion.and/or migration.
The present invention further relates to the regulation of protein secretion from a cell by a PSP94 family member. The present invention further provides a mean to control cellular Rho ?5 GTPase levels (e.g. RhoA) and activity by contacting a cell with a PSP94 family member. In accordance with the present invention, the PSP94 family member may further be used to control activation of Rho GTPase downstream effectors.
The present invention, in one aspect thereof, provides a method of preventing, inhibiting or 30 suppressing cell adhesion in a mammal which may comprise the step of administering to the mammal a compound (or pharmaceutical composition comprising a compound) selected from the group consisting of a) SEQ ID NO.:5, b) a SEQ ID NO.:5 derivative able to reduce (i.e., reducing) cell adhesion or able to induce (i.e., inducing) shedding of an integrin from the cell surface, c) a SEQ ID NO.:5 fragment able to reduce cell adhesion or able to induce shedding 35 of an integrin from the cell surface, d) a SEQ ID NO.:5 analog able to reduce cell adhesion or able to induce shedding of an integrin from the cell surface, and e) combination of any one of a) through d) thereof or any other PSP94 family member.
In accordance with the present invention the method may be used for preventing, inhibiting or suppressing, for example, cell-adhesion associated inflammation, a cell-adhesion associated immune or autoimmune response, etc. Further in accordance with the present invention, the method may be used to treat or prevent a disease selected from the group consisting of metastasis, cancer (tumor) progression, arthritis, psoriasis, transplantation rejection, multiple sclerosis, diabetes, inflammatory bowel disease or any disease for which prevention, inhibition or suppression of cell adhesion is desired or needed.
The present invention further provides in an additional aspect, the use of a compound selected from the group consisting of a) SEQ ID NO.: 5, b) a SEQ ID NO.:5 derivative able to reduce (i.e., reducing) cell adhesion (in vitro) or able to induce (i.e., inducing) shedding of an integrin from the cell surface, c) a SEQ ID NO.:5 fragment able to reduce cell adhesion (in vitro)or able to induce shedding of an integrin from.the cell surface, d) a SEQ ID NO.:5 analog able to reduce cell adhesion (in vitro) or able to induce shedding of an integrin from the cell surface, and e) combination of any one of a) through d) thereof or any other PSP94 family member, in the prevention inhibition or suppression of cell adhesion in a mammal.
In accordance with the present invention, the adhesion may be an adhesion mediated though (with the help of) an integrin. Further in accordance with the present invention, the integrin may be, for example, CD44.
The present invention provides, in an additional aspect thereof, a method of preventing, inhibiting or suppressing cell migration in a mammal which may comprise the step of ?5 administering to the mammal, a compound (or pharmaceutical composition comprising a compound) selected from the group consisting of a) SEQ ID NO.:5, b) a SEQ ID
NO.:5 derivative able to reduce cell migration (in vitro), c) a SEQ ID NO.:5 fragment able to reduce cell migration (in vitro); d) a SEQ ID NO.:5 analog able to reduce cell migration (in vitro), and e) combination of any one of a) through d) thereof or any other PSP94 family member.
~0 The present invention further relates to the use of a compound selected from the group consisting of a) SEQ ID NO.:5, b) a SEQ ID NO.:5 derivative able to reduce (i.e., reducing) cell migration (in an in vitro assay), c) a SEQ ID NO.:5 fragment able to reduce cell migration (for example, in a migration assay as described herein, (i.e., in vitro)), d) a SEQ ID NO.:5 5 analog able to reduce cell migration, and e) combination of any one of a) through d) thereof or any other PSP94 family member, in the prevention inhibition or suppression of cell migration in a mammal.
The present invention further provides in an additional aspect, the use of a compound selected from the group consisting of a) SEQ ID NO.: 5, b) a SEQ ID NO.:5 derivative able to reduce (i.e., reducing) cell adhesion (in vitro) or able to induce (i.e., inducing) shedding of an integrin from the cell surface, c) a SEQ ID NO.:5 fragment able to reduce cell adhesion (in vitro)or able to induce shedding of an integrin from.the cell surface, d) a SEQ ID NO.:5 analog able to reduce cell adhesion (in vitro) or able to induce shedding of an integrin from the cell surface, and e) combination of any one of a) through d) thereof or any other PSP94 family member, in the prevention inhibition or suppression of cell adhesion in a mammal.
In accordance with the present invention, the adhesion may be an adhesion mediated though (with the help of) an integrin. Further in accordance with the present invention, the integrin may be, for example, CD44.
The present invention provides, in an additional aspect thereof, a method of preventing, inhibiting or suppressing cell migration in a mammal which may comprise the step of ?5 administering to the mammal, a compound (or pharmaceutical composition comprising a compound) selected from the group consisting of a) SEQ ID NO.:5, b) a SEQ ID
NO.:5 derivative able to reduce cell migration (in vitro), c) a SEQ ID NO.:5 fragment able to reduce cell migration (in vitro); d) a SEQ ID NO.:5 analog able to reduce cell migration (in vitro), and e) combination of any one of a) through d) thereof or any other PSP94 family member.
~0 The present invention further relates to the use of a compound selected from the group consisting of a) SEQ ID NO.:5, b) a SEQ ID NO.:5 derivative able to reduce (i.e., reducing) cell migration (in an in vitro assay), c) a SEQ ID NO.:5 fragment able to reduce cell migration (for example, in a migration assay as described herein, (i.e., in vitro)), d) a SEQ ID NO.:5 5 analog able to reduce cell migration, and e) combination of any one of a) through d) thereof or any other PSP94 family member, in the prevention inhibition or suppression of cell migration in a mammal.
The present invention therefore provides a treatment of a disease for which prevention, inhibition or suppression of cell migration is desired or needed.
In an additional aspect, the present invention relates to a method of inhibiting or lowering protein secretion in a mammal, which may comprise the step of.administering to the mammal a compound (a pharmaceutical composition comprising a compound) which may be selected from the group consisting of a) SEQ ID NO.: 5, b) a SEQ ID NO.:5 derivative able to reduce (i.e., reducing) secretion of a protein (for example in a cell base assay described herein), c) a SEQ ID NO.:5 fragment able to reduce secretion of a protein, d) a SEQ ID NO.:5 analog able to reduce secretion of a protein, and e) combination of any one of a) through d) thereof or any other PSP94 family member.
"Secretion of a protein" or "protein secretion" is to be understood herein as the process in which a protein travels from within the intracellular space out to the extra-cellular environment.
In accordance with the present invention, the secretion of aprotein may be for example, a constitutive secretion or an induced secretion, etc. Further in accordance with the present ?0 invention, the protein may be selected, for example, from the group of gelatinases or from the group consisting of a matrix metalloproteinase and a pro-matrix metalloproteinase. The matrix metalloproteinase may be MMP-2. The pro-matrix metalloproteinase may be pro-MMP-2. The matrix metalloproteinase may also be MMP-9 and the pro-matrix metalloproteinase may be pro-MMP-9.
?5 In yet a further aspect the present invention relates to the use of a compound selected, for example, from the group consisting of a) SEQ ID NO.: 5, b) a SEQ ID NO.:5 derivative able to reduce secretion of a protein, c) a SEQ ID NO.:5 fragment able to reduce secretion of a protein, d) a SEQ ID NO.:5 analog able to reduce secretion of a protein, and e) combination ;0 of any one of a) through d) thereof or any other PSP94 family member, in the inhibition or lowering of protein secretion in a mammal.
The present invention therefore provides a treatment of a disease for which inhibition or lowering of protein secretion is desired or needed.
In an additional aspect, the present invention provides a method of inducing RhoGTPase expression in a mammal comprising the step of administering to the mammal a compound which may be selected from the group consisting of a) SEQ ID NO.:5, b) a SEQ
ID NO.:5 derivative able to induce RHoA protein, gene or mRNA expression in a cell based assay, c) a SEQ ID NO.:5 fragment able to induce RHoA protein, gene or mRNA expression in a cell based assay, d) a SEQ ID NO.:5 analog able to induce RHoA protein, gene or mRNA
expression in a cell based assay, and; e) combination of any one of a) through d) thereof or any other PSP94 family member.
In yet an additional aspect, the present invention relates to the use of a compound selected, for example, from the group consisting of a) SEQ ID NO.: 5, b) a SEQ ID NO.:5 derivative able to induce RHoA protein, gene or mRNA expression in a cell based assay, c) a SEQ ID
NO.:5 fragment able to induce RHoA protein, gene or mRNA expression in a cell based assay, d) a SEQ ID NO.:5 analog able to induce RHoA protein, gene or mRNA
expression in a cell based assay, and e) combination of any one of a) through d) thereof or any other PSP94 family member, in the induction of RhoGTPase expression in a mammal.
In accordance with the present invention, the RhoGTPase may be, for example, RhoA.
In another aspect the present invention relates to the use of a compound selected, for example, from the group consisting of a) SEQ ID NO.: 5, b) a SEQ ID NO.:5 derivative c) a SEQ ID NO.:5 fragment, d) a SEQ ID NO.:5 analog, and e) combination of any one of a) through d) thereof or any other PSP94 family member in the manufacture of a pharmaceutical composition for inducing RhoGTPase expression in a mammal, for preventing, inhibiting or suppressing cell adhesion in a mammal, for preventing, inhibiting or suppressing cell migration in a mammal or for inhibiting or lowering protein secretion in a Z5 mammal.
The present invention therefore provides a treatment of a disease for which induction of RhoGTPase is desired or needed.
In yet another aspect the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a compound selected, for example, from the group consisting of a) SEQ ID NO.: 5, b) a SEQ ID NO.:5 derivative c) a SEQ ID
NO.:5 fragment, d) a SEQ ID NO.:5 analog, and e) combination of any one of a) through d) thereof or any other PSP94 family member for inducing RhoGTPase expression in a mammal, for preventing, inhibiting or suppressing cell adhesion in a mammal, for preventing, inhibiting or suppressing cell migration in a mammal or for inhibiting or lowering protein secretion in a mammal.
In a further aspect the present invention relates to a compound selected, for example, from the group consisting of a) SEQ ID NO.: 5, b) a SEQ ID NO.:5 derivative c) a SEQ ID NO.:5 fragment, d) a SEQ ID NO.:5 analog, and e) combination of any one of a) through d) thereof or any other PSP94 family member for inducing RhoGTPase expression in a mammal, for preventing, inhibiting or suppressing cell adhesion in a mammal, for preventing, inhibiting or suppressing cell migration in a mammal or for inhibiting or lowering protein secretion in a mammal.
[0 In an additional aspect, the present invention relates to a compound member of the PSP94 family for use in the treatment of a condition related to the activity or the expression of a protease (e.g., a serine protease). The condition may happen through the activity or expression of the protease itself or onto another factor (e.g., a factor which may be part of.a cascade of event activated by the protease) which may be responsible for the condition.
In another aspect, the present invention provides a compound member of the PSP94 family for use in the treatment of a condition (state, disease) related, for example, to the activity or to the expression of a polypeptide which may be, for example, selected from the group consisting of matrix metalloproteinases and pro-matrix metalloproteinases.
?0 The present invention therefore provides a treatment of a disease for which reduction in the levels or activity of a matrix metalloproteinases or pro-matrix metalloproteinases is desired or needed. More particularly, diseases for which circulating (in the blood, or other bodily fluid) levels of a matrix metalloproteinases or pro-matrix metalloproteinases needs to be reduced ?5 are encompassed by the present invention.
Therefore, this invention also relates to the regulation (either directly or indirectly) of matrix metalloproteinases (MMPs), (e.g., MMP-9, MMP-2, MT1-MMP, etc.) by PSP94 family members. More particularly, the present invention relates to the use of a PSP94 family 30 member for the treatment of a condition related to the activity or expression of MMPs or pro-MMPs and/or to antagonize MMPs or pro-MMPs mediated cellular events (e.g., intracellular transduction mechanisms).
PSP94, PSP94 derivatives, PCK3145, PCK3145 derivatives, fragments, analogues and 35 homologues thereof may therefore find utility in cancer treatment, wound healing, anti-angiogesis, anti-inflammation, anti-osteoarthritis, inhibition of hair growth, reduction of degradation of some cytokine (e.g., IFN-beta) as well as for skin treatment (e.g., prevention of blistering photo-aging, psoriasis), wound healing, tissue remodeling, pulmonary fibrosis, etc More particularly, the member of the PSP94 family (PSP94 family member) may be selected, for example, from the group consisting of;
a)SEQIDNO.:1, b) a SEQ ID NO.:1 derivative which may be able to reduce (in a tissue, a cell or cell environment (e.g., extracellular environment)) the activity or the level of expression of a polypeptide selected from the group consisting of a pro-matrix metalloproteinase and a matrix metalloproteinase (e.g., MMP-2 and/or pro-MMP-2, MMP-9 and/or pro-MMP-9, etc.), c) a SEQ ID NO.:1 fragment which may be able to reduce the activity or the level of expression of a polypeptide selected from the group consisting of a pro-matrix metalloproteinase and a matrix metalloproteinase (e.g., MMP-2 and/or pro-MMP-2, MMP-9 and/or pro-MMP-9, etc.), d) SEQ ID NO.:1 analogue which may be able to reduce the activity or the level of expression of a polypeptide selected from the group consisting of a pro-matrix metalloproteinase and a matrix metalloproteinase (e.g., MMP-2 and/or pro-MMP-2, MMP-9 and/or pro-MMP-9, etc.), e) SEQ ID NO.:5, f) a SEQ ID NO.:5 derivative which may be able to reduce the activity or the level of expression of a polypeptide selected from the group consisting of a pro-matrix metalloproteinase and a matrix metalloproteinase (e.g., MMP-2 and/or pro-MMP-2, MMP-9 and/or pro-MMP-9, etc.), ?5 g) a SEQ ID NO.:5 fragment which may be able to reduce the activity or the level of expression of a polypeptide selected from the group consisting of a pro-matrix metalloproteinase and a matrix metalloproteinase (e.g., MMP-2 and/or pro-MMP-2, MMP-9 and/or pro-MMP-9, etc.), h) a SEQ ID NO.:5 analogue which may be able to reduce the activity or the level ~0 of expression of a polypeptide selected from the group consisting of a pro-matrix metalloproteinase and a matrix metalloproteinase (e.g., MMP-2 and/or pro-MMP-2, MMP-9 and/or pro-MMP-9, etc.), i) SEQ ID NO.:7, and j) combination of any one of a) through i) thereof.
In a further aspect, the present invention provides the use of a PSP94 family member for the treatment of a condition related to the expressionor related to the (e.g., biological, enzymatic) activity of a polypeptide which may be selected, for example, from the group consisting of matrix metalloproteinases and pro-matrix metalloproteinases.
In yet a further aspect, the present invention relates to the use of a PSP94 family member for the manufacture of a medicament (or pharmaceutical composition) for the treatment of a condition related to the expression or activity of a polypeptide which may be, for example, selected from the group consisting of matrix metalloproteinases and pro-matrix metalloproteinases.
In accordance with the present invention, the condition may be selected from the group consisting of angiogenesis, inflammation, atheroscelerotic plaque rupture, skin disease, uncontrolled tissue remodeling and pulmonary fibrosis or any other condition or utility described herein.
In yet another aspect, the present invention relates to the use of a PSP94 family member for reducing or controlling the development or spreading of metastasis or metastatic cancer (i.e, cancer progression to other (secondary) sites or spreading of tumor cells to other sites) other than skeletal metastasis.
In another aspect, the present invention relates to the use of a PSP94 family member for the promotion of wound healing, for reducing (inhibiting) angiogenesis, for reducing (preventing) inflammation, for preventing atheroscelerotic plaque rupture, for skin treatment, for treating osteoarthritis, for treating pulmonary fibrosis or for the inhibition of (unwanted) hair growth.
In a further aspect, the present invention provides a pharmaceutical composition for treating a condition which may be related to the activity and/or to the expression (level) of a polypeptide, which may be, selected from the group consisting of matrix metalloproteinases and pro-matrix metalloproteinases, the pharmaceutical composition may comprise;
a PSP94 family member as defined herein, and;
a pharmaceutically acceptable carrier.
In yet a further aspect, the present invention provides a method for treating a patient having a condition related to the activity and/or expression of a polypeptide selected from the group consisting of matrix metalloproteinases and pro-matrix metalloproteinases, the method comprising administering to the patient a compound which is a member of the PSP94 family.
In another aspect, the present invention relates to a method of treating a patient having a metastatic cancer or a metastasis other than skeletal metastasis, the method comprising administering to the patient a PSP94 family member.
In an additional aspect, the present invention relates to a matrix metalloproteinase regulation drug and/or a pro-matrix metalloproteinase regulation drug comprising a PSP94 family member.
In another aspect, the present invention provides a compound able to reduce the expression or activity of a polypeptide selected from the group consisting of a matrix metalloproteinases and a pro-matrix metalloproteinases, the compound may comprise or consist essentially of the amino acid sequence identified in SEQ ID NO.:5 and may further comprise a stabilizing group (e.g. a group increasing in vivo stability of the compound or polypeptide without affecting deleteriously the biological activity of the compound or polypeptide) covalently attached to an amino acid of the (SEQ ID NO.:5) sequence.
In accordance with the present invention the group may be, for example, an acetylaminomethyl group attached to a sulfur atom of a cysteine or a polyethylene glycol (PEG) group attached to at least one amino acid of the sequence or any other modification which improves a desired property (e.g., stability) of the compound/polypeptide.
In yet another aspect the present invention relates to a compound selected, for example, from the group consisting of a) SEQ ID NO.: 5, b) a SEQ ID NO.:5 derivative c) a SEQ ID
NO.:5 fragment, d) a SEQ ID NO.:5 analog, and e) combination of any one of a) through d) ?5 thereof or any other PSP94 family member for controling (reducing) protein secretion or for reducing the levels of a matrixmetalloproteinase or pro-matrixmetalloproteinase levels in a mammal in need thereof.
In a further aspect, the present invention provides a method for evaluating the efficacy of a ,0 treatment with a PSP94 family member in a patient having a metastatic cancer or metastasis, the method may comprise, for example, the steps of a) collecting a serum sample from the patient after treatment of the patient with a PSP94 family member;
b) measuring the (serum) levels of a polypeptide which may be selected from the 5 group consisting of MMP-9.and pro-MMP-9 in the sample obtained in step a) and;
c) comparing measured levels of step b) with another MMP-9 and/or pro-MMP-9 level selected from the group consisting of levels measured from a normal individual, standard levels or levels measured before treatment of the individual.
The method may also comprise the step of establishing the clinical outcome of the patient based on the comparison of the measured levels.
In accordance with the present invention, the method for evaluating the efficacy of a PSP94 treatment may also measure any other parameters which might correlate with the level of expression of the polypeptide (MMP-9 and/or pro-MMP-9, MMP-2 and/or pro-MMP-2) such as for example, RNA levels.
In accordance with the present invention, the matrix metalloproteinase may be, for example, MMP-2 or may be MMP-9 or any other MMPs. Also in accordance with the present invention, the pro-matrix metalloproteinase may be, for example, pro- MMP-2 or may be pro-MMP-9 or any other pro-MMPs.
More particularly, the present invention relates to a method of inhibiting angiogenesis in an ?0 individual in need thereof, the method comprising administering to the individual a compound selected from the group consisting of, SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce VEGF-induced VEGFR phosphorylation in an in vitro assay, 15 a SEQ ID NO.:5 fragment able to reduce VEGF-induced VEGFR phosphorylation in an in vitro assay, a SEQ ID NO.:5 analog able to reduce VEGF-induced VEGFR phosphorylation in an in vitro assay, and;
combination of any one of a) through d) thereof.
In accordance with the present invention, the compound may further comprise a grouping for increasing the stability of the compound. The grouping may be, for example, an acetylaminomethyl moiety attached to a sulfur atom of a cysteine.
The present invention also relates to a method of treating a mammal having ocular neovascularization or inflammation, the method may comprise administering to the mammal a compound selected from the group consisting of;
SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce VEGF-induced VEGFR phosphorylation in an in vitro assay, a SEQ ID NO.:5 fragment able to reduce VEGF-induced VEGFR phosphorylation in an in vitro assay, a SEQ ID NO.:5 analog able to reduce VEGF-induced VEGFR phosphorylation in an in vitro assay, and;
combination of any one of a) through d) thereof.
l0 Additionally the present invention relates to a pharmaceutical composition for treating angiogenesis, ocular neovascularization or inflammation, the composition may comprise a compound selected from the group consisting of SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce VEGF-induced VEGFR phosphorylation in an in vitro assay, a SEQ ID NO.:5 fragment able to reduce VEGF-induced VEGFR
l5 phosphorylation in an in vitro assay, a SEQ ID NO.:5 analog able to reduce VEG F-induced VEGFR phosphorylation in an in vitro assay and combination thereof, and;
a pharmaceutically acceptable carrier.
?0 In addition, the present invention relates to a method of preventing cancer progression in a mammal in need thereof, the method may comprise administering to the mammal a compound selected from the group consisting of;
SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or ?5 able to reduce the level of expression of MMP-9 in an in vitro assay, a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
30 combination of any one of a) through d) thereof.
The present invention also relates in a further aspect to a method of preventing metastasis in a mammal in need thereof, the method may comprise administering to the mammal a compound selected from the group consisting of;
35 SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
combination of any one of a) through d) thereof.
The present invention further relates to a method of treating a patient having a metastatic cancer or metastasis other than skeletal metastasis, the method may comprise administering to the patient a compound selected from the group consisting of SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
combination of any one of a) through d) thereof.
The present invention further relates to a pharmaceutical composition for preventing 10 metastasis in a mammal in need thereof, the pharmaceutical composition may comprise a compound selected from the group consisting of;
SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, ?5 a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
combination of any one of a) through d) thereof and:
30 a pharmaceutically acceptable carrier.
The present invention also relates to a pharmaceutical composition for preventing cancer progression in a mammal in need thereof, the pharmaceutical composition may comprise a compound selected from the group consisting of;
35 SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
combination of any one of a) through d) thereof and:
a pharmaceutically acceptable carrier.
Additionnally, the present invention relates to a pharmaceutical composition for treating metastatic cancer or metastasis other than skeletal metastasis in a mammal in need thereof, [0 the pharmaceutical composition may comprise a compound selected from the group consisting of;
SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, [5 a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expressionof MMP-9 in an in vitro assay, a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
combination of any one of a) through d) thereof and:
?0 a pharmaceutically acceptable carrier.
The present invention also provides a compound able to inhibit angiogenesis, the compound may consist essentially of the amino acid sequence identified in SEQ ID NO.:5 and may further comprise a stabilizing group covalently attached, for example, to an amino acid of the >_5 sequence.
The stabilizing group may be, for example, an acetylaminomethyl moiety attached to a sulfur atom of a cysteine. The compound may have, for example, the composition defined in SEQ
ID NO.:7 As used herein, "VEGF' means vascular endothelial growth factor and VEGFR or VEGF-R
means vascular endothelial growth factor receptor and includes VEGFR-2 which means endothelial growth factor receptor type-2.
As used herein, "PDGF' means platelet-derived growth factor and PDGFR or PDGF-R
means platelet-derived growth factor receptor.
A "PSP94 family member" or "a member of the PSP94 family" is understood herein as any polypeptide originating from PSP94. For example, "PSP94 family members" may comprise wild type PSP94 (SEQ ID NO.:1) a PSP94 fragment, a PSP94 derivative, a PSP94 analogue, PCK3145 (SEQ ID NO.:5), a PCK3145 fragment, a PCK3145 derivative (SEQ ID
NO.:7), a PCK3145 analogue, etc. PSP94 family members therefore also include, for example, SEQ ID
NO.:2, SEQ ID NO.: 3, SEQ ID NO.:4, SEQ ID NO.:6, as well as SEQ ID NO.: 9 to 98.
A"fragment" is to be understood herein as a polypeptide originating from a portion of an original or parent sequence. Fragments encompass polypeptides having truncations of one or more amino acids, wherein the truncation may originate from the amino terminus (N-terminus), carboxy terminus (C-terminus), or from the interior of the protein.
A fragment may comprise the same sequence as the corresponding portion of the original sequence. For example, SEQ ID NO.: 4, SEQ ID NO.: 5 and SEQ ID NO.: 6 fall into the definition of "a PSP94 fragmenY'; when considering PSP94 (SEQ ID NO.:1) as an original sequence.
A "derivative" is to be understood herein as a polypeptide originating from an original sequence or from a portion of an original sequence and which may comprise one or more modification; for example, one or more modification in the amino acid sequence (e.g., an amino acid addition, deletion, insertion, substitution etc.), one or more modification in the 10 backbone or side-chain of one or more amino acid, or an addition of a group or another molecule to one or more amino acids (side-chains or backbone). For example, SEQ ID NO.:
2, SEQ ID NO.: 3 and SEQ ID NO.: 7 fall into the definition of "a PSP94 derivative"; when considering PSP94 (SEQ ID NO.:1) as an original sequence.
?5 It is to be understood herein that SEQ ID NO.: 7 may fall into the definition of "a PCK3145 derivative" or "SEQ ID NO.:5 derivative) when considering PCK3145 (SEQ ID
NO.:5) as an original sequence. The addition of polyethylene glycol group (i.e., pegylation) to PCK3145 (SEQ ID NO.:5 or SEQ ID NO.: 7) also falls within the definition of "a PCK3145 derivative".
30 In accordance with the present invention the SEQ ID NO.:1 fragment may be selected, for example, from the group consisting of SEQ ID NO.:4 and SEQ ID NO.:6.
Also in accordance with the present invention the SEQ ID NO.:1 derivative may be selected, for example, from the group consisting of SEQ ID NO.:2 and SEQ ID NO.:3.
An "analogue" is to be understood herein as a molecule having a biological activity and chemical structure similar to that of a polypeptide described herein. An "analogue" may have sequence similarity with that of an original sequence or a portion of an original sequence and may also have a modification of its structure as discussed herein. For example, an "analogue" may have at least 90 % sequence similarity with an original sequence or a portion of an original sequence. An "analogue" may also have, for example; at least 70 % or even 50 % sequence similarity (or less, i.e., at least 40%) with an original sequence or a portion of an original sequence. Also, an "analogue" may have, for example, 50 % sequence similarity to an original sequence with a combination of one or more modification in a backbone or side-chain of an amino acid, or an addition of a group or another molecule, etc.
Thus, biologically active polypeptides in the form of the original polypeptides, fragments (modified or not), analogues (modified or not), derivatives (modified or not), homologues, (modified or not) of PSP94 and PCK3145 are encompassed by the present invention.
Therefore, any polypeptide having a modification compared to an original polypeptide (e.g., PSP94, PCK3145) which does not destroy significantly a desired biological activity is encompassed herein. It is well known in the art, that a number of modifications may be made to the polypeptides of the present invention without deleteriously affecting their biological activity. These modifications may, on the other hand, may keep or increase the biological activity of the original polypeptide or may optimize one or more of the particularity (e.g.
stability, bioavailability, etc.) of the polypeptides of the present invention which, in some instance might be desirable. Polypeptides of the present invention comprises for example, those containing amino acid sequences modified either by natural processes, such as posttranslational processing, or by chemical modification techniques which are known in the art. Modifications may occur anywhere in a polypeptide including the polypeptide backbone, the amino acid side-chains and the amino- or carboxy-terminus. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications.
Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from posttranslational natural processes or may be made by synthetic methods.
Modifications comprise for example, without limitation, pegylation, acetylation, acylation, addition of acetomidomethyl (Acm) group, ADP-ribosylation, alkylation, amidation, biotinylation, carbamoylation, carboxyethylation, esterification, covalent attachment to fiavin, covalent attachment to a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of drug, covalent attachment of a marker (e.g., fluorescent, radioactive, etc.), covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation and ubiquitination, etc. It is to be understood herein that more than one modification to the polypeptides described herein are encompassed by the present invention to the extent that the biological activity is similar to the original (parent) polypeptide.
As discussed above, polypeptide modification may comprise, for example, amino acid insertion (i.e., addition), deletion and substitution (i.e., replacement), either conservative or non-conservative (e.g., D-amino acids, desamino acids) in the polypeptide sequence where such changes do not substantially alter the overall biological activity of the polypeptide.
Example of substitutions may be those, which are conservative (i.e., wherein a residue is replaced by another of the same general type or group) or when wanted, non-conservative (i.e., wherein a residue is replaced by an amino acid of another type). In addition, a non-naturally occurring amino acid may substitute for a naturally occurring amino acid (i.e., non-naturally occurring conservative amino acid substitution or a non-naturally occurring non-conservative amino acid substitution).
As is understood, naturally occurring amino acids may be sub-classified as acidic, basic, neutral and polar, or neutral and non-polar. Furthermore, three of the encoded amino acids are aromatic. It may be of use that encoded polypeptides differing from the determined ?5 polypeptide of the present invention contain substituted codons for amino acids, which are from the same type or group as that of the amino acid be replaced. Thus, in some cases, the basic amino acids Lys, Arg and His may be interchangeable; the acidic amino acids Asp and.
Glu may be interchangeable; the neutral polar amino acids Ser, Thr, Cys, GIn, and Asn may be interchangeable; the non-polar aliphatic amino acids Gly, Ala, Val, IIe, and Leu are f0 interchangeable but because of size Gly. and Ala are more closely related and Val, IIe and Leu are more closely related to each other, and the aromatic amino acids Phe, Trp and Tyr may be interchangeable.
It should be further noted that if the polypeptides are made synthetically, substitutions by 6 amino acids, which are not naturally encoded by DNA (non-naturally occurring or unnatural amino acid) may also be made.
A non-naturally occurring amino acid is to be understood herein as an amino acid which is not naturally produced or found in a mammal. A non-naturally occurring amino acid comprises a D-amino acid, an amino acid having an acetylaminomethyl group attached to a sulfur atom of a cysteine, a pegylated amino acid, etc. The inclusion of a non-naturally occurring amino acid in a defined polypeptide sequence will therefore generate a derivative of the original polypeptide. Non-naturally occurring amino acids (residues) include also the omega amino acids of the formula NH2(CH2)nCOOH wherein n is 2-6, neutral nonpolar amino acids, such as sarcosine, t-butyl alanine, t-butyl glycine, N-methyl isoleucine, norleucine, etc.
Phenylglycine may substitute for Trp, Tyr or Phe; citrulline and methionine sulfoxide are neutral nonpolar, cysteic acid is acidic, and ornithine is basic. Proline may be substituted with hydroxyproline and retain the conformation conferring properties.
It is known in the art that analogues may be generated by substitutional mutagenesis and retain the biological activity of the polypeptides of the present invention.
These analogues have at least one amino acid residue in the protein molecule removed and a different residue inserted in its place. For example, one site of interest for substitutional mutagenesis may include but are not restricted to sites identified as the active site(s), or immunological site(s).
Other sites of interest may be those, for example, in which particular residues obtained from various species are identical. These positions may be important for biological activity.
Examples of substitutions identified as "conservative substitutions" are shown in table 1. If such substitutions result in a change not desired, then other type of substitutions, denominated "exemplary substitutions" in table 1, or as further described herein in reference to amino acid classes, are introduced and the products screened.
In some cases it may be of interest to modify the biological activity of a polypeptide by amino acid substitution, insertion, or deletion. For example, modification of a polypeptide may result in an increase in the polypeptide's biological activity, may modulate its toxicity, may result in changes in bioavailability or in stability, or may modulate its immunological activity or immunological identity. Substantial modifications in function or immunological identity are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation. (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side chain properties:
(1) hydrophobic: norleucine, methionine (Met), Alanine (Ala), Valine (Val), Leucine (Leu), Isoleucine (IIe) (2) neutral hydrophilic: Cysteine (Cys), Serine (Ser), Threonine (Thr) (3) acidic: Aspartic acid (Asp), Glutamic acid (Glu) (4) basic: Asparagine (Asn), Glutamine (Gln), Histidine (His), Lysine (Lys), Arginine (Arg) (5) residues that influence chain orientation: Glycine (Gly), Proline (Pro);
and aromatic: Tryptophan (Trp), Tyrosine (Tyr), Phenylalanine (Phe) Non-conservative substitutions will entail exchanging a member of one of these classes for another.
10. TABLE 1. amino acid substitution Original residue Exemplary substitution Conservative substitution Ala (A) Val, Leu, Ile Val Arg (R) Lys, Gln, Asn Lys Asn (N) Gin, His, Lys, Arg Gin Asp (D) Glu Glu Cys (C) Ser Ser Gln (Q) Asn Asn Glu (E) Asp Asp Gly (G) Pro Pro His (H) Asn, Gln, Lys, Arg Arg Ile (I) Leu, Val, Met, Ala, Phe, Leu norleucine Leu (L) Norieucine, Ile, Val, Met, Ile Ala, Phe Lys (K) Arg, Gln, Asn Arg Met (M) Leu, Phe, Ile Leu Phe (F) Leu, Val, Ile, Ala Leu Pro (P) Gly Gly Ser (S) Thr Thr Thr(T) Ser Ser Trp (W) Tyr Tyr Tyr (Y) Trp, Phe, Thr, Ser Phe Val (V) Ile, Leu, Met, Phe, Ala, Leu norleucine Example of biologically active analogues of PCK3145 (SEQ ID NO: 5) exemplified by amino acid substitutions is illustrated below.
Position 1 5 10 15 (SEQ ID
X, W Q X2 D X, C X, X2 C X2 C X3 X, X2 NO.:88) For example, X, may be glutamic acid (i.e., glutamate) (Glu), aspartic acid (aspartate) (Asp), or asparagine (Asn), X2 may be threonine (Thr) or serine (Ser) and X3 may be tyrosine (Tyr) or phenylalanine (Phe). Any replacement of an original residue in SEQ ID NO.:5 with a conserved amino acid (i.e. conservative substitution) is encompassed by the present invention.
Another example of a PCK3145 (SEQ ID NO: 5) analogue may include, for example, a polypeptide as exemplified in SEQ ID NO.:88 or any other polypeptide having at least one conservative amino acid substitution (illustrated in bold below) as defined in Table 1, such as, 1.5 for example;
Glu Tyr GIn Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr (SEQ ID NO.:92) Glu Trp Asn Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr (SEQ ID NO.:93) Glu Trp Gin ThrAsp Gin Ser Glu Thr Cys Thr Cys Tyr Asp Thr (SEQ ID NO.:94) Examples of a PCK3145 (SEQ ID NO: 5) derivative may include, for example, a polypeptide having an addition in one or both of the terminal region (amino-terminal or carboxy-terminal) 25 as illustrated in SEQ IDs No.: 9 to 87, or a peptide having a stabilizing group such as exemplified in SEQ ID NO.:7, or a peptide having one or more repeats of SEQ ID
No.:5 such as exemplified in SEQ ID NOs.: 89 to 91, a polypeptide having at least one D-amino acid as exemplified in SEQ ID No. 98 and combination thereof.
An example of a PCK3145 (SEQ ID NO: 5) fragment may include, for example, a polypeptide having a truncation in one or both of the amino acid terminal region as illustrated below.
Trp Gin Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr (SEQ ID NO.:95) Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr GIu-Thr (SEQ ID NO.:96) Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys (SEQ ID NO.:97) Polypeptides may be either naturally occurring (that is to say, substantially purified or isolated from a natural source) or synthetic (for example, by performing site-directed mutagenesis on the encoding DNA or made by other synthetic methods such as chemical synthesis). It is thus apparent that the polypeptides of the invention can be either naturally occurring or l0 recombinant (that is to say prepared from the recombinant DNA techniques) or made by chemical synthesis (e.g., organic synthesis).
As used herein, "pharmaceutical composition" means therapeutically effective amounts of the agent together with pharmaceutically acceptable diluents, preservatives, solubilizers, l5 emulsifiers, adjuvant and/or carriers. A "therapeutically effective amount"
as used herein refers to that amount which provides a therapeutic effect for a given condition and administration regimen. Such compositions are liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (e.g., Tris-HCI., acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent absorption ?0 to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts). Solubilizing agents (e.g., glycerol, polyethylene glycerol), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (e.g., lactose, mannitol), covalent attachment of polymers such as polyethylene glycol to the protein, complexation with metal ions, or incorporation of the >.5 material into or onto particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, hydrogels, etc, or onto liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts. Such compositions will influence the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance.
Controlled or sustained release compositions include formulation in lipophilic depots (e.g., W fatty acids, waxes, oils). Also comprehended by the invention are particulate compositions coated with polymers (e.g., poloxamers or poloxamines). Other embodiments of the compositions of the invention incorporate particulate forms protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal, oral, vaginal, rectal routes. In one embodiment the pharmaceutical 35 composition is administered parenterally, paracancerally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, subcutaneously, intraperitonealy, intraventricularly, intracranially and intratumorally., The formulations include those suitable for oral, rectal, ophthalmic, (including intravitreal or intracameral) nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intratracheal, and epidural) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by conventional pharmaceutical techniques. Such techniques include the step of bringing into association the active ingredient and the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into associate the active ingredient with liquid carriers or finely divided solid carriers or both, [0 and then, if necessary, shaping the product.
Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules,.cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil emulsion and as a bolus, etc.
A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, ?0 the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent. Molded tablets may be made by molding, in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may be optionally coated or scored and may be formulated so as to provide a slow or controlled release of the active >.5 ingredient therein.
Formulations suitable for topical administration in the mouth include lozenges comprising the ingredients in a flavored basis, usually sucrose and acacia or tragacanth;
pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia;
10 and mouthwashes comprising the ingredient to be administered in a suitable liquid carrier.
Formulations suitable for topical administration to the skin may be presented as ointments, creams, gels and pastes comprising the ingredient to be administered in a pharmaceutical acceptable carrier. An example of a topical delivery system is a transdermal patch containing f5 the ingredient to be administered.
Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.
Formulations suitable for nasal administration, wherein the carrier is a solid, include a coarse powder having a particle size, for example, in the range of 20 to 500 microns which is administered in the manner in which snuff is administered, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
Suitable formulations, wherein the carrier is a liquid, for administration, as for example, a nasal spray or as nasal drops, include aqueous or oily solutions of the active ingredient.
Formulations suitable for vaginal administration may be presented as pessaries, tamports, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) >.0 conditions requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
Further, as used herein "pharmaceutically acceptable carrier" or "pharmaceutical carrier" are ?5 known in the art and include, but are not limited to, 0.01-0.1 M or 0.05 M
phosphate buffer or 0.8 % saline. Additionally, such pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, 30 emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's orfixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like.
Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, collating 35 agents, inert gases and the like.
It is to be understood herein, that if a "range" or "group" of substances (e.g. amino acids), substituents" or the like is mentioned or if other types of a particular characteristic (e.g.
temperature, pressure, chemical structure, time, etc.) is mentioned, the present invention relates to and explicitly incorporates herein each and every specific member and combination of sub-ranges or sub-groups therein whatsoever. Thus, any specified range or group is to be understood as a shorthand way of referring to each and every member of a range or group individually as well as each and every possible sub-ranges or sub-groups encompassed therein; and similarly with respect to any sub-ranges or sub-groups therein.
Thus, for example, with respect to a temperature greater than 1000 C, this is to be understood as specifically incorporating herein each and every individual temperature state, as well as sub-range, above 1000 C, such as for example 1010 C, 105 C and up, 1100 C
and up, 1150 C and up, 110 to 135 C, 115 c to 135 C, 102 C to 150 C, up to 210 C, [5 etc.;
and similarly with respect to other parameters such as, concentrations, elements, etc...
It is in particular to be understood herein that the polypeptides of the present invention each ?0 include each and every individual polypeptide described thereby as well as each and every possible mutant, variant, homolog, analogue or else whether such mutant, variant, homolog, analogue or else is defined as positively including particular polypeptides, as excluding particular polypeptides or a combination thereof; for example an exclusionary definition for a polypeptide analogue (e.g. X,WQX2DX,CX,X2CX2CX3X,X2 (SEQ ID NO.88)) may read as ?5 follows: "provided that when one of X, is glutamic acid and X2 is threonine X3 may not be phenylaianine".
It is also to be understood herein that "g" or "gm" is a reference to the gram weight unit; that "C" is a reference to the Celsius temperature unit.
BRIEF DESCRIPTION OF DRAWINGS
In drawings which illustrates exemplary embodiment of the present invention;
Fig. 1 is a picture of a zymography gel showing the effect of the PCK3145 derivative (SEQ ID
NO.:7) on MMP-9 levels and activity on collagen type 1- treated MatLyLu cells (first lane:marker; second lane:cells; third lane:cells and collagen; fourth lane:cells, collagen and 500 g/ml of SEQ ID NO.:7; fifth lane:cells, collagen and 1 mg/ml of SEQ ID
NO.:7), Fig. 2 is a picture of a western blot membrane showing the effect of the PCK3145 derivative (SEQ ID NO.:7) on MMP-9 expression level (fist lane: MMP9 standard; second lane:cells;
third lane:cells and collagen; fourth Iane:cells, collagen and 100 g/ml of SEQ
ID NO.:7; fifth lane: cells, collagen and 500 g/ml of SEQ ID NO.:7; sixth lane: cells, collagen and 1 mg/ml of SEQ ID NO.:7), l0 Fig 3A. is a picture of a zymography gel showing the effect of the PCK3145 derivative (SEQ
ID NO.:7) on MMP-2 levels and VEGF-induced MMP-2 levels (PD =PD98059, PCK=PCK3145 derivative), Fig. 3B is an histogram expressing the results of Fig. 3A in a quantitative manner, l5 Fig. 4A is picture of a western blot showing the effect of the PCK3145 derivative (SEQ ID
NO.:7) on induced ERK phosphorylation (Ctl=control, PCK=PCK3145 derivative), Fig. 4B is an histogram expressing the results of Fig. 4A in a quantitative manner, ?0 Fig. 4C is picture of a western blot showing the dose-dependent effect of the PCK3145 derivative (SEQ ID NO.:7) on VEGF-induced ERK phosphorylation (PD =PD98059, PCK=PCK3145 derivative), Fig. 4D is an histogram expressing the results of Fig. 4C in a quantitative manner, ?5 Fig. 4E is picture of a western blot showing the absence of inhibition of VEGF-induced ERK' phosphorylation by a scrambled polypeptide (SEQ ID NO.:99) (Ctl=control), Fig. 4F is an histogram expressing the results of Fig. 4E in a quantitative manner, , Fig. 4G is picture of a western blot of a time-course illustrating the reduction of VEGF-induced ERK phosphorylation by PCK3145 derivative (SEQ ID NO.:7) (Ctl=control, PCK=PCK3145 derivative), Fig. 4H is an histogram expressing the results of Fig. 4G in a quantitative manner, Fig. 5A is a picture illustrating the effect of the PCK3145 derivative on capillary-like structure formation, Fig. 5B is an histogram expressing the results of Fig. 5A in a quantitative manner (PCK=PCK3145 derivative), Fig. 6A is picture of a western blot showing the effect of the PCK3145 derivative (SEQ ID
NO.:7) on VEGF-induced VEGFR-2 phosphorylation (Ctl=control, PCK=PCK3145 derivative), [0 Fig. 6B is an histogram expressing the results of Fig. 6A in a quantitative manner, Fig. 6C is a picture of a western blot showing the dose-dependent effect of the PCK3145 derivative (SEQ ID NO.:7) on VEGF-induced VEGFR-2 phosphorylation (PD
=PD98059, PCK=PCK3145 derivative, PTK= PTK787), Fig. 6D is an histogram expressing the results of Firg. 6C in a quantitative manner, Fig. 6E is a picture of a western blot showing the absence of inhibition of VEGF-induced VEGFR-2 phosphorylation by a scrambled polypeptide (SEQ ID NO.:99) (Ctl=control), ?0 Fig..6F is an histogram expressing the results of Fig. 6E in a quantitative manner, Fig. 7A is a picture of a western blot showing the effect of the PCK3145 derivative (SEQ ID
NO.:7) on PDGF-induced PDGFR phosphorylation (Ctl=control, PCK=PCK3145 derivative), ?5 Fig. 7B is an histogram expressing the results of Fig. 7A in a quantitative manner, Fig. 7C is a picture of a western blot showing the dose-dependent effect of the PCK3145 derivative (SEQ ID NO.:7) on PDGF-induced ERK phosphorylation (PD. =PD98059, W PCK=PCK3145 derivative), Fig. 7D is an histogram expressing the results of Fig. 7C in a quantitative manner, Fig. 8A is an histogram illustrating the results of alcaline phosphatase secretion in the 35 presence or absence of the PCK3145 derivative (SEQ ID NO.:7) from cells containing a vector expressing a SEAP gene driven by (operatively linked with) specific response elements, Fig. 8B is a picture of a western blot of a time-course assay illustrating the effect of PCK3145 derivative (SEQ ID NO.:7) on ERK phosphorylation (PCK=PCK3145 derivative), Fig. 8C is a picture of a western blot of a dose-response assay illustrating the effect of PCK3145 derivative (SEQ ID NO.:7) on ERK phosphorylation (PCK=PCK3145 derivative), Fig. 8D is a picture of a western blot illustrating the effect of PCK3145 derivative (SEQ ID
NO.:7) on ERK phosphorylation (PCK=PCK3145 derivative), Fig. 9A is a histogram quantifying U-87 cell migration on hyaluronic acid (HA) in the presence or absence of the PCK3145 derivative (Ctl=control, PCK=PCK3145 derivative), Fig. 9B is a histogram quantifying U-87 cell adhesion to hyaluronic acid (HA) in the presence or absence of the PCK3145 derivative (Ctl=control, PCK=PCK3145 derivative), Fig. 10 is a picture of a western blot showing the effect of the PCK3145 derivative on MT1 -MMP celi expression and CD44 shedding from the cell surface, ?0 Fig. 11A is a picture of a western blot showing the effect of the PCK3145 derivative on MT1-MMP expression in transfected cells and RhoA expression in cells, Fig. 11B is an histogram illustrating in a quantitative manner, MMT1-MMP
expression in the presence or absence of PCK3145 obtained in Fig. 11 A, ?5 Fig. 11 C is an histogram illustrating in a quantitative manner, RhoA
expression in the presence or absence of PCK3145 obtained in Fig. 11 A, and;
Fig. 11 D is a picture of a gel illustrating the effect of the PCK3145 derivative on Rho RNA
30 levels.
DETAILED DESCRIPTION OF THE INVENTION
Polypeptides which are members of the PSP94 family include; wild type PSP94 as defined in 35 SEQ ID NO.: 1, a recombinant PSP94 as defined in SEQ ID NO.:2 and PSP94 derivatives, fragments and analogues as defined, for example in the amino acid sequence defined in SEQ ID NO.: 3, SEQ ID NO.:4, SEQ ID NO.:5, SEQ ID NO.:6 and SEQ ID NO.:7.
PCK3145 (SEQ ID NO.:5) was chosen as a representative of the PSP94 family based on previous encouraging results of tumor growth inhibition observed in animals.
Test compound. The wild type amino acid sequence of PCK3145 has. been disclosed, for example, in international application No.: PCT/CA01/01463 and is defined herein in SEQ ID
NO.: 5. A PCK3145 derivative has been generated by attaching an acetylaminomethyl group to the sulfur atom of each of the three cysteines of PCK3145. These groups stabilize the compound by preventing formation of peptide dimers or polymer by blocking the sulfhydryl .0 group of cysteines. This PCK3145 derivative is defined in SEQ ID NO.: 7.
The drug was manufactured by Multiple Peptide Systems (3550) (General Atomics Court, San Diego, Calif.) using standard solid-phase peptide chemistry and lyophilized into a powder.
Other type of synthesis or manufacture method may however be performed to make a peptide or polypeptide of the invention. Other PCK3145 derivatives, analogs and fragments (e.g., SEQ
.5 IDs NO: 88, 98, etc.) may be generated similarly.
The reconstituted drug used in the present example is made from a solution containing a 20 mg/mL of PCK3145 derivative (SEQ ID NO.:5 derivative); SEQ ID NO.: 7, in a phosphate buffer at pH 7.4 for dilution in sterile saline (0.9% NaCI, BP) prior to intravenous !0 administration. The solutions is filled into Type 1 glass vials, stoppered with Teflon -faced butyl stoppers, and sealed with flip-off seals.
CLINICAL TR/AL
Trial Design !5 The clinical trial is a multiple.ascending dose, open-label, Phase Ila study evaluating the safety and tolerability of PCK3145 derivative; SEQ ID NO.:7 administered intravenously in patients with metastatic hormone resistant prostatic cancer (HRPC). The study is not randomized. Patients have been enrolled sequentially and chronologically.
S0 Inclusion Criteria Patients had fulfilled the following criteria prior to receiving the first administration of the test drug:
Signed informed consent, Have a histologically confirmed metastatic adenocarcinoma of the prostate, i5 Be characterized as a stage IV prostatic cancer, Have a metastatic hormone resistant prostatic cancer; resistance being defined as progressive disease after at least one hormonal therapy (orchiectomy, oestrogens, LHRH
therapy). Progressive disease is defined in accordance with the recommendations of the Prostate Specific Antigen Working Group (Bubley, J.G., et al., J. of Clinic.
Oncol. 17:
3461-3467, 1999) which defines progressive disease as:
an increasing or development of new measurable disease or presence of new bone lesions on bone scan with a PSA level greater or equal to ng/mL or two consecutive increases in PSA. The first increase should occur a minimum of week from the reference value, and PSA level should be greater or equal to 5ng/mL, Be minimally symptomatic or asymptomatic defined as patients that may require chronic opioid analgesics but have been on a stable pain management regimen for at least 4 weeks, Be males of at least 18 years of age, Have baseline laboratory values as specified below:
Aspartate aminiotransferase (ASAT) (S.I. Unit Value = Upper Normal Limit 42 u/L or <0.7kat/L) less than or equal to 2.0 times the upper limit of normal and alanine aminotransferase (ALAT) (S.l.Unit Value = Upper Normal Limit <48u/L
or s0.8Nkat/L) less than or equal to 2.0 times the upper limit of normal Bilirubin less than 1.8mg/dL (S. I. Unit Value = s25.4NmoL/L) ?0 Creatinine less than 1.8 mg/dL (S.I.Unit Value = s 159 NmoL/L) Platelets > 100,000/mm3 (S.I. Unit Value =>100x 109 /L), Have a life expectancy of at least 6 months, Have a Karnofsky Performance status of 70% or greater, Have the ability to understand the requirements of the study, provide written informed ?5 consent, abide by the study restrictions, and agree to return for the required assessments, Reliable contraception must be used throughout the study.
Organisation of the study 30 The drug was therefore administered to patients characterized as having metastatic adenocarcinoma of the prostate, stage IV prostatic cancer and as having a metastatic hormone resistant prostatic cancer. Four patients per cohort and 4 ascending doses were evaluated. The ascending doses were 5, 20, 40 and 80 mg/m2. The dose escalation decision has been based on dose-limiting toxicity (DLT).
The 33-day cycle of treatment consisted of a PCK3145 derivative; SEQ ID NO.:7 administration three times per week (day 1, 3 and 5) for 26 days, followed by a 7 day post-treatment observation period. The maximum tolerated dose (MTD) is the dose level below the one inducing grade 3 or 4 drug related toxicity (DLT) in two patients from a cohort of a minimum of 4 patients. Only DLT's observed during the first cycle have been used for the dose escalation decision.
Each patient's participation consisted of the following study periods: a screening period held (between days -14 to -1), a baseline visit (at day 1) and before administration of the drug, a treatment period (from day 1 to day 26), a 7 days post-treatment observation period (from day 27 to day 33), a 6 month follow-up period where survival status, disease status and information about the occurrence of second primary tumors are assessed and a long term follow up period where survival status is assessed.
The treatment period consisted of intravenous administration of the PCK3145 derivative (SEQ ID NO.:5 derivative) i.e., SEQ ID NO.:7, three times per week (day 1, 3 and 5) for 26 consecutive days during which patients were closely monitored and undergone regular examination. After a week of treatment break and in the absence of toxicity and disease progression, patients optionally received additional treatment cycles.
Biological samples were drawn during different time points of the study for the purpose of ?0 safety monitoring and have been assayed for MMP-9 levels. Plasma samples were placed on dry ice and stored frozen (approximately -70 C) and subsequently analyzed for total MMP-9 levels.
:5 MMP-9 assay methodology. An Elisa assay measuring total MMP-9, i.e., human active and pro-MMP-9, (Quantikine , Cat. No.: DMP900, R&D Systems Inc.) was performed on plasma-heparin samples. Plasma samples have been collected from individuals at day 1 (before treatment) and at day 27 of each treatment cycle.
0 The Quantikine MMP-9 immunoassay 'is a solid phase ELISA designed to measure total MMP-9 (92kDa pro- and 82kDa active forms) in serum, plasma, saliva, urine and cell culture supernatants. It is calibrated with CHO-cells expressed recombinant human pro-MMP-9 and the antibodies were raised against the recombinant factor. Both antibodies also recognize recombinant human active MMP-9. Natural human MMP-9 showed dose-response curves 5 that were parallel to the standard curves obtained using the recombinant Quantikine kit standards, indicating that the Quantikine kit may be used to determine relative mass values of natural human MMP-9.
The assay employs the quantitative sandwich enzyme immunoassay technique. A
monoclonal antibody specific for MMP-9 has been pre-coated onto a microplate.
Standards and samples are added into the wells, and MMP-9 is thus bound by the immobilized antibody. After washing away unbound substances, an enzyme-linked polyclonal antibody specific for MMP-9 is added to the wells. Following a wash to remove unbound antibody-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of total MMP-9 (pro and/or active) bound in the initial step.
The color development is stopped and the intensity of the color is measured.
Zymography. Zymography is a technique generally used to analyze the activity of matrix metalloproteinases (MMPs) in biological samples. It involves the electrophoretic separation of proteins under denaturing (Sodium Dodecyl Sulfate (SDS)) but non-reducing conditions through a polyacrylamide gel containing gelatin (for example, 10% gel containing 1 mg/mI
gelatin for MMP-9 and MMP-2 assays). The resolved proteins are re-natured by exchanging SDS with a non-ionic detergent such asTriton X-100 and the gel is incubated in an incubation buffer for activation of MMP-2 and MMP-9 (for example at 37 C for 18 hrs). The gel is stained with Coomassie blue and the MMP-2 a.nd MMP-9 bands may be visualized as clear bands against a blue background (i.e., the MMPs degrade the gelatin and are visualized as clear !0 bands; pro MMP-2 is 68 kDa and pro-MMP-9 is 92 kDa). These bands can be quantified using densitometry. For example, prior to stimulation, quiescent HUVEC were serum-starved for 16 h in the presence or absence of PCK3145 or PD98059 and then stimulated with VEGF. The conditioned media were collected 24 h after stimulation, and clarified by centrifugation. Identical volume of conditioned media were mixed with non reducing Laemmli !5 sample buffer and subjected to 7.5% SDS-polyacrylamide gels containing 1 mg/ml gelatin (Sigma). The gels were then incubated for 30 min at room temperature twice in 2.5% (v/v) Triton X-100 and rinsed five times in doubly distilled water. The gels were incubated at 37 C
for a further 18 h in 200 mM NaCI/5 mM CaCI2/0.02% (v/v) Brij-35/50 mM
Tris/HCI buffer (pH
7.6), then stained with 0.1% Coomassie Brilliant Blue R-250, followed by destaining in 10%
0 (v/v) acetic acid/30% (v/v) methanol in water. Gelatinolytic activity was detected as unstained bands on a blue background.
Materials. Cell culture media were obtained from Life Technologies (Burlington, Ontario, 5 Canada) and serum was purchased from Hyclone Laboratories (Logan, UT).
Electrophoresis reagents were purchased from Bio-Rad (Mississauga, Ontario, Canada). The polyclonal (C-1158) and monoclonal (A3) antibodies, used for precipitation and detection, respectively, of VEGFR-2, and the anti-PDGFR pAb (958) were obtained from Santa Cruz Biotechnologies (Santa Cruz, CA). Antiphosphotyrosine mAb PY99 was also purchased from Santa Cruz Biotechnologies. Anti-phospho-ERK polyclonal antibodies were from Cell Signaling Technology (Beverly, MA). Anti-mouse and anti-rabbit horseradish peroxidase-linked secondary antibodies were purchased from Jackson lmmunoResearch Laboratories (West Grove, PA) and enhanced chemiluminescence (ECL) reagents were from Amersham Pharmacia Biotech (Baie d'Urfe, Quebec, Canada). Human recombinant PDGF was obtained from R&D Systems (Minneapolis, MN). Micro bicinchoninic acid protein assay reagents were from Pierce (Rockford, IL). Matrigel basement membrane matrix was from Becton Dickinson Labware (Bedford, MA). PTK787 was obtained from Novartis Pharmaceuticals. The MEK
kinase inhibitor PD98059 was from Calbiochem (La Jolla, CA). All other reagents were from Sigma-Aldrich Canada.
VEGF production. Vascular endothelial growth factor (isoform 165) was PCR-amplified from [5 a pBlast/VEGF plasmid (Invivogen, San Diego, CA) and cloned into the pTT
vector (Durocher, Y, et al., Nucleic Acids Res 2002;30:E9). VEGF was produced following large-scale transient transfection of human 293SFE cells in serum-free medium. The recombinant protein was expressed by the transiently transfected cells and secreted into the medium. The culture was harvested five days after transfection; the medium was clarified by centrifugation >.0 at 3,500g for 10 minutes and filtered through a 0.22 pm membrane.
Clarified culture medium was loaded onto a heparin-Sepharose column and the bound VEGF was then eluted using a NaCI gradient in PBS. A buffer exchange for PBS was performed by gel filtration and the final purified material was sterile-filtered, and stored in aliquots at -80 C.
?5 Cell culture. Human umbilical vein endothelial cells (HUVEC) and pulmonary aortic smooth muscle cells (PASMC) were obtained from Clonetics and maintained in endothelial cell basal medium-2 (EBM-2; Clonetics) and smooth muscle medium-2 (SmGM-2; Clonetics), respectively. Cells were cultured at 37 C under a humidified atmosphere containing 5% C02.
For experimental purposes, cells were plated in 8 100-mm plastic dishes at 5,000 cells/cm2 30 and were grown to confluence before overnight serum starvation. Cells were treated with vehicle or with a PCK3145 derivative diluted in 0.1 N NaOH, and stimulated with 50-100 ng/ml VEGF or PDGF, with 10 ng/ml of bFGF (basic fibroblast growth factor) or with 1NM
S1 P (sphingosine-1 -ph osphate).
35 lmmunoprecipitation and immunoblotting procedures. After treatment, cells were washed once with phosphate-buffered saline (PBS) containing 1 mM sodium orthovanadate and were incubated in the same medium for 1 h at 4 C. The cells were solubilized on ice in lysis buffer (150 mM NaCI, 10 mM Tris-HCI, pH 7.4, 1 mM EDTA, 1 mM EGTA, 0.5%
Nonidet P-40, 1% Triton X-1 00) containing 1 mM sodium orthovanadate. The cells were then scraped from the culture dishes and the resulting lysates were clarified by centrifugation at 10,000g for 10 min: Protein concentrations were determined using the micro bicinchoninic acid method (Pierce). For immunoprecipitation studies, lysates were clarified by a 1 h incubation at 4 C with a mixture of Protein A/Protein G Sepharose beads. After removal of the Sepharose beads by low-speed centrifugation, identical amounts of protein (200 jig) from each sample were transferred to fresh tubes and incubated in lysis buffer overnight at 4 C in the presence of 2 Ng/ml of specific antibodies. Immunocomplexes were collected by incubating the mixture with 25,u1 (50% suspension) of Protein A- (rabbit primary antibody) or Protein G- (mouse primary antibody) Sepharose beads, for 2 h. Nonspecifically-bound material was removed by washing the beads three times in 1 ml of lysis buffer containing 1 mM sodium orthovanadate, and, bound material was solubilized in 25 ,ul of two-fold concentrated Laemmli sample buffer (125 mM Tris-HCI (pH 6.8), 20% glycerol, 4%
SDS, 10% f3-mercaptoethanol, and 0.00125% bromphenol blue), boiled 5 min, and resolved by SDS-PAGE. The proteins were transferred onto polyvinylidene difluoride (PVDF) membranes, blocked 1 h at room temperature with Tris-buffered saline/Tween 20 (147 mM
NaCI, 20. mM Tris/HCI, pH 7.5, and 0.1% Tween 20) containing 2% bovine serum albumin and incubated overnight at 4 C with primary antibody. Immunoreactive bands were revealed W after a 1 h incubation with horseradish peroxidase-conjugated anti-mouse or anti-rabbit antibodies, and the signals were visualized by enhanced chemiluminescence (Amersham Biosciences, Baie d'Urfee, QC). The immunoreactive bands were quantified by scanning densitometry (Molecular Dynamics).
>.5 Cell culture. Human umbilical vein endothelial cells (HUVEC) and pulmonary aortic smooth muscle cells (PASMC) were obtained from Clonetics and maintained in endothelial cell basal medium-2 (EBM-2; Clonetics) and smooth muscle medium-2 (SmGM-2; Clonetics), respectively. Cells were cultured at 37 C under a humidified atmosphere containing 5% C02.
For experimental purposes, cells were plated in 8 100-mm plastic dishes at 5,000 cells/cm2 30 and were grown to confluence before overnight serum starvation. Cells were treated with vehicle or with PCK3145 diluted in 0.1 N NaOH, and stimulated with 50 ng/ml VEGF, PDGF
or with 1,uM S1 P.
Angiogenesis assays 35 Rat aortic ring assay. The isolated rat aorta is cut into segments that are placed in culture, in a matrix-containing environment such as Matrigel. Over the next 7-14 days, the explants are monitored for the outgrowth of endothelial (and other) cells as this is affected by the addition of test substances. Quantification is achieved by measurement of the length and abundance of vessel-like extensions from the explant. Use of endothelium-selective reagents such as fluorescein-labeled BSL-1 allows quantification by pixel counts.
Chick aortic arch assay. Aortic arches are dissected from day 12-14 chick embryos and cut into rings similar to those of the rat aorta. When the rings are placed on Matrigel, substantial outgrowth of cells occurs within 48 h, with the formation of vessel-like structures readily apparent. Test substance is added to the medium and quantification of endothelial cell outgrowth is achieved by the use of fluorescein-labeled lectins such as BSL-1 and BSL-B4 or by staining of the cultures with labeled antibodies to CD31. Standard imaging techniques are used for the enumeration of endothelial cells and for delineating the total outgrowth area.
Cornea angiogenesis assay: A pocket is made in the cornea of a rabbit's eye or mice's eye and angiogenesis is stimulated by an angiogenesis inducer (e.g. VEGF) introduced into this pocket. The inducer elicits ingrowth of new vessels from the peripheral limbal vasculature.
Slow-release materials such as ELVAX (ethylene vinyl copolymer), Hydron or sponge may be used to introduce test substances into the corneal pocket.
Inhibition of angiogenesis is, monitored by the effect of the inhibitor on the locally induced (e.g., sponge implant) angiogenic reaction in the cornea (e.g., VEGF). The test inhibitor may be administered by several administration mode including, orally, systemically, the latter either by bolus injection or, for example, by use of a sustained- release method such as ?0 implantation of osmotic pumps loaded with the test inhibitor.
The vascular response is monitored by direct observation throughout the course of the experiment. This may be done by using a slit lamp for the rabbit but needs only a simple stereomicroscope in mice. Visualization of the mouse corneal vasculature may be achieved by injecting India ink or fluorochrome-labeled high-molecular weight dextran.
Methods for !5 quantification include measuring the area of vessel penetration, the progress of vessels toward the angiogenic stimulus overtime, or in the case of fluorescence, histogram analysis or pixel counts above a specific (background) threshold.
Cam assay. The CAM of day 7-9 chick embryos is exposed by making a window in the egg 0 shell, and tissue or organ grafts are then placed directly on the CAM. The window is sealed, eggs are reincubated, and the grafts are recovered after an appropriate length of incubation tirrie. The grafts are then scored for growth and vascularization. The angiogenic reaction may be evaluated by ranking the vascularization on a 0 to 4 basis but also using imaging techniques such as the measurement of bifurcation points in a designated area around the test material. Alternatively, an entire egg contents may be used. Test substances are administered by placing them on membranes or on the underside of coverslips and applied to a desired area. Test compounds are assessed by their effect either on the normal development of the CAM vasculature itself or on induced angiogenesis.
Alternatively, fertilized chick embryos are removed from their shell on day 3 or 4, and a methylcellulose disc containing the test compound is implanted on the chorioallantoic membrane. The embryos are examined 48 hours later, if a clear avascular zone appears around the methylcellulose disc, the diameter of that zone is measured. Such avascular zone indicates a compound having an anti-angiogenic activity (U.S. patent no.
5,001,116 (col.7, incorporated herein by reference).
Matrigel endothelial cell tube formation assay. Matrigel (12.5 mg/mI) was thawed at 4 C, and 50 ,ul were quickly added to each well of a 96-well plate and allowed to solidify for 10 min at 37 C. The wells were then incubated for 18 h at 37 C with HUVEC (25,000 cells/well). The formation of capillary-like structures was examined microscopically and pictures (50X) were taken using a Retiga 1300 camera and a Zeiss Axiovert S100 microscope. The extent to which capillary-like structures formed in the gel was quantified by analysis of digitized images to determine the thread length of the capillary-like network, using a commercially available image analysis program (Northern Eclipse).
Matrigel plug assay.Matrigel containing test cells or substances is injected subcutaneously, where it solidifies to form a plug. This plug is recovered after 7-21 days in the animal and examined histologically to determine the extent to which blood vessels have entered it.
Fluorescence measurement of plasma volume is achieved using fluorescein isothiocyanate (FITC)-labeled dextran 150. Quantification may alternatively be achieved by measuring the !5 amount of hemoglobin contained in the plug.
In another alternative assay (the sponge/Matrigel assay) Matrigel alone is first introduced into the mouse. A sponge or tissue fragment is then inserted into the plug. New vessels are measured by injection of FITC.
Other angiogenesis assays are described, for example, in Staton, C.A. et a/., (Int. J. Exp.
0 Path. (2004), 85, 233-248) the entire content of which is incorporated herein by reference.
Migration Assays. Transwells filters (8-pm pore size; Costar, Cambridge, MA) were pre-coated with 0.5% gelatin/PBS for 24 h at 4 C. The transwells were then washed with PBS
and assembled in 24-well plates. The upper chamber of each transwell was filled with 100,u1 of HUVEC (1 x 106 cells/mI) and cells were allowed to adhere for 1 h. Cells were then treated for 2 h by adding 100,u1 of 2-fold concentrated drug solution prepared in serum-free medium into the upper chamber and 600 NI of the drug solution into the lower chamber.
Migration was initiated by adding VEGF (10 ng/ml), or S1 P (1 ,uM) to the lower chamber. The plate was placed at 37 C in 5% C02/95% air for 4 h. Cells that had migrated to the lower surface of the filters were fixed with 10% formalin phosphate and stained with 0.1 % Crystal Violet/20% (v/v) methanol. The migration was quantified using computer-assisted imaging and data are expressed as the average density of migrated cells per four fields (magnification x 50).
Matrigel endothelial cell tube formation assay. Matrigel (12.5 mg/mI) was thawed at 4 C, and 50,u1 were quickly added to each well of a 96-well plate and allowed to solidify for 10 min at 37 C. The wells were then incubated for 30 min at 37 C in 5% C02/95% air, with 100,u1 of HUVEC (20,000 cells/well) containing 1% fetal bovine serum to allow adequate adhesion to Matrigel. Cells were then treated for 18 h by adding 100 ,ul of 2-fold concentrated PCK3145 prepared in serum-free medium into the well. The formation of capillary-like structures was examined microscopically and pictures (50X) were taken using a Retiga 1300 camera coupled to a Zeiss Axiovert S100 microscope. The extent to which capillary-like structures formed in the gel was quantified by analysis of digitized images using a commercially 22 0 available image analysis software (Northern Eclipse) (25).
Statistical data analysis. Data are representative of three or more independent experiments and are represented as means SEM. Statistical comparisons between groups were assessed using 1-way ANOVA followed by Student's unpaired t-test.
?5 Biologically active PSP94 family member; Fragments, derivatives and analogues may be prepared by techniques known in the art (recombinant technology, solid phase synthesis, etc.). The biological activity of derivatives, fragments and analogues may be determined by any of the techniques described herein or known in the field to be relevant for any of the 10 biological activity described above.
For example, serum-starved quiescent endothelial cells (HUVEC) may be incubated with different doses of a putative PCK3145 derivative, analog or fragment (e.g., any of SEQ ID
NOs.:9 to 98, combinations) for 24 h and then stimulated with VEGF. Cells may be washed 5 with PBS containing NaF/Na3VO4 and incubated in the same medium buffer for 1 h at 4 C.
The cells may be scraped from the culture dishes and the resulting lysates clarified by centrifugation. SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) may be performed to separate the proteins. Western blotting and immunodetection may be performed by using anti-phosphoERK and anti-ERK antibodies. The bands may be quantified to determine the level of inhibition of ERK phosphorylation by the putative PCK3145 derivative. An inhibitory effect of VEGF-induced ERK phosphorylation (or VEGFR-induced ERK phosphorylation) by the putative PCK3145 derivative, analog or fragment means that the derivative, analog or fragment is biologically active.
In another example, a matrigel containing a putative PCK3145 derivative, fragment or analog with an angiogenesis-inducer is injected subcutaneously, to an animal. This plug is recovered after 7-21 days from the animal and examined histologically to determine the extent to which blood vessels have entered it. Quantification is performed as described above.
A biologically active PCK3145 derivative, fragment or analog is identified by the reduction in the number of blood vessels which have entered the matrigel plug or the extent to which blood vessels have entered it.
A derivative, fragment or analog causing a diminution in the formation or propagation of blood vessel (tubes, capillary-like structures) in an agiogenesis assay described herein is considered to be a biologically active derivative, fragment or analog.
A putative PCK3145 derivative, analog or fragment which is biologically active may also be identified in one of the assay described herein where an inhibitory effect on PDGF=induced ERK phosphorylation (or PDGFR-induced ERK phosphorylation) by the putative derivative, analog or fragment is observed or measured.
15 The biological activity of a desired polypeptide may also be determined, for example, by contacting a cell expressing a metalloproteinase (e.g., MMP-9, MMP-2) and/or pro-metalloproteinase (e.g., pro-MMP-9, pro-MMP-2) with a polypeptide of the present invention (a PSS94 family member (e.g.: original polypeptide, fragment, derivative, analogue, and/or any modified form of an original polypeptide, fragment, derivative or analogue) and, following 10 incubation of the polypeptide and cell, evaluating the levels (inside the cell or in the extracellular environment (supernatant or blood (plasma or serum))) of expression of the, metalloproteinase by western blot or the enzymatic activity of the metalloproteinase by zymography as described herein or by any other techniques known in the art to be representative of inetalloproteinase activity or expression (e.g., northern blot, PCR, 5 immunochemistry methods, etc.). A modification (e.g., reduction or in some cases an increase) of the level of expression or enzymatic activity of a metalloproteinase (and/or pro-metalloproteinase) will identify a biologically active polypeptide.
The biological activity of a desired polypeptide may further be determined using migration assays. U-87 cells are treated with a polypeptide of the present invention (e.g., any PCK3145 derivative, fragment, analog, such as for example, any one of or combinations of SEQ ID NOs.: 9 to 98). The treated cells are trypsinised, counted, and seeded on HA-coated filters inserted in modified Boyden Chambers as described herein or in the art. Cell migration is allowed to proceed for 2 hours at 37 C. Filters are then stained for cells that have migrated through the filter. A decreased basal U-87 cell migration observed in cells treated with a polypeptide of the present invention is indicative of a biologically active polypeptide (i.e., a biologically active PCK3145 derivative, fragment, analog).
Each putative derivative, fragment or analogue may be tested using this technique or any other techniques described herein or known in the art.
IN VIVO MMPs MEASUREMENTS
MMP-9 assay results Results of MMP-9 levels in patient's plasma, before and after one or more treatment cycle with PCK3145 derivative; SEQ ID NO.: 7 are illustrated in Table 2.
Normal values of healthy volunteers were not determined in this study but lizasa et al., has determined that the normal range of plasma MMP-9 concentrations is about 11.4 to 59.4 !5 ng/mI. Based on theses values, patients were sub-divided into two categories; those having normal value of MMP-9 (below 100pg/L) and those having an elevated level of (higher than 100Ng/L) at baseline (see column identified as Dl C1 in Table2).
In the normal value MMP-9 category (patients identified as E, F, G, H and I), there was no ;0 significant decrease in MMP-9 levels after one cycle of treatment (column identified D27C1) compared to baseline levels. For patients E and G, no decrease in MMP-9 levels was observed compared to baseline values even after 2 cycles of treatment (column identified D27C2). There was still no MMP-9 decrease even after 3 cycles of treatment for patient E
(D27C3) In the elevated MMP-9 category (patients identified as A, B, C and D), a significant decrease was observed for each patient after only one cycle of treatment (see column identified as D27C1). For example a decrease of up to 89 % in MMP-9 levels was observed for patient A
compared to baseline levels. For patient B, the decrease in MMP-9 was 41 %
after cycle 1.
For patients C and D the decrease at cycle 1 was 90 % and 34 % respectively.
This decrease was maintained for patients B and C who have received more treatment cycles (see columns identified as D27C2, D27C3 and D27C4). For example, at treatment cycle 2, patient B showed a reduction of 64 % of its baseline level of MMP-9.
A similar reduction was also measured for patient B at treatment cycle 3; i.e., a 65 %
reduction, and at treatment cycle 4; a 75 % reduction. In the case of patient C, a reduction of 76 % in MMP-9 levels was measured at cycle 2.
TABLE 2.
Elevated MMP-9: Baseline =100pg/L
Patient D1 C1 D27C1 D27C2 D27C3 D27C4 Maximum Reduction A 424 47.3 N.A. N.A. N.A. 89 %
B 156.5 91.6 55.6 54.5 39.4 75%
C 155 14.9 37.7 N.A. N.A. 90 %
D 130.2 85.2 N.A. N.A. 34%
Normal MMP-9: Baseline =100Ng/L
E 57.5 58 60.1 101.8 N.A.
F 53.2 73.1 N.A. N.A. N.A.
G 33.9 45.4 189.6 N.A.
H 57.0 44.0 65 I 22.1 18.8 N.A.=not applicable .5 Effect on MMP-9 secretion ,0 In order to support in vivo results described in Example 1, zymography assays and western blots were performed on cell lines incubated with a PCK3145 derivative (SEQ ID
NO.:7).
In the experiment presented in Fig. 1, 2.5x105 MatLyLu tumor cells (American Type Culture Collection No.: JHU-5)) were seeded in T-25 flasks containing RPMI with 10%
fetal bovine serum (FBS). After overnight incubation, the cells were washed once with serum free medium and treated with various concentrations of the PCK3145 derivative (500ug/ml and 1 mg/mi) in the presence of 50ug/ml collagen type-I in serum free RPMI for 72 hrs. Control cells received 50ug/ml collagen or only serum free medium.
The media were collected after 72 hours of exposure to the PCK3145 derivative and subjected to gelatin zymography. Zymography for MMP-2 and MMP-9 was performed in SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (10%) containing 0.1 %
gelatin (Invitrogen). Twenty-four microliters of culture media was mixed with non-reducing sample buffer and subjected to electrophoresis without boiling. After electrophoresis, gels were soaked for 30 minutes in 2.5% Triton X-100 solution with 2-3 washing steps.
The gels were then incubated for 18 hours at 379C in buffer containing 50 mM Tris/HCI, pH
7.6, 50 mM
NaCI, 10mM CaCI2 and 0.05% Brij-35. After incubation, the gels were stained with 0.2%
Coomassie blue and de-stained until clear proteolytic bands appeared. Gels were scanned with Microtek flatbed scanner (Scanmaker 5 software; Microtek lab, Redondo Beach, CA).
The band intensities were determined using the Image Quant software (version 5.0) from molecular Dynamics.
The MMP-9 and MMP-2 gelatinase zymography standard were purchased from Chemicon 10 (catalogue no. CC073). One nanogram of purified human pro-MMP-2 and pro-MMP-standards were used in every gel run.
Results of this experiment are illustrated in Fig.1 and indicate that PCK3145 derivative treatment of MatLyLu cells resulted in a dose-dependent reduction of MMP-9 secreted in the !5 cell culture media, as detected by zymography.
Western blot A separate western blot experiment was performed in which MatLyLu cells were treated with 100ug/ml, 500ug/ml and 1 mg/mI of the PCK3145 derivative for 72 hrs. At the end of the ,0 experiment, the media were collected and concentrated 5 times using Amicon centrifugal filter devices (3500 molecular weight cut-off).
Twenty five microliters samples were separated on SDS-PAGE gel under reducing conditions using pre-cast gels of 4-12% Bis-Tris (Invitrogen). Following electrophoresis, the proteins 5 were transferred on nitrocellulose membrane. Non-specific binding sites were blocked using 5 % skimmed milk in 10mM phosphate buffer saline (PBS) containing 0.05% Tween-20 for 1 hour at room temperature. The membrane was later incubated with a primary antibody (monoclonal, RDI-MMP-9abm-2A5) at a concentration of 1 ug/mI (in 10 mM PBS, containing 0.5% bovine serum albumin (BSA) and 0.05% Tween-20) for 3 hours at room temperature.
The membranes were washed three times in PBS (5 minutes each wash) to remove non-specific binding and they were incubated with the secondary antibody (Rabbit anti-mouse IgG
horseradish peroxidase-conjugated (Dako no. 0260)) at a dilution of 1:5000 for one hour.
Detection of specific MMP-9 protein was made by incubating the membrane in ECLT"' reagent (electro-chemoluminescence, Roche) and exposing to the X-ray film.
Results of this experiment are illustrated in Fig.2 and again indicate that treatment of MatLyLu cells PCK3145 derivative resulted in.a dose-dependent reduction of MMP-9 levels.
Effect on VEGF induced MMP-2 secretion Matrix metalloproteinases (MMPs) secreted by EC seem to play a key role in the processes of matrix remodeling and EC sprouting during angiogenesis. While proMMP-9 secretion is absent or at low levels in basal conditions, proMMP-2 secretion can however be increased by VEGF in HUVEC.
The effect of the PCK3145 derivative (SEQ ID NO.:7) on MMP extracellular levels was thus assessed by gelatin-zymography in the conditioned media of serum-starved HUVEC. After 16 hours of starvation, HUVEC were stimulated with VEGF in the presence or not of the PCK3145 derivative. A further 24 hours treatment shows that PCK3145 derivative effectively downregulated by approximately 35% the basal proMMP-2 levels in the extracellular media (Fig 3A, Fig. 3B). Most importantly, the effect of PCK3145 derivative (300 g/ml) was also observed on VEGF-induced proMMP-2 secretion as the inhibition was of approximately 50%.
When these experiments were performed in serum-free media, but in the presence of the MAPK inhibitor PD98059, VEGF-induced proMMP-2 extracellular levels were also significantly decreased. These results suggest that the effect of PCK3145 derivative towards MMP secretion is indeed regulated through a MAPK pathway in endothelial cells.
The effect of PCK3145 on MMP-9 secretion could not be observed in HUVEC
because only very low to undetectable levels of MMP-9 are secreted.
Phosphorylation of ERK-1/-2 pathway in endothelial cells VEGF is a strong activator of ERKs (Extracellular-signal-Regulated protein Kinases) 1 and 2 via VEGF receptor 2. In order to test the ability of the PCK3145 derivative in potentially antagonizing VEGF-mediated ERK phosphorylation, serum-starved quiescent endothelial cells (HUVEC) were incubated with vehicle (phosphate-buffered saline (PBS) pH
7.4) or PCK3145 derivative (300 ,ug/mI) for 24 h and then stimulated with VEGF, bFGF
(basic Fibroblast Growth Factor) or S1 P (sphingosine- 1 -phosphate). Cells were washed with PBS
containing NaF/Na3VO4 and incubated in the same medium buffer for 1 h at 4 C.
The cells were scraped from the culture dishes and the resulting lysates clarified by centrifugation.
Western blotting and immunodetection using anti-phosphoERK and anti-ERK
antibodies was then performed.
The results show a specific inhibitory effect of the PCK3145 derivative on ERK
phosphorylation induced by VEGF (Fig 4A, Fig. 4B) but-not that induced by bFGF
or S1P
(Fig 4A, Fig. 4B). This inhibitory effect was confirmed for two endothelial cells, HUVEC and BAEC (not shown). The total amount of ERK in each sample of cells was unaffected by the PCK3145 derivative (Fig 4A, Fig. 4B). Although, PCK3145 derivative also seemed, to stimulate ERK phosphorylation induced by S1 P in HUVEC (Fig 4A, Fig, 4B), that'result was found not statistically significant. Moreover, a dose-response to PCK3145 derivative was found to gradually inhibit the extent of ERK phosphorylation by VEGF (Fig 4C, Fig. 4D):' The effect of PCK3145 derivative was found comparable to that of PD98059, a documented pharmacological inhibitor of ERK phosphorylation. The lack of effect of a scrambled peptide ?5 (SEQ ID No.:99)"is demonstrated as a negative control (Fig 4E, Fig. 4F).
Finally, a time-course of PCK3145 derivative effect is shown at 3 and 24 hrs demonstrating the necessity of a long term action of PCK3145 derivative (Fig 4G, Fig. 4H).
~0 Effect on capillary-like structure formation by HUVEC
This three dimensional ECM model assay provides physiologically relevant environment for studies of cell morphology, biochemical function, and gene expression in endothelial cells (EC) that can be modulated for instance by tumor growth factors or hypoxic culture 5 conditions. Moreover, proteomic-based approaches to monitor levels of protein expression can also be achieved. When plated on Matrigel, EC have the ability to form capillary-like structures. The extent of capillary-like structures formation (density and size of structures) can be quantified by analysis of digitized images to determine the relative size and area covered by the tube-like network,. using an image analysis software (Un-Scan-it, Empix Imaging). HUVEC were trypsinised, counted and seeded on Matrigel. Adhesion to Matrigel was left to proceed for 30 minutes. Treatment with increasing concentrations of the PCK3145 derivative (0-300 g/ml) was then performed in serum-free media for 24 hours.
The extent of capillary-like structure formation was then assessed afterwards. The results show that the PCK3145 derivative negatively affects tubulogenesis (Fig 5A, Fig. 5B).
Cells were plated onto gelatin-coated filters inserted in modified Boyden chemotactic chambers. The effect of PCK3145 on basal migration and on VEGF-induced migration was monitored by the number of cells that had migrated comparatively to untreated control cells.
HUVEC were dislodged from the flasks by trypsinization, washed and resuspended in serum-free media. Cells were placed onto gelatin-coated filters inserted in chambers and incubated at 37 C, 5% CO2 for 30 min to allow adequate anchoring to the filters. The monolayers were then exposed to serum-free media containing PCK3145 (300 ,ug/mi) added within the upper and lower compartment of the chambers. After 2 h, VEGF (50 ng/ml) was added in the lower chamber as a chemoattractant. Cell migration was allowed to proceed for another 3 h. Filters were then fixed, stained, and the migrated cells quantified by microscopy as described in the Methods section. The results show that PCK3145 treatment had no significant effect on basal ?0 cell migration or on VEGF-induced cell migration (not shown) in this particular assay. The effect of. PCK on S1 P-induced HUVEC migration was also measured, but no inhibition was observed (not shown) in this particular assay.
?5 EXAMPLE 6 Phosphorylation of VEGF receptors in endothelial cells The multifunctionality of VEGF at the cellular level results from its ability to initiate a diverse, complex and integrated network of signaling pathways via its major receptor, VEGFR-2.
30 Thus, the inhibitory effect of the PCK3145 derivative on ERK
phosphorylation induced by VEGF was examined to verify whether it was a consequence of an inhibition of the phosphorylation of VEGFR-2. HUVEC were grown, serum-starved, pretreated with the PCK3145 derivative (300,ug/mI; 24 h), and stimulated with VEGF as described in Gingras et al. [Biochem J 348:273-280, (2000)]. After each treatment, equal amounts of protein were 35 immunoprecipitated with anti-VEGFR-2 polyclonal antibodies and analysed by Western blotting. Results of this experiment show that the PCK3145 derivative inhibited the phosphorylation of VEGFR-2 induced by VEGF in HUVEC (Fig 6A, Fig. 6B). This inhibitory effect of the PCK3145 derivative is also shown to be dose-dependent (Fig 6C, Fig. 6D), and could be to a certain extent compared to the action of PTK787, a known pharmacological inhibitor of the tyrosine kinase activity associated to the VEGFR-2. Finally, the lack. of effect of a scrambled peptide is shown (Fig 6E, Fig. 6F) and suggests the specificity of action of the PCK3145 derivative.
Phosphorylation of PDGF receptors in smooth muscle cells [0 The potential inhibitory action of the PCK3145 derivative towards the tyrosine kinase activity associated to the VEGFR-2 was also tested on the kinase activity associated to another receptor the PDGF receptor (PDGFR) in PASMC (pulmonary aortic smooth muscle cells).
Similar treatment of the PCK3145 derivative as for HUVEC was performed.
Interestingly, PCK3145 derivative leads to the inhibition of PDGFR phosphorylation induced.
by PDGF (Fig [5 7A, Fig. 7B); as well as of the PDGF-induced ERK phosphorylation (Fig 7C, Fig. 7D).
Intrinsic effect on ERK phosphorylation ?0 In order to investigate the potential intracellular pathways triggered by the PCK3145 derivative, a gene-reporter assay using the SEAP (Secreted Alkaline Phosphatase) Mercury Profiling Kit (CLONTECH) was performed in glioma cells (U-87). This assay enables the monitoring of transcription factors that are triggered by a particular experimental condition by assaying the alkaline phosphatase activity in the extracellular media. The ?5 derivative triggers significantly two pathways: the MAPK/JNK pathway (SRE) and the NFkB
pathway (Fig 8A). The MAPK pathway induction is extremely strong as compared to that of the NFkB pathway. The latter however potentially suggests the involvement of.
pro-apoptotic pathways that would be triggered by the PCK3145 derivative. Interestingly, the secretion of the constitutively expressed SEAP was found to be inhibited suggesting a potential effect of 30 the PCK3145 derivative on a more general constitutive secretion pathway.
The induction of the MAPK pathway by the PCK3145 derivative is further confirmed by the rapid and transient induction of ERK phosphorylation between 5-10 minutes (Fig 8B) and is shown to be dose-dependent (Fig 8C). Finally, the effects of the PCK3145 derivative were 35 also compared to those of a scrambled peptide. These results show that the scrambled peptide was unable to induce ERK phosphorylation comparable to that of the derivative (Fig 8D). Finally, these results also indicate that the MAPK
inhibitor PD98059 antagonized the induction of ERK phosphorylation by the PCK3145 derivative.
Effect on angiogenesis Matrigel containing the PCK3145 or its derivative (SEQ ID NO.:5 or SEQ ID
NO.:7) is injected subcutaneously to a rat. This solidified plug is recovered after 7-21 days in the animal and examined histologically to determine the extent to which blood vessels have entered the plugs.
In another assay, fertilized chick embryos are removed from their shell on day 3 or 4, and a methylcellulose disc containing PCK3145 (SEQ.ID NO.:5 or SEQ ID NO.:7) is implanted on the chorioallantoic membrane. The embryos are examined 48 hours later and the diameter of the avascular zone is measured.
The proangiogenic factor VEGF is secreted by many tumors in high concentrations, and suppression of the VEGF-VEGFR signalin.g pathway is an intensively explored avenue for suppression of tumor growth through the inhibition of angiogenesis. Although prostate cells of normal, benign, and of malignant phenotype have been shown to express VEGF, expression of the cognate receptors VEGFR-2 is generally believed to be restricted to EC.
In light of the results presented herein, two main lines of evidence suggest and support the pleiotropic molecular effects of PCK3145 in EC (PCK3145 is therefore a pleiotropic factor).
PCK3145 antagonizes the VEGFR-2 tyrosine kinase-associated activity as well as the subsequent intracellular transduction through the MAPK pathway. Moreover, inhibited capillary-like structure formation by EC as well as MMP secretion, two cellular pre-?5 requisite for angiogenesis to occur. The inhibitory effect on MMP is interesting since in genera, al correlation between the stage of tumor progression and level of MMP
expression has been observed. Collectively, these properties reflect PCK3145 antiangiogenic action on EC.
S0 Treatment of established human tumors might require not only prevention of further angiogenesis but also destruction of tumor blood vessels to reduce the already existing tumor mass. Although interference with VEGF-mediated signalling events is effective in preventing the early growth of neovessels (blocking early-stage angiogenesis), mature vessels from more established tumors are largely resistant to inhibitors directed against either VEGF or its 6 receptor VEGFR-2. These mature vessels are surrounded by periendothelial cells, such as pericytes and smooth muscle cells (SMC), and the contact between these cells stabilizes new blood vessels, promotes endothelial survival, and inhibits EC
proliferation. PDGF-B/PDGFR-f3 system is involved in vessel stabilization, and interference with this signalling system resulting in disruption of already established endothelial/periendothelial associations and vessel destabilization. Furthermore, the inhibition of both VEGF and PDGF
receptors, by either simultaneous exposure to receptor-specific receptor tyrosine kinase inhibitors or by an inhibitor with broad kinase specificity (SU6668), blocks further growth of end-stage and well-vascularized tumors, eliciting detachment of pericytes and disruption of tumor vascularity (blocking late-stage angiogenesis) (e.g., blocking late-stage angiogenesis).
As such PCK3145 may inhibit angiogenesis in highly vascularized tumors.
As PCK3145 as been found to interfere with both VEGFR and PDGFR signalling, may be used as a therapeutic agent in strategies devised either to interrupt or inhibit one or more of the pathogenic steps involved in the process of tumor neovascularization or to directly target and destroy the tumor vasculature and therefore blocking both the early- and late-stage angiogenesis. The inhibition of both receptors function by PCK3145 may confer an intrinsic advantage to the use of this peptide to inhibit angiogenesis.
?0 EXAMPLE 10 Effect on U-87 cell migration on hyaluronic acid Migration/invasion of cancer cells is a key event in tumor metastasis. In vitro, this process can be reconstituted by plating cells onto ECM-coated filters inserted in modified Boyden ?5 chemotactic chambers. The effect of the PCK3145 derivative can be monitored by the number of cells that had migrated comparatively to untreated control cells. In light of previous observations, the diminished migration onto hyaluronic acid (HA) matrice was confirmed. U-87 cells were treated with the PCK3145 derivative (300 ug/mI, 48 hrs), trypsinised, counted, and seeded on HA-coated filters inserted in modified Boyden Chambers. Cell migration was 30 allowed to proceed for 2 hours at 37 C. Filters were then stained for cells that have migrated through the filter. The results show that pretreatment with the PCK3145 derivative decreased basal U-87 cell migration by approximately 3-fold (Fig 9A). This result was performed for 3 more-times with new cell preparations.
Effect on U-87 cell adhesion to hyaluronic acid (HA) ECM recognition is a crucial event in the cell adhesion processes involved in tumor progression. This process is mediated and regulated through specialized cell surface receptors or integrins. While recent evidence suggests that a potential crosstalk between soluble MMP and cell surface integrins may regulate the cell's ability to recognize and adhere to its ECM environment, the PCK3145 derivative was tested in its ability to downregulate U-87 cell adhesion onto HA. U-87 cells were treated with the PCK3145 derivative (300 ug/mI, 48 hrs), trypsinised, counted, and seeded on wells coated with 10 ug/mI BSA
(bovine serum albumin) or HA. Cells were allowed to adhere for 3 hours. Three independent experiments were performed. Results of these experiments show that adhesion of cells treated with the PCK3145 derivative was significantly diminished on HA by 45-76% (Fig 9B).
Collectively, the inhibitory action of the PCK3145 derivative on ECM recognition and cell adhesion processes suggests that the expression of specific integrins or HA cell surface receptors such as those from the CD44 family could be targeted. Alternatively, such result also suggests that intracellular signalling regulating the activation states of cell surface integrins may be triggered by the PCK3145 derivative. One such potential intracellular protein is the GTPase RhoA, which is likely to mediate mechanisms regulating cytoskeletal morphogenesis.
Effect on CD44 cell surface shedding Decreased cell migration and adhesion on HA was observed when U-87 cells were pretreated with the PCK3145 derivative. This can be interpreted as either a potential ?5 downregulation of CD44 expression at the cell surface or by a potential cell surface shedding.
The latter hypothesis was tested by incubating serum-starve U-87 cells for 24 hours with the PCK3145 derivative (300 ug/mi), a concentration known to antagonize MMP
secretion. The conditioned media was then TCA-precipitated and Westernblotting an immunodetection for a 75 kDa immunoreactive protein using the anti-CD44 antibody was performed. An increased 10 CD44 cell surface shedding was demonstrated by the strong immunoreactive band observed in the cells which had been pre-treated with PCK3145.derivative (Fig. 10).
This effect is also shown in parallel with MT1-MMP-transfected cells. Such effect has been already reported by many groups and is established as one of the MT1-MMP-mediated functions in the regulation of the ECM adhesion. Interestingly, a slight increase in MT1-MMP expression in the cells 5 treated with the PCK3145 derivative was observed that may partially explain how PCK may lead to CD44 shedding. This induction has subsequently been reproduced below.
Altogether, these observations provide a rational for the diminished cell migration/adhesion. to HA.
Moreover, it is tempting to further suggest that this may also be a secondary regulation by the PCK3145 derivative of diminished cell surfacedocking of MMP-9 to CD44.
Effect on MT1-MMP and RhoA expression Specific manipulation of the GTPase Rho activity can be used to suppress or enhance the organizational behaviour of endothelial cells as well as it can restrict cancer cells proliferation. In particular, RhoA mediates cell contractility by organizing actin filaments which consequently regulates cell migration. Moreover, recent evidence suggested that RhoA/CD44/MMP-9 colocalized at common cell surface microdomains. Tests were carried out in order to determine whether the PCK3145 derivative affected RhoA gene and protein expression. U-87 cells were either treated with the PCK3145 derivative (300 ug/mI, 48 hrs).
Results of this experiment confirm that the PCK3145 derivative induced endogenous RhoA
protein expression in U-87 cells as assessed by Western blotting (Fig 11 A, Fig. 11C).
Finally, results show that RhoA protein expression induced by the PCK3145 derivative paralleled that of its gene expression as assessed by reverse transcription-polymerase chain reaction (RT-PCR) (Fig 11 D). Altogether, these results highlight the potential role of RhoA as being an intracellular mediator in the subsequent inhibitory activities of the derivative.
The overall effects of PSP94 family members described herein make them useful for treatment of several diseases in addition to the previously disclosed utility (inhibition of tumor 15 cell growth and skeletal metastasis).
For example, the effect of PSP94 family members on MMP-9 and MMP-2 makes them useful for reduction of cancer spreading and invasion of any type of cancer and not only for reduction of skeletal metastasis as disclosed and claimed in International application No.:
~0 PCT/CA02/01737. As such', PSP94 family member are able to prevent cancer (tumor) progression and metastasis as well as inhibiting angiogenesis.
The content of each publication, patent and patent application mentioned in the present application is incorporated herein by reference.
Although the present invention has been described in details herein and illustrated in the accompanying drawings, it is to be understood that the invention is not limited to the DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.
NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME
NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:
In an additional aspect, the present invention relates to a method of inhibiting or lowering protein secretion in a mammal, which may comprise the step of.administering to the mammal a compound (a pharmaceutical composition comprising a compound) which may be selected from the group consisting of a) SEQ ID NO.: 5, b) a SEQ ID NO.:5 derivative able to reduce (i.e., reducing) secretion of a protein (for example in a cell base assay described herein), c) a SEQ ID NO.:5 fragment able to reduce secretion of a protein, d) a SEQ ID NO.:5 analog able to reduce secretion of a protein, and e) combination of any one of a) through d) thereof or any other PSP94 family member.
"Secretion of a protein" or "protein secretion" is to be understood herein as the process in which a protein travels from within the intracellular space out to the extra-cellular environment.
In accordance with the present invention, the secretion of aprotein may be for example, a constitutive secretion or an induced secretion, etc. Further in accordance with the present ?0 invention, the protein may be selected, for example, from the group of gelatinases or from the group consisting of a matrix metalloproteinase and a pro-matrix metalloproteinase. The matrix metalloproteinase may be MMP-2. The pro-matrix metalloproteinase may be pro-MMP-2. The matrix metalloproteinase may also be MMP-9 and the pro-matrix metalloproteinase may be pro-MMP-9.
?5 In yet a further aspect the present invention relates to the use of a compound selected, for example, from the group consisting of a) SEQ ID NO.: 5, b) a SEQ ID NO.:5 derivative able to reduce secretion of a protein, c) a SEQ ID NO.:5 fragment able to reduce secretion of a protein, d) a SEQ ID NO.:5 analog able to reduce secretion of a protein, and e) combination ;0 of any one of a) through d) thereof or any other PSP94 family member, in the inhibition or lowering of protein secretion in a mammal.
The present invention therefore provides a treatment of a disease for which inhibition or lowering of protein secretion is desired or needed.
In an additional aspect, the present invention provides a method of inducing RhoGTPase expression in a mammal comprising the step of administering to the mammal a compound which may be selected from the group consisting of a) SEQ ID NO.:5, b) a SEQ
ID NO.:5 derivative able to induce RHoA protein, gene or mRNA expression in a cell based assay, c) a SEQ ID NO.:5 fragment able to induce RHoA protein, gene or mRNA expression in a cell based assay, d) a SEQ ID NO.:5 analog able to induce RHoA protein, gene or mRNA
expression in a cell based assay, and; e) combination of any one of a) through d) thereof or any other PSP94 family member.
In yet an additional aspect, the present invention relates to the use of a compound selected, for example, from the group consisting of a) SEQ ID NO.: 5, b) a SEQ ID NO.:5 derivative able to induce RHoA protein, gene or mRNA expression in a cell based assay, c) a SEQ ID
NO.:5 fragment able to induce RHoA protein, gene or mRNA expression in a cell based assay, d) a SEQ ID NO.:5 analog able to induce RHoA protein, gene or mRNA
expression in a cell based assay, and e) combination of any one of a) through d) thereof or any other PSP94 family member, in the induction of RhoGTPase expression in a mammal.
In accordance with the present invention, the RhoGTPase may be, for example, RhoA.
In another aspect the present invention relates to the use of a compound selected, for example, from the group consisting of a) SEQ ID NO.: 5, b) a SEQ ID NO.:5 derivative c) a SEQ ID NO.:5 fragment, d) a SEQ ID NO.:5 analog, and e) combination of any one of a) through d) thereof or any other PSP94 family member in the manufacture of a pharmaceutical composition for inducing RhoGTPase expression in a mammal, for preventing, inhibiting or suppressing cell adhesion in a mammal, for preventing, inhibiting or suppressing cell migration in a mammal or for inhibiting or lowering protein secretion in a Z5 mammal.
The present invention therefore provides a treatment of a disease for which induction of RhoGTPase is desired or needed.
In yet another aspect the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a compound selected, for example, from the group consisting of a) SEQ ID NO.: 5, b) a SEQ ID NO.:5 derivative c) a SEQ ID
NO.:5 fragment, d) a SEQ ID NO.:5 analog, and e) combination of any one of a) through d) thereof or any other PSP94 family member for inducing RhoGTPase expression in a mammal, for preventing, inhibiting or suppressing cell adhesion in a mammal, for preventing, inhibiting or suppressing cell migration in a mammal or for inhibiting or lowering protein secretion in a mammal.
In a further aspect the present invention relates to a compound selected, for example, from the group consisting of a) SEQ ID NO.: 5, b) a SEQ ID NO.:5 derivative c) a SEQ ID NO.:5 fragment, d) a SEQ ID NO.:5 analog, and e) combination of any one of a) through d) thereof or any other PSP94 family member for inducing RhoGTPase expression in a mammal, for preventing, inhibiting or suppressing cell adhesion in a mammal, for preventing, inhibiting or suppressing cell migration in a mammal or for inhibiting or lowering protein secretion in a mammal.
[0 In an additional aspect, the present invention relates to a compound member of the PSP94 family for use in the treatment of a condition related to the activity or the expression of a protease (e.g., a serine protease). The condition may happen through the activity or expression of the protease itself or onto another factor (e.g., a factor which may be part of.a cascade of event activated by the protease) which may be responsible for the condition.
In another aspect, the present invention provides a compound member of the PSP94 family for use in the treatment of a condition (state, disease) related, for example, to the activity or to the expression of a polypeptide which may be, for example, selected from the group consisting of matrix metalloproteinases and pro-matrix metalloproteinases.
?0 The present invention therefore provides a treatment of a disease for which reduction in the levels or activity of a matrix metalloproteinases or pro-matrix metalloproteinases is desired or needed. More particularly, diseases for which circulating (in the blood, or other bodily fluid) levels of a matrix metalloproteinases or pro-matrix metalloproteinases needs to be reduced ?5 are encompassed by the present invention.
Therefore, this invention also relates to the regulation (either directly or indirectly) of matrix metalloproteinases (MMPs), (e.g., MMP-9, MMP-2, MT1-MMP, etc.) by PSP94 family members. More particularly, the present invention relates to the use of a PSP94 family 30 member for the treatment of a condition related to the activity or expression of MMPs or pro-MMPs and/or to antagonize MMPs or pro-MMPs mediated cellular events (e.g., intracellular transduction mechanisms).
PSP94, PSP94 derivatives, PCK3145, PCK3145 derivatives, fragments, analogues and 35 homologues thereof may therefore find utility in cancer treatment, wound healing, anti-angiogesis, anti-inflammation, anti-osteoarthritis, inhibition of hair growth, reduction of degradation of some cytokine (e.g., IFN-beta) as well as for skin treatment (e.g., prevention of blistering photo-aging, psoriasis), wound healing, tissue remodeling, pulmonary fibrosis, etc More particularly, the member of the PSP94 family (PSP94 family member) may be selected, for example, from the group consisting of;
a)SEQIDNO.:1, b) a SEQ ID NO.:1 derivative which may be able to reduce (in a tissue, a cell or cell environment (e.g., extracellular environment)) the activity or the level of expression of a polypeptide selected from the group consisting of a pro-matrix metalloproteinase and a matrix metalloproteinase (e.g., MMP-2 and/or pro-MMP-2, MMP-9 and/or pro-MMP-9, etc.), c) a SEQ ID NO.:1 fragment which may be able to reduce the activity or the level of expression of a polypeptide selected from the group consisting of a pro-matrix metalloproteinase and a matrix metalloproteinase (e.g., MMP-2 and/or pro-MMP-2, MMP-9 and/or pro-MMP-9, etc.), d) SEQ ID NO.:1 analogue which may be able to reduce the activity or the level of expression of a polypeptide selected from the group consisting of a pro-matrix metalloproteinase and a matrix metalloproteinase (e.g., MMP-2 and/or pro-MMP-2, MMP-9 and/or pro-MMP-9, etc.), e) SEQ ID NO.:5, f) a SEQ ID NO.:5 derivative which may be able to reduce the activity or the level of expression of a polypeptide selected from the group consisting of a pro-matrix metalloproteinase and a matrix metalloproteinase (e.g., MMP-2 and/or pro-MMP-2, MMP-9 and/or pro-MMP-9, etc.), ?5 g) a SEQ ID NO.:5 fragment which may be able to reduce the activity or the level of expression of a polypeptide selected from the group consisting of a pro-matrix metalloproteinase and a matrix metalloproteinase (e.g., MMP-2 and/or pro-MMP-2, MMP-9 and/or pro-MMP-9, etc.), h) a SEQ ID NO.:5 analogue which may be able to reduce the activity or the level ~0 of expression of a polypeptide selected from the group consisting of a pro-matrix metalloproteinase and a matrix metalloproteinase (e.g., MMP-2 and/or pro-MMP-2, MMP-9 and/or pro-MMP-9, etc.), i) SEQ ID NO.:7, and j) combination of any one of a) through i) thereof.
In a further aspect, the present invention provides the use of a PSP94 family member for the treatment of a condition related to the expressionor related to the (e.g., biological, enzymatic) activity of a polypeptide which may be selected, for example, from the group consisting of matrix metalloproteinases and pro-matrix metalloproteinases.
In yet a further aspect, the present invention relates to the use of a PSP94 family member for the manufacture of a medicament (or pharmaceutical composition) for the treatment of a condition related to the expression or activity of a polypeptide which may be, for example, selected from the group consisting of matrix metalloproteinases and pro-matrix metalloproteinases.
In accordance with the present invention, the condition may be selected from the group consisting of angiogenesis, inflammation, atheroscelerotic plaque rupture, skin disease, uncontrolled tissue remodeling and pulmonary fibrosis or any other condition or utility described herein.
In yet another aspect, the present invention relates to the use of a PSP94 family member for reducing or controlling the development or spreading of metastasis or metastatic cancer (i.e, cancer progression to other (secondary) sites or spreading of tumor cells to other sites) other than skeletal metastasis.
In another aspect, the present invention relates to the use of a PSP94 family member for the promotion of wound healing, for reducing (inhibiting) angiogenesis, for reducing (preventing) inflammation, for preventing atheroscelerotic plaque rupture, for skin treatment, for treating osteoarthritis, for treating pulmonary fibrosis or for the inhibition of (unwanted) hair growth.
In a further aspect, the present invention provides a pharmaceutical composition for treating a condition which may be related to the activity and/or to the expression (level) of a polypeptide, which may be, selected from the group consisting of matrix metalloproteinases and pro-matrix metalloproteinases, the pharmaceutical composition may comprise;
a PSP94 family member as defined herein, and;
a pharmaceutically acceptable carrier.
In yet a further aspect, the present invention provides a method for treating a patient having a condition related to the activity and/or expression of a polypeptide selected from the group consisting of matrix metalloproteinases and pro-matrix metalloproteinases, the method comprising administering to the patient a compound which is a member of the PSP94 family.
In another aspect, the present invention relates to a method of treating a patient having a metastatic cancer or a metastasis other than skeletal metastasis, the method comprising administering to the patient a PSP94 family member.
In an additional aspect, the present invention relates to a matrix metalloproteinase regulation drug and/or a pro-matrix metalloproteinase regulation drug comprising a PSP94 family member.
In another aspect, the present invention provides a compound able to reduce the expression or activity of a polypeptide selected from the group consisting of a matrix metalloproteinases and a pro-matrix metalloproteinases, the compound may comprise or consist essentially of the amino acid sequence identified in SEQ ID NO.:5 and may further comprise a stabilizing group (e.g. a group increasing in vivo stability of the compound or polypeptide without affecting deleteriously the biological activity of the compound or polypeptide) covalently attached to an amino acid of the (SEQ ID NO.:5) sequence.
In accordance with the present invention the group may be, for example, an acetylaminomethyl group attached to a sulfur atom of a cysteine or a polyethylene glycol (PEG) group attached to at least one amino acid of the sequence or any other modification which improves a desired property (e.g., stability) of the compound/polypeptide.
In yet another aspect the present invention relates to a compound selected, for example, from the group consisting of a) SEQ ID NO.: 5, b) a SEQ ID NO.:5 derivative c) a SEQ ID
NO.:5 fragment, d) a SEQ ID NO.:5 analog, and e) combination of any one of a) through d) ?5 thereof or any other PSP94 family member for controling (reducing) protein secretion or for reducing the levels of a matrixmetalloproteinase or pro-matrixmetalloproteinase levels in a mammal in need thereof.
In a further aspect, the present invention provides a method for evaluating the efficacy of a ,0 treatment with a PSP94 family member in a patient having a metastatic cancer or metastasis, the method may comprise, for example, the steps of a) collecting a serum sample from the patient after treatment of the patient with a PSP94 family member;
b) measuring the (serum) levels of a polypeptide which may be selected from the 5 group consisting of MMP-9.and pro-MMP-9 in the sample obtained in step a) and;
c) comparing measured levels of step b) with another MMP-9 and/or pro-MMP-9 level selected from the group consisting of levels measured from a normal individual, standard levels or levels measured before treatment of the individual.
The method may also comprise the step of establishing the clinical outcome of the patient based on the comparison of the measured levels.
In accordance with the present invention, the method for evaluating the efficacy of a PSP94 treatment may also measure any other parameters which might correlate with the level of expression of the polypeptide (MMP-9 and/or pro-MMP-9, MMP-2 and/or pro-MMP-2) such as for example, RNA levels.
In accordance with the present invention, the matrix metalloproteinase may be, for example, MMP-2 or may be MMP-9 or any other MMPs. Also in accordance with the present invention, the pro-matrix metalloproteinase may be, for example, pro- MMP-2 or may be pro-MMP-9 or any other pro-MMPs.
More particularly, the present invention relates to a method of inhibiting angiogenesis in an ?0 individual in need thereof, the method comprising administering to the individual a compound selected from the group consisting of, SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce VEGF-induced VEGFR phosphorylation in an in vitro assay, 15 a SEQ ID NO.:5 fragment able to reduce VEGF-induced VEGFR phosphorylation in an in vitro assay, a SEQ ID NO.:5 analog able to reduce VEGF-induced VEGFR phosphorylation in an in vitro assay, and;
combination of any one of a) through d) thereof.
In accordance with the present invention, the compound may further comprise a grouping for increasing the stability of the compound. The grouping may be, for example, an acetylaminomethyl moiety attached to a sulfur atom of a cysteine.
The present invention also relates to a method of treating a mammal having ocular neovascularization or inflammation, the method may comprise administering to the mammal a compound selected from the group consisting of;
SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce VEGF-induced VEGFR phosphorylation in an in vitro assay, a SEQ ID NO.:5 fragment able to reduce VEGF-induced VEGFR phosphorylation in an in vitro assay, a SEQ ID NO.:5 analog able to reduce VEGF-induced VEGFR phosphorylation in an in vitro assay, and;
combination of any one of a) through d) thereof.
l0 Additionally the present invention relates to a pharmaceutical composition for treating angiogenesis, ocular neovascularization or inflammation, the composition may comprise a compound selected from the group consisting of SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce VEGF-induced VEGFR phosphorylation in an in vitro assay, a SEQ ID NO.:5 fragment able to reduce VEGF-induced VEGFR
l5 phosphorylation in an in vitro assay, a SEQ ID NO.:5 analog able to reduce VEG F-induced VEGFR phosphorylation in an in vitro assay and combination thereof, and;
a pharmaceutically acceptable carrier.
?0 In addition, the present invention relates to a method of preventing cancer progression in a mammal in need thereof, the method may comprise administering to the mammal a compound selected from the group consisting of;
SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or ?5 able to reduce the level of expression of MMP-9 in an in vitro assay, a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
30 combination of any one of a) through d) thereof.
The present invention also relates in a further aspect to a method of preventing metastasis in a mammal in need thereof, the method may comprise administering to the mammal a compound selected from the group consisting of;
35 SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
combination of any one of a) through d) thereof.
The present invention further relates to a method of treating a patient having a metastatic cancer or metastasis other than skeletal metastasis, the method may comprise administering to the patient a compound selected from the group consisting of SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
combination of any one of a) through d) thereof.
The present invention further relates to a pharmaceutical composition for preventing 10 metastasis in a mammal in need thereof, the pharmaceutical composition may comprise a compound selected from the group consisting of;
SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, ?5 a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
combination of any one of a) through d) thereof and:
30 a pharmaceutically acceptable carrier.
The present invention also relates to a pharmaceutical composition for preventing cancer progression in a mammal in need thereof, the pharmaceutical composition may comprise a compound selected from the group consisting of;
35 SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
combination of any one of a) through d) thereof and:
a pharmaceutically acceptable carrier.
Additionnally, the present invention relates to a pharmaceutical composition for treating metastatic cancer or metastasis other than skeletal metastasis in a mammal in need thereof, [0 the pharmaceutical composition may comprise a compound selected from the group consisting of;
SEQ ID NO.:5, a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, [5 a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expressionof MMP-9 in an in vitro assay, a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
combination of any one of a) through d) thereof and:
?0 a pharmaceutically acceptable carrier.
The present invention also provides a compound able to inhibit angiogenesis, the compound may consist essentially of the amino acid sequence identified in SEQ ID NO.:5 and may further comprise a stabilizing group covalently attached, for example, to an amino acid of the >_5 sequence.
The stabilizing group may be, for example, an acetylaminomethyl moiety attached to a sulfur atom of a cysteine. The compound may have, for example, the composition defined in SEQ
ID NO.:7 As used herein, "VEGF' means vascular endothelial growth factor and VEGFR or VEGF-R
means vascular endothelial growth factor receptor and includes VEGFR-2 which means endothelial growth factor receptor type-2.
As used herein, "PDGF' means platelet-derived growth factor and PDGFR or PDGF-R
means platelet-derived growth factor receptor.
A "PSP94 family member" or "a member of the PSP94 family" is understood herein as any polypeptide originating from PSP94. For example, "PSP94 family members" may comprise wild type PSP94 (SEQ ID NO.:1) a PSP94 fragment, a PSP94 derivative, a PSP94 analogue, PCK3145 (SEQ ID NO.:5), a PCK3145 fragment, a PCK3145 derivative (SEQ ID
NO.:7), a PCK3145 analogue, etc. PSP94 family members therefore also include, for example, SEQ ID
NO.:2, SEQ ID NO.: 3, SEQ ID NO.:4, SEQ ID NO.:6, as well as SEQ ID NO.: 9 to 98.
A"fragment" is to be understood herein as a polypeptide originating from a portion of an original or parent sequence. Fragments encompass polypeptides having truncations of one or more amino acids, wherein the truncation may originate from the amino terminus (N-terminus), carboxy terminus (C-terminus), or from the interior of the protein.
A fragment may comprise the same sequence as the corresponding portion of the original sequence. For example, SEQ ID NO.: 4, SEQ ID NO.: 5 and SEQ ID NO.: 6 fall into the definition of "a PSP94 fragmenY'; when considering PSP94 (SEQ ID NO.:1) as an original sequence.
A "derivative" is to be understood herein as a polypeptide originating from an original sequence or from a portion of an original sequence and which may comprise one or more modification; for example, one or more modification in the amino acid sequence (e.g., an amino acid addition, deletion, insertion, substitution etc.), one or more modification in the 10 backbone or side-chain of one or more amino acid, or an addition of a group or another molecule to one or more amino acids (side-chains or backbone). For example, SEQ ID NO.:
2, SEQ ID NO.: 3 and SEQ ID NO.: 7 fall into the definition of "a PSP94 derivative"; when considering PSP94 (SEQ ID NO.:1) as an original sequence.
?5 It is to be understood herein that SEQ ID NO.: 7 may fall into the definition of "a PCK3145 derivative" or "SEQ ID NO.:5 derivative) when considering PCK3145 (SEQ ID
NO.:5) as an original sequence. The addition of polyethylene glycol group (i.e., pegylation) to PCK3145 (SEQ ID NO.:5 or SEQ ID NO.: 7) also falls within the definition of "a PCK3145 derivative".
30 In accordance with the present invention the SEQ ID NO.:1 fragment may be selected, for example, from the group consisting of SEQ ID NO.:4 and SEQ ID NO.:6.
Also in accordance with the present invention the SEQ ID NO.:1 derivative may be selected, for example, from the group consisting of SEQ ID NO.:2 and SEQ ID NO.:3.
An "analogue" is to be understood herein as a molecule having a biological activity and chemical structure similar to that of a polypeptide described herein. An "analogue" may have sequence similarity with that of an original sequence or a portion of an original sequence and may also have a modification of its structure as discussed herein. For example, an "analogue" may have at least 90 % sequence similarity with an original sequence or a portion of an original sequence. An "analogue" may also have, for example; at least 70 % or even 50 % sequence similarity (or less, i.e., at least 40%) with an original sequence or a portion of an original sequence. Also, an "analogue" may have, for example, 50 % sequence similarity to an original sequence with a combination of one or more modification in a backbone or side-chain of an amino acid, or an addition of a group or another molecule, etc.
Thus, biologically active polypeptides in the form of the original polypeptides, fragments (modified or not), analogues (modified or not), derivatives (modified or not), homologues, (modified or not) of PSP94 and PCK3145 are encompassed by the present invention.
Therefore, any polypeptide having a modification compared to an original polypeptide (e.g., PSP94, PCK3145) which does not destroy significantly a desired biological activity is encompassed herein. It is well known in the art, that a number of modifications may be made to the polypeptides of the present invention without deleteriously affecting their biological activity. These modifications may, on the other hand, may keep or increase the biological activity of the original polypeptide or may optimize one or more of the particularity (e.g.
stability, bioavailability, etc.) of the polypeptides of the present invention which, in some instance might be desirable. Polypeptides of the present invention comprises for example, those containing amino acid sequences modified either by natural processes, such as posttranslational processing, or by chemical modification techniques which are known in the art. Modifications may occur anywhere in a polypeptide including the polypeptide backbone, the amino acid side-chains and the amino- or carboxy-terminus. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications.
Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from posttranslational natural processes or may be made by synthetic methods.
Modifications comprise for example, without limitation, pegylation, acetylation, acylation, addition of acetomidomethyl (Acm) group, ADP-ribosylation, alkylation, amidation, biotinylation, carbamoylation, carboxyethylation, esterification, covalent attachment to fiavin, covalent attachment to a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of drug, covalent attachment of a marker (e.g., fluorescent, radioactive, etc.), covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation and ubiquitination, etc. It is to be understood herein that more than one modification to the polypeptides described herein are encompassed by the present invention to the extent that the biological activity is similar to the original (parent) polypeptide.
As discussed above, polypeptide modification may comprise, for example, amino acid insertion (i.e., addition), deletion and substitution (i.e., replacement), either conservative or non-conservative (e.g., D-amino acids, desamino acids) in the polypeptide sequence where such changes do not substantially alter the overall biological activity of the polypeptide.
Example of substitutions may be those, which are conservative (i.e., wherein a residue is replaced by another of the same general type or group) or when wanted, non-conservative (i.e., wherein a residue is replaced by an amino acid of another type). In addition, a non-naturally occurring amino acid may substitute for a naturally occurring amino acid (i.e., non-naturally occurring conservative amino acid substitution or a non-naturally occurring non-conservative amino acid substitution).
As is understood, naturally occurring amino acids may be sub-classified as acidic, basic, neutral and polar, or neutral and non-polar. Furthermore, three of the encoded amino acids are aromatic. It may be of use that encoded polypeptides differing from the determined ?5 polypeptide of the present invention contain substituted codons for amino acids, which are from the same type or group as that of the amino acid be replaced. Thus, in some cases, the basic amino acids Lys, Arg and His may be interchangeable; the acidic amino acids Asp and.
Glu may be interchangeable; the neutral polar amino acids Ser, Thr, Cys, GIn, and Asn may be interchangeable; the non-polar aliphatic amino acids Gly, Ala, Val, IIe, and Leu are f0 interchangeable but because of size Gly. and Ala are more closely related and Val, IIe and Leu are more closely related to each other, and the aromatic amino acids Phe, Trp and Tyr may be interchangeable.
It should be further noted that if the polypeptides are made synthetically, substitutions by 6 amino acids, which are not naturally encoded by DNA (non-naturally occurring or unnatural amino acid) may also be made.
A non-naturally occurring amino acid is to be understood herein as an amino acid which is not naturally produced or found in a mammal. A non-naturally occurring amino acid comprises a D-amino acid, an amino acid having an acetylaminomethyl group attached to a sulfur atom of a cysteine, a pegylated amino acid, etc. The inclusion of a non-naturally occurring amino acid in a defined polypeptide sequence will therefore generate a derivative of the original polypeptide. Non-naturally occurring amino acids (residues) include also the omega amino acids of the formula NH2(CH2)nCOOH wherein n is 2-6, neutral nonpolar amino acids, such as sarcosine, t-butyl alanine, t-butyl glycine, N-methyl isoleucine, norleucine, etc.
Phenylglycine may substitute for Trp, Tyr or Phe; citrulline and methionine sulfoxide are neutral nonpolar, cysteic acid is acidic, and ornithine is basic. Proline may be substituted with hydroxyproline and retain the conformation conferring properties.
It is known in the art that analogues may be generated by substitutional mutagenesis and retain the biological activity of the polypeptides of the present invention.
These analogues have at least one amino acid residue in the protein molecule removed and a different residue inserted in its place. For example, one site of interest for substitutional mutagenesis may include but are not restricted to sites identified as the active site(s), or immunological site(s).
Other sites of interest may be those, for example, in which particular residues obtained from various species are identical. These positions may be important for biological activity.
Examples of substitutions identified as "conservative substitutions" are shown in table 1. If such substitutions result in a change not desired, then other type of substitutions, denominated "exemplary substitutions" in table 1, or as further described herein in reference to amino acid classes, are introduced and the products screened.
In some cases it may be of interest to modify the biological activity of a polypeptide by amino acid substitution, insertion, or deletion. For example, modification of a polypeptide may result in an increase in the polypeptide's biological activity, may modulate its toxicity, may result in changes in bioavailability or in stability, or may modulate its immunological activity or immunological identity. Substantial modifications in function or immunological identity are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation. (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side chain properties:
(1) hydrophobic: norleucine, methionine (Met), Alanine (Ala), Valine (Val), Leucine (Leu), Isoleucine (IIe) (2) neutral hydrophilic: Cysteine (Cys), Serine (Ser), Threonine (Thr) (3) acidic: Aspartic acid (Asp), Glutamic acid (Glu) (4) basic: Asparagine (Asn), Glutamine (Gln), Histidine (His), Lysine (Lys), Arginine (Arg) (5) residues that influence chain orientation: Glycine (Gly), Proline (Pro);
and aromatic: Tryptophan (Trp), Tyrosine (Tyr), Phenylalanine (Phe) Non-conservative substitutions will entail exchanging a member of one of these classes for another.
10. TABLE 1. amino acid substitution Original residue Exemplary substitution Conservative substitution Ala (A) Val, Leu, Ile Val Arg (R) Lys, Gln, Asn Lys Asn (N) Gin, His, Lys, Arg Gin Asp (D) Glu Glu Cys (C) Ser Ser Gln (Q) Asn Asn Glu (E) Asp Asp Gly (G) Pro Pro His (H) Asn, Gln, Lys, Arg Arg Ile (I) Leu, Val, Met, Ala, Phe, Leu norleucine Leu (L) Norieucine, Ile, Val, Met, Ile Ala, Phe Lys (K) Arg, Gln, Asn Arg Met (M) Leu, Phe, Ile Leu Phe (F) Leu, Val, Ile, Ala Leu Pro (P) Gly Gly Ser (S) Thr Thr Thr(T) Ser Ser Trp (W) Tyr Tyr Tyr (Y) Trp, Phe, Thr, Ser Phe Val (V) Ile, Leu, Met, Phe, Ala, Leu norleucine Example of biologically active analogues of PCK3145 (SEQ ID NO: 5) exemplified by amino acid substitutions is illustrated below.
Position 1 5 10 15 (SEQ ID
X, W Q X2 D X, C X, X2 C X2 C X3 X, X2 NO.:88) For example, X, may be glutamic acid (i.e., glutamate) (Glu), aspartic acid (aspartate) (Asp), or asparagine (Asn), X2 may be threonine (Thr) or serine (Ser) and X3 may be tyrosine (Tyr) or phenylalanine (Phe). Any replacement of an original residue in SEQ ID NO.:5 with a conserved amino acid (i.e. conservative substitution) is encompassed by the present invention.
Another example of a PCK3145 (SEQ ID NO: 5) analogue may include, for example, a polypeptide as exemplified in SEQ ID NO.:88 or any other polypeptide having at least one conservative amino acid substitution (illustrated in bold below) as defined in Table 1, such as, 1.5 for example;
Glu Tyr GIn Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr (SEQ ID NO.:92) Glu Trp Asn Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr (SEQ ID NO.:93) Glu Trp Gin ThrAsp Gin Ser Glu Thr Cys Thr Cys Tyr Asp Thr (SEQ ID NO.:94) Examples of a PCK3145 (SEQ ID NO: 5) derivative may include, for example, a polypeptide having an addition in one or both of the terminal region (amino-terminal or carboxy-terminal) 25 as illustrated in SEQ IDs No.: 9 to 87, or a peptide having a stabilizing group such as exemplified in SEQ ID NO.:7, or a peptide having one or more repeats of SEQ ID
No.:5 such as exemplified in SEQ ID NOs.: 89 to 91, a polypeptide having at least one D-amino acid as exemplified in SEQ ID No. 98 and combination thereof.
An example of a PCK3145 (SEQ ID NO: 5) fragment may include, for example, a polypeptide having a truncation in one or both of the amino acid terminal region as illustrated below.
Trp Gin Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr (SEQ ID NO.:95) Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr GIu-Thr (SEQ ID NO.:96) Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys (SEQ ID NO.:97) Polypeptides may be either naturally occurring (that is to say, substantially purified or isolated from a natural source) or synthetic (for example, by performing site-directed mutagenesis on the encoding DNA or made by other synthetic methods such as chemical synthesis). It is thus apparent that the polypeptides of the invention can be either naturally occurring or l0 recombinant (that is to say prepared from the recombinant DNA techniques) or made by chemical synthesis (e.g., organic synthesis).
As used herein, "pharmaceutical composition" means therapeutically effective amounts of the agent together with pharmaceutically acceptable diluents, preservatives, solubilizers, l5 emulsifiers, adjuvant and/or carriers. A "therapeutically effective amount"
as used herein refers to that amount which provides a therapeutic effect for a given condition and administration regimen. Such compositions are liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (e.g., Tris-HCI., acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent absorption ?0 to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts). Solubilizing agents (e.g., glycerol, polyethylene glycerol), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (e.g., lactose, mannitol), covalent attachment of polymers such as polyethylene glycol to the protein, complexation with metal ions, or incorporation of the >.5 material into or onto particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, hydrogels, etc, or onto liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts. Such compositions will influence the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance.
Controlled or sustained release compositions include formulation in lipophilic depots (e.g., W fatty acids, waxes, oils). Also comprehended by the invention are particulate compositions coated with polymers (e.g., poloxamers or poloxamines). Other embodiments of the compositions of the invention incorporate particulate forms protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal, oral, vaginal, rectal routes. In one embodiment the pharmaceutical 35 composition is administered parenterally, paracancerally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, subcutaneously, intraperitonealy, intraventricularly, intracranially and intratumorally., The formulations include those suitable for oral, rectal, ophthalmic, (including intravitreal or intracameral) nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intratracheal, and epidural) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by conventional pharmaceutical techniques. Such techniques include the step of bringing into association the active ingredient and the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into associate the active ingredient with liquid carriers or finely divided solid carriers or both, [0 and then, if necessary, shaping the product.
Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules,.cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil emulsion and as a bolus, etc.
A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, ?0 the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent. Molded tablets may be made by molding, in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may be optionally coated or scored and may be formulated so as to provide a slow or controlled release of the active >.5 ingredient therein.
Formulations suitable for topical administration in the mouth include lozenges comprising the ingredients in a flavored basis, usually sucrose and acacia or tragacanth;
pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia;
10 and mouthwashes comprising the ingredient to be administered in a suitable liquid carrier.
Formulations suitable for topical administration to the skin may be presented as ointments, creams, gels and pastes comprising the ingredient to be administered in a pharmaceutical acceptable carrier. An example of a topical delivery system is a transdermal patch containing f5 the ingredient to be administered.
Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.
Formulations suitable for nasal administration, wherein the carrier is a solid, include a coarse powder having a particle size, for example, in the range of 20 to 500 microns which is administered in the manner in which snuff is administered, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
Suitable formulations, wherein the carrier is a liquid, for administration, as for example, a nasal spray or as nasal drops, include aqueous or oily solutions of the active ingredient.
Formulations suitable for vaginal administration may be presented as pessaries, tamports, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) >.0 conditions requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
Further, as used herein "pharmaceutically acceptable carrier" or "pharmaceutical carrier" are ?5 known in the art and include, but are not limited to, 0.01-0.1 M or 0.05 M
phosphate buffer or 0.8 % saline. Additionally, such pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, 30 emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's orfixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like.
Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, collating 35 agents, inert gases and the like.
It is to be understood herein, that if a "range" or "group" of substances (e.g. amino acids), substituents" or the like is mentioned or if other types of a particular characteristic (e.g.
temperature, pressure, chemical structure, time, etc.) is mentioned, the present invention relates to and explicitly incorporates herein each and every specific member and combination of sub-ranges or sub-groups therein whatsoever. Thus, any specified range or group is to be understood as a shorthand way of referring to each and every member of a range or group individually as well as each and every possible sub-ranges or sub-groups encompassed therein; and similarly with respect to any sub-ranges or sub-groups therein.
Thus, for example, with respect to a temperature greater than 1000 C, this is to be understood as specifically incorporating herein each and every individual temperature state, as well as sub-range, above 1000 C, such as for example 1010 C, 105 C and up, 1100 C
and up, 1150 C and up, 110 to 135 C, 115 c to 135 C, 102 C to 150 C, up to 210 C, [5 etc.;
and similarly with respect to other parameters such as, concentrations, elements, etc...
It is in particular to be understood herein that the polypeptides of the present invention each ?0 include each and every individual polypeptide described thereby as well as each and every possible mutant, variant, homolog, analogue or else whether such mutant, variant, homolog, analogue or else is defined as positively including particular polypeptides, as excluding particular polypeptides or a combination thereof; for example an exclusionary definition for a polypeptide analogue (e.g. X,WQX2DX,CX,X2CX2CX3X,X2 (SEQ ID NO.88)) may read as ?5 follows: "provided that when one of X, is glutamic acid and X2 is threonine X3 may not be phenylaianine".
It is also to be understood herein that "g" or "gm" is a reference to the gram weight unit; that "C" is a reference to the Celsius temperature unit.
BRIEF DESCRIPTION OF DRAWINGS
In drawings which illustrates exemplary embodiment of the present invention;
Fig. 1 is a picture of a zymography gel showing the effect of the PCK3145 derivative (SEQ ID
NO.:7) on MMP-9 levels and activity on collagen type 1- treated MatLyLu cells (first lane:marker; second lane:cells; third lane:cells and collagen; fourth lane:cells, collagen and 500 g/ml of SEQ ID NO.:7; fifth lane:cells, collagen and 1 mg/ml of SEQ ID
NO.:7), Fig. 2 is a picture of a western blot membrane showing the effect of the PCK3145 derivative (SEQ ID NO.:7) on MMP-9 expression level (fist lane: MMP9 standard; second lane:cells;
third lane:cells and collagen; fourth Iane:cells, collagen and 100 g/ml of SEQ
ID NO.:7; fifth lane: cells, collagen and 500 g/ml of SEQ ID NO.:7; sixth lane: cells, collagen and 1 mg/ml of SEQ ID NO.:7), l0 Fig 3A. is a picture of a zymography gel showing the effect of the PCK3145 derivative (SEQ
ID NO.:7) on MMP-2 levels and VEGF-induced MMP-2 levels (PD =PD98059, PCK=PCK3145 derivative), Fig. 3B is an histogram expressing the results of Fig. 3A in a quantitative manner, l5 Fig. 4A is picture of a western blot showing the effect of the PCK3145 derivative (SEQ ID
NO.:7) on induced ERK phosphorylation (Ctl=control, PCK=PCK3145 derivative), Fig. 4B is an histogram expressing the results of Fig. 4A in a quantitative manner, ?0 Fig. 4C is picture of a western blot showing the dose-dependent effect of the PCK3145 derivative (SEQ ID NO.:7) on VEGF-induced ERK phosphorylation (PD =PD98059, PCK=PCK3145 derivative), Fig. 4D is an histogram expressing the results of Fig. 4C in a quantitative manner, ?5 Fig. 4E is picture of a western blot showing the absence of inhibition of VEGF-induced ERK' phosphorylation by a scrambled polypeptide (SEQ ID NO.:99) (Ctl=control), Fig. 4F is an histogram expressing the results of Fig. 4E in a quantitative manner, , Fig. 4G is picture of a western blot of a time-course illustrating the reduction of VEGF-induced ERK phosphorylation by PCK3145 derivative (SEQ ID NO.:7) (Ctl=control, PCK=PCK3145 derivative), Fig. 4H is an histogram expressing the results of Fig. 4G in a quantitative manner, Fig. 5A is a picture illustrating the effect of the PCK3145 derivative on capillary-like structure formation, Fig. 5B is an histogram expressing the results of Fig. 5A in a quantitative manner (PCK=PCK3145 derivative), Fig. 6A is picture of a western blot showing the effect of the PCK3145 derivative (SEQ ID
NO.:7) on VEGF-induced VEGFR-2 phosphorylation (Ctl=control, PCK=PCK3145 derivative), [0 Fig. 6B is an histogram expressing the results of Fig. 6A in a quantitative manner, Fig. 6C is a picture of a western blot showing the dose-dependent effect of the PCK3145 derivative (SEQ ID NO.:7) on VEGF-induced VEGFR-2 phosphorylation (PD
=PD98059, PCK=PCK3145 derivative, PTK= PTK787), Fig. 6D is an histogram expressing the results of Firg. 6C in a quantitative manner, Fig. 6E is a picture of a western blot showing the absence of inhibition of VEGF-induced VEGFR-2 phosphorylation by a scrambled polypeptide (SEQ ID NO.:99) (Ctl=control), ?0 Fig..6F is an histogram expressing the results of Fig. 6E in a quantitative manner, Fig. 7A is a picture of a western blot showing the effect of the PCK3145 derivative (SEQ ID
NO.:7) on PDGF-induced PDGFR phosphorylation (Ctl=control, PCK=PCK3145 derivative), ?5 Fig. 7B is an histogram expressing the results of Fig. 7A in a quantitative manner, Fig. 7C is a picture of a western blot showing the dose-dependent effect of the PCK3145 derivative (SEQ ID NO.:7) on PDGF-induced ERK phosphorylation (PD. =PD98059, W PCK=PCK3145 derivative), Fig. 7D is an histogram expressing the results of Fig. 7C in a quantitative manner, Fig. 8A is an histogram illustrating the results of alcaline phosphatase secretion in the 35 presence or absence of the PCK3145 derivative (SEQ ID NO.:7) from cells containing a vector expressing a SEAP gene driven by (operatively linked with) specific response elements, Fig. 8B is a picture of a western blot of a time-course assay illustrating the effect of PCK3145 derivative (SEQ ID NO.:7) on ERK phosphorylation (PCK=PCK3145 derivative), Fig. 8C is a picture of a western blot of a dose-response assay illustrating the effect of PCK3145 derivative (SEQ ID NO.:7) on ERK phosphorylation (PCK=PCK3145 derivative), Fig. 8D is a picture of a western blot illustrating the effect of PCK3145 derivative (SEQ ID
NO.:7) on ERK phosphorylation (PCK=PCK3145 derivative), Fig. 9A is a histogram quantifying U-87 cell migration on hyaluronic acid (HA) in the presence or absence of the PCK3145 derivative (Ctl=control, PCK=PCK3145 derivative), Fig. 9B is a histogram quantifying U-87 cell adhesion to hyaluronic acid (HA) in the presence or absence of the PCK3145 derivative (Ctl=control, PCK=PCK3145 derivative), Fig. 10 is a picture of a western blot showing the effect of the PCK3145 derivative on MT1 -MMP celi expression and CD44 shedding from the cell surface, ?0 Fig. 11A is a picture of a western blot showing the effect of the PCK3145 derivative on MT1-MMP expression in transfected cells and RhoA expression in cells, Fig. 11B is an histogram illustrating in a quantitative manner, MMT1-MMP
expression in the presence or absence of PCK3145 obtained in Fig. 11 A, ?5 Fig. 11 C is an histogram illustrating in a quantitative manner, RhoA
expression in the presence or absence of PCK3145 obtained in Fig. 11 A, and;
Fig. 11 D is a picture of a gel illustrating the effect of the PCK3145 derivative on Rho RNA
30 levels.
DETAILED DESCRIPTION OF THE INVENTION
Polypeptides which are members of the PSP94 family include; wild type PSP94 as defined in 35 SEQ ID NO.: 1, a recombinant PSP94 as defined in SEQ ID NO.:2 and PSP94 derivatives, fragments and analogues as defined, for example in the amino acid sequence defined in SEQ ID NO.: 3, SEQ ID NO.:4, SEQ ID NO.:5, SEQ ID NO.:6 and SEQ ID NO.:7.
PCK3145 (SEQ ID NO.:5) was chosen as a representative of the PSP94 family based on previous encouraging results of tumor growth inhibition observed in animals.
Test compound. The wild type amino acid sequence of PCK3145 has. been disclosed, for example, in international application No.: PCT/CA01/01463 and is defined herein in SEQ ID
NO.: 5. A PCK3145 derivative has been generated by attaching an acetylaminomethyl group to the sulfur atom of each of the three cysteines of PCK3145. These groups stabilize the compound by preventing formation of peptide dimers or polymer by blocking the sulfhydryl .0 group of cysteines. This PCK3145 derivative is defined in SEQ ID NO.: 7.
The drug was manufactured by Multiple Peptide Systems (3550) (General Atomics Court, San Diego, Calif.) using standard solid-phase peptide chemistry and lyophilized into a powder.
Other type of synthesis or manufacture method may however be performed to make a peptide or polypeptide of the invention. Other PCK3145 derivatives, analogs and fragments (e.g., SEQ
.5 IDs NO: 88, 98, etc.) may be generated similarly.
The reconstituted drug used in the present example is made from a solution containing a 20 mg/mL of PCK3145 derivative (SEQ ID NO.:5 derivative); SEQ ID NO.: 7, in a phosphate buffer at pH 7.4 for dilution in sterile saline (0.9% NaCI, BP) prior to intravenous !0 administration. The solutions is filled into Type 1 glass vials, stoppered with Teflon -faced butyl stoppers, and sealed with flip-off seals.
CLINICAL TR/AL
Trial Design !5 The clinical trial is a multiple.ascending dose, open-label, Phase Ila study evaluating the safety and tolerability of PCK3145 derivative; SEQ ID NO.:7 administered intravenously in patients with metastatic hormone resistant prostatic cancer (HRPC). The study is not randomized. Patients have been enrolled sequentially and chronologically.
S0 Inclusion Criteria Patients had fulfilled the following criteria prior to receiving the first administration of the test drug:
Signed informed consent, Have a histologically confirmed metastatic adenocarcinoma of the prostate, i5 Be characterized as a stage IV prostatic cancer, Have a metastatic hormone resistant prostatic cancer; resistance being defined as progressive disease after at least one hormonal therapy (orchiectomy, oestrogens, LHRH
therapy). Progressive disease is defined in accordance with the recommendations of the Prostate Specific Antigen Working Group (Bubley, J.G., et al., J. of Clinic.
Oncol. 17:
3461-3467, 1999) which defines progressive disease as:
an increasing or development of new measurable disease or presence of new bone lesions on bone scan with a PSA level greater or equal to ng/mL or two consecutive increases in PSA. The first increase should occur a minimum of week from the reference value, and PSA level should be greater or equal to 5ng/mL, Be minimally symptomatic or asymptomatic defined as patients that may require chronic opioid analgesics but have been on a stable pain management regimen for at least 4 weeks, Be males of at least 18 years of age, Have baseline laboratory values as specified below:
Aspartate aminiotransferase (ASAT) (S.I. Unit Value = Upper Normal Limit 42 u/L or <0.7kat/L) less than or equal to 2.0 times the upper limit of normal and alanine aminotransferase (ALAT) (S.l.Unit Value = Upper Normal Limit <48u/L
or s0.8Nkat/L) less than or equal to 2.0 times the upper limit of normal Bilirubin less than 1.8mg/dL (S. I. Unit Value = s25.4NmoL/L) ?0 Creatinine less than 1.8 mg/dL (S.I.Unit Value = s 159 NmoL/L) Platelets > 100,000/mm3 (S.I. Unit Value =>100x 109 /L), Have a life expectancy of at least 6 months, Have a Karnofsky Performance status of 70% or greater, Have the ability to understand the requirements of the study, provide written informed ?5 consent, abide by the study restrictions, and agree to return for the required assessments, Reliable contraception must be used throughout the study.
Organisation of the study 30 The drug was therefore administered to patients characterized as having metastatic adenocarcinoma of the prostate, stage IV prostatic cancer and as having a metastatic hormone resistant prostatic cancer. Four patients per cohort and 4 ascending doses were evaluated. The ascending doses were 5, 20, 40 and 80 mg/m2. The dose escalation decision has been based on dose-limiting toxicity (DLT).
The 33-day cycle of treatment consisted of a PCK3145 derivative; SEQ ID NO.:7 administration three times per week (day 1, 3 and 5) for 26 days, followed by a 7 day post-treatment observation period. The maximum tolerated dose (MTD) is the dose level below the one inducing grade 3 or 4 drug related toxicity (DLT) in two patients from a cohort of a minimum of 4 patients. Only DLT's observed during the first cycle have been used for the dose escalation decision.
Each patient's participation consisted of the following study periods: a screening period held (between days -14 to -1), a baseline visit (at day 1) and before administration of the drug, a treatment period (from day 1 to day 26), a 7 days post-treatment observation period (from day 27 to day 33), a 6 month follow-up period where survival status, disease status and information about the occurrence of second primary tumors are assessed and a long term follow up period where survival status is assessed.
The treatment period consisted of intravenous administration of the PCK3145 derivative (SEQ ID NO.:5 derivative) i.e., SEQ ID NO.:7, three times per week (day 1, 3 and 5) for 26 consecutive days during which patients were closely monitored and undergone regular examination. After a week of treatment break and in the absence of toxicity and disease progression, patients optionally received additional treatment cycles.
Biological samples were drawn during different time points of the study for the purpose of ?0 safety monitoring and have been assayed for MMP-9 levels. Plasma samples were placed on dry ice and stored frozen (approximately -70 C) and subsequently analyzed for total MMP-9 levels.
:5 MMP-9 assay methodology. An Elisa assay measuring total MMP-9, i.e., human active and pro-MMP-9, (Quantikine , Cat. No.: DMP900, R&D Systems Inc.) was performed on plasma-heparin samples. Plasma samples have been collected from individuals at day 1 (before treatment) and at day 27 of each treatment cycle.
0 The Quantikine MMP-9 immunoassay 'is a solid phase ELISA designed to measure total MMP-9 (92kDa pro- and 82kDa active forms) in serum, plasma, saliva, urine and cell culture supernatants. It is calibrated with CHO-cells expressed recombinant human pro-MMP-9 and the antibodies were raised against the recombinant factor. Both antibodies also recognize recombinant human active MMP-9. Natural human MMP-9 showed dose-response curves 5 that were parallel to the standard curves obtained using the recombinant Quantikine kit standards, indicating that the Quantikine kit may be used to determine relative mass values of natural human MMP-9.
The assay employs the quantitative sandwich enzyme immunoassay technique. A
monoclonal antibody specific for MMP-9 has been pre-coated onto a microplate.
Standards and samples are added into the wells, and MMP-9 is thus bound by the immobilized antibody. After washing away unbound substances, an enzyme-linked polyclonal antibody specific for MMP-9 is added to the wells. Following a wash to remove unbound antibody-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of total MMP-9 (pro and/or active) bound in the initial step.
The color development is stopped and the intensity of the color is measured.
Zymography. Zymography is a technique generally used to analyze the activity of matrix metalloproteinases (MMPs) in biological samples. It involves the electrophoretic separation of proteins under denaturing (Sodium Dodecyl Sulfate (SDS)) but non-reducing conditions through a polyacrylamide gel containing gelatin (for example, 10% gel containing 1 mg/mI
gelatin for MMP-9 and MMP-2 assays). The resolved proteins are re-natured by exchanging SDS with a non-ionic detergent such asTriton X-100 and the gel is incubated in an incubation buffer for activation of MMP-2 and MMP-9 (for example at 37 C for 18 hrs). The gel is stained with Coomassie blue and the MMP-2 a.nd MMP-9 bands may be visualized as clear bands against a blue background (i.e., the MMPs degrade the gelatin and are visualized as clear !0 bands; pro MMP-2 is 68 kDa and pro-MMP-9 is 92 kDa). These bands can be quantified using densitometry. For example, prior to stimulation, quiescent HUVEC were serum-starved for 16 h in the presence or absence of PCK3145 or PD98059 and then stimulated with VEGF. The conditioned media were collected 24 h after stimulation, and clarified by centrifugation. Identical volume of conditioned media were mixed with non reducing Laemmli !5 sample buffer and subjected to 7.5% SDS-polyacrylamide gels containing 1 mg/ml gelatin (Sigma). The gels were then incubated for 30 min at room temperature twice in 2.5% (v/v) Triton X-100 and rinsed five times in doubly distilled water. The gels were incubated at 37 C
for a further 18 h in 200 mM NaCI/5 mM CaCI2/0.02% (v/v) Brij-35/50 mM
Tris/HCI buffer (pH
7.6), then stained with 0.1% Coomassie Brilliant Blue R-250, followed by destaining in 10%
0 (v/v) acetic acid/30% (v/v) methanol in water. Gelatinolytic activity was detected as unstained bands on a blue background.
Materials. Cell culture media were obtained from Life Technologies (Burlington, Ontario, 5 Canada) and serum was purchased from Hyclone Laboratories (Logan, UT).
Electrophoresis reagents were purchased from Bio-Rad (Mississauga, Ontario, Canada). The polyclonal (C-1158) and monoclonal (A3) antibodies, used for precipitation and detection, respectively, of VEGFR-2, and the anti-PDGFR pAb (958) were obtained from Santa Cruz Biotechnologies (Santa Cruz, CA). Antiphosphotyrosine mAb PY99 was also purchased from Santa Cruz Biotechnologies. Anti-phospho-ERK polyclonal antibodies were from Cell Signaling Technology (Beverly, MA). Anti-mouse and anti-rabbit horseradish peroxidase-linked secondary antibodies were purchased from Jackson lmmunoResearch Laboratories (West Grove, PA) and enhanced chemiluminescence (ECL) reagents were from Amersham Pharmacia Biotech (Baie d'Urfe, Quebec, Canada). Human recombinant PDGF was obtained from R&D Systems (Minneapolis, MN). Micro bicinchoninic acid protein assay reagents were from Pierce (Rockford, IL). Matrigel basement membrane matrix was from Becton Dickinson Labware (Bedford, MA). PTK787 was obtained from Novartis Pharmaceuticals. The MEK
kinase inhibitor PD98059 was from Calbiochem (La Jolla, CA). All other reagents were from Sigma-Aldrich Canada.
VEGF production. Vascular endothelial growth factor (isoform 165) was PCR-amplified from [5 a pBlast/VEGF plasmid (Invivogen, San Diego, CA) and cloned into the pTT
vector (Durocher, Y, et al., Nucleic Acids Res 2002;30:E9). VEGF was produced following large-scale transient transfection of human 293SFE cells in serum-free medium. The recombinant protein was expressed by the transiently transfected cells and secreted into the medium. The culture was harvested five days after transfection; the medium was clarified by centrifugation >.0 at 3,500g for 10 minutes and filtered through a 0.22 pm membrane.
Clarified culture medium was loaded onto a heparin-Sepharose column and the bound VEGF was then eluted using a NaCI gradient in PBS. A buffer exchange for PBS was performed by gel filtration and the final purified material was sterile-filtered, and stored in aliquots at -80 C.
?5 Cell culture. Human umbilical vein endothelial cells (HUVEC) and pulmonary aortic smooth muscle cells (PASMC) were obtained from Clonetics and maintained in endothelial cell basal medium-2 (EBM-2; Clonetics) and smooth muscle medium-2 (SmGM-2; Clonetics), respectively. Cells were cultured at 37 C under a humidified atmosphere containing 5% C02.
For experimental purposes, cells were plated in 8 100-mm plastic dishes at 5,000 cells/cm2 30 and were grown to confluence before overnight serum starvation. Cells were treated with vehicle or with a PCK3145 derivative diluted in 0.1 N NaOH, and stimulated with 50-100 ng/ml VEGF or PDGF, with 10 ng/ml of bFGF (basic fibroblast growth factor) or with 1NM
S1 P (sphingosine-1 -ph osphate).
35 lmmunoprecipitation and immunoblotting procedures. After treatment, cells were washed once with phosphate-buffered saline (PBS) containing 1 mM sodium orthovanadate and were incubated in the same medium for 1 h at 4 C. The cells were solubilized on ice in lysis buffer (150 mM NaCI, 10 mM Tris-HCI, pH 7.4, 1 mM EDTA, 1 mM EGTA, 0.5%
Nonidet P-40, 1% Triton X-1 00) containing 1 mM sodium orthovanadate. The cells were then scraped from the culture dishes and the resulting lysates were clarified by centrifugation at 10,000g for 10 min: Protein concentrations were determined using the micro bicinchoninic acid method (Pierce). For immunoprecipitation studies, lysates were clarified by a 1 h incubation at 4 C with a mixture of Protein A/Protein G Sepharose beads. After removal of the Sepharose beads by low-speed centrifugation, identical amounts of protein (200 jig) from each sample were transferred to fresh tubes and incubated in lysis buffer overnight at 4 C in the presence of 2 Ng/ml of specific antibodies. Immunocomplexes were collected by incubating the mixture with 25,u1 (50% suspension) of Protein A- (rabbit primary antibody) or Protein G- (mouse primary antibody) Sepharose beads, for 2 h. Nonspecifically-bound material was removed by washing the beads three times in 1 ml of lysis buffer containing 1 mM sodium orthovanadate, and, bound material was solubilized in 25 ,ul of two-fold concentrated Laemmli sample buffer (125 mM Tris-HCI (pH 6.8), 20% glycerol, 4%
SDS, 10% f3-mercaptoethanol, and 0.00125% bromphenol blue), boiled 5 min, and resolved by SDS-PAGE. The proteins were transferred onto polyvinylidene difluoride (PVDF) membranes, blocked 1 h at room temperature with Tris-buffered saline/Tween 20 (147 mM
NaCI, 20. mM Tris/HCI, pH 7.5, and 0.1% Tween 20) containing 2% bovine serum albumin and incubated overnight at 4 C with primary antibody. Immunoreactive bands were revealed W after a 1 h incubation with horseradish peroxidase-conjugated anti-mouse or anti-rabbit antibodies, and the signals were visualized by enhanced chemiluminescence (Amersham Biosciences, Baie d'Urfee, QC). The immunoreactive bands were quantified by scanning densitometry (Molecular Dynamics).
>.5 Cell culture. Human umbilical vein endothelial cells (HUVEC) and pulmonary aortic smooth muscle cells (PASMC) were obtained from Clonetics and maintained in endothelial cell basal medium-2 (EBM-2; Clonetics) and smooth muscle medium-2 (SmGM-2; Clonetics), respectively. Cells were cultured at 37 C under a humidified atmosphere containing 5% C02.
For experimental purposes, cells were plated in 8 100-mm plastic dishes at 5,000 cells/cm2 30 and were grown to confluence before overnight serum starvation. Cells were treated with vehicle or with PCK3145 diluted in 0.1 N NaOH, and stimulated with 50 ng/ml VEGF, PDGF
or with 1,uM S1 P.
Angiogenesis assays 35 Rat aortic ring assay. The isolated rat aorta is cut into segments that are placed in culture, in a matrix-containing environment such as Matrigel. Over the next 7-14 days, the explants are monitored for the outgrowth of endothelial (and other) cells as this is affected by the addition of test substances. Quantification is achieved by measurement of the length and abundance of vessel-like extensions from the explant. Use of endothelium-selective reagents such as fluorescein-labeled BSL-1 allows quantification by pixel counts.
Chick aortic arch assay. Aortic arches are dissected from day 12-14 chick embryos and cut into rings similar to those of the rat aorta. When the rings are placed on Matrigel, substantial outgrowth of cells occurs within 48 h, with the formation of vessel-like structures readily apparent. Test substance is added to the medium and quantification of endothelial cell outgrowth is achieved by the use of fluorescein-labeled lectins such as BSL-1 and BSL-B4 or by staining of the cultures with labeled antibodies to CD31. Standard imaging techniques are used for the enumeration of endothelial cells and for delineating the total outgrowth area.
Cornea angiogenesis assay: A pocket is made in the cornea of a rabbit's eye or mice's eye and angiogenesis is stimulated by an angiogenesis inducer (e.g. VEGF) introduced into this pocket. The inducer elicits ingrowth of new vessels from the peripheral limbal vasculature.
Slow-release materials such as ELVAX (ethylene vinyl copolymer), Hydron or sponge may be used to introduce test substances into the corneal pocket.
Inhibition of angiogenesis is, monitored by the effect of the inhibitor on the locally induced (e.g., sponge implant) angiogenic reaction in the cornea (e.g., VEGF). The test inhibitor may be administered by several administration mode including, orally, systemically, the latter either by bolus injection or, for example, by use of a sustained- release method such as ?0 implantation of osmotic pumps loaded with the test inhibitor.
The vascular response is monitored by direct observation throughout the course of the experiment. This may be done by using a slit lamp for the rabbit but needs only a simple stereomicroscope in mice. Visualization of the mouse corneal vasculature may be achieved by injecting India ink or fluorochrome-labeled high-molecular weight dextran.
Methods for !5 quantification include measuring the area of vessel penetration, the progress of vessels toward the angiogenic stimulus overtime, or in the case of fluorescence, histogram analysis or pixel counts above a specific (background) threshold.
Cam assay. The CAM of day 7-9 chick embryos is exposed by making a window in the egg 0 shell, and tissue or organ grafts are then placed directly on the CAM. The window is sealed, eggs are reincubated, and the grafts are recovered after an appropriate length of incubation tirrie. The grafts are then scored for growth and vascularization. The angiogenic reaction may be evaluated by ranking the vascularization on a 0 to 4 basis but also using imaging techniques such as the measurement of bifurcation points in a designated area around the test material. Alternatively, an entire egg contents may be used. Test substances are administered by placing them on membranes or on the underside of coverslips and applied to a desired area. Test compounds are assessed by their effect either on the normal development of the CAM vasculature itself or on induced angiogenesis.
Alternatively, fertilized chick embryos are removed from their shell on day 3 or 4, and a methylcellulose disc containing the test compound is implanted on the chorioallantoic membrane. The embryos are examined 48 hours later, if a clear avascular zone appears around the methylcellulose disc, the diameter of that zone is measured. Such avascular zone indicates a compound having an anti-angiogenic activity (U.S. patent no.
5,001,116 (col.7, incorporated herein by reference).
Matrigel endothelial cell tube formation assay. Matrigel (12.5 mg/mI) was thawed at 4 C, and 50 ,ul were quickly added to each well of a 96-well plate and allowed to solidify for 10 min at 37 C. The wells were then incubated for 18 h at 37 C with HUVEC (25,000 cells/well). The formation of capillary-like structures was examined microscopically and pictures (50X) were taken using a Retiga 1300 camera and a Zeiss Axiovert S100 microscope. The extent to which capillary-like structures formed in the gel was quantified by analysis of digitized images to determine the thread length of the capillary-like network, using a commercially available image analysis program (Northern Eclipse).
Matrigel plug assay.Matrigel containing test cells or substances is injected subcutaneously, where it solidifies to form a plug. This plug is recovered after 7-21 days in the animal and examined histologically to determine the extent to which blood vessels have entered it.
Fluorescence measurement of plasma volume is achieved using fluorescein isothiocyanate (FITC)-labeled dextran 150. Quantification may alternatively be achieved by measuring the !5 amount of hemoglobin contained in the plug.
In another alternative assay (the sponge/Matrigel assay) Matrigel alone is first introduced into the mouse. A sponge or tissue fragment is then inserted into the plug. New vessels are measured by injection of FITC.
Other angiogenesis assays are described, for example, in Staton, C.A. et a/., (Int. J. Exp.
0 Path. (2004), 85, 233-248) the entire content of which is incorporated herein by reference.
Migration Assays. Transwells filters (8-pm pore size; Costar, Cambridge, MA) were pre-coated with 0.5% gelatin/PBS for 24 h at 4 C. The transwells were then washed with PBS
and assembled in 24-well plates. The upper chamber of each transwell was filled with 100,u1 of HUVEC (1 x 106 cells/mI) and cells were allowed to adhere for 1 h. Cells were then treated for 2 h by adding 100,u1 of 2-fold concentrated drug solution prepared in serum-free medium into the upper chamber and 600 NI of the drug solution into the lower chamber.
Migration was initiated by adding VEGF (10 ng/ml), or S1 P (1 ,uM) to the lower chamber. The plate was placed at 37 C in 5% C02/95% air for 4 h. Cells that had migrated to the lower surface of the filters were fixed with 10% formalin phosphate and stained with 0.1 % Crystal Violet/20% (v/v) methanol. The migration was quantified using computer-assisted imaging and data are expressed as the average density of migrated cells per four fields (magnification x 50).
Matrigel endothelial cell tube formation assay. Matrigel (12.5 mg/mI) was thawed at 4 C, and 50,u1 were quickly added to each well of a 96-well plate and allowed to solidify for 10 min at 37 C. The wells were then incubated for 30 min at 37 C in 5% C02/95% air, with 100,u1 of HUVEC (20,000 cells/well) containing 1% fetal bovine serum to allow adequate adhesion to Matrigel. Cells were then treated for 18 h by adding 100 ,ul of 2-fold concentrated PCK3145 prepared in serum-free medium into the well. The formation of capillary-like structures was examined microscopically and pictures (50X) were taken using a Retiga 1300 camera coupled to a Zeiss Axiovert S100 microscope. The extent to which capillary-like structures formed in the gel was quantified by analysis of digitized images using a commercially 22 0 available image analysis software (Northern Eclipse) (25).
Statistical data analysis. Data are representative of three or more independent experiments and are represented as means SEM. Statistical comparisons between groups were assessed using 1-way ANOVA followed by Student's unpaired t-test.
?5 Biologically active PSP94 family member; Fragments, derivatives and analogues may be prepared by techniques known in the art (recombinant technology, solid phase synthesis, etc.). The biological activity of derivatives, fragments and analogues may be determined by any of the techniques described herein or known in the field to be relevant for any of the 10 biological activity described above.
For example, serum-starved quiescent endothelial cells (HUVEC) may be incubated with different doses of a putative PCK3145 derivative, analog or fragment (e.g., any of SEQ ID
NOs.:9 to 98, combinations) for 24 h and then stimulated with VEGF. Cells may be washed 5 with PBS containing NaF/Na3VO4 and incubated in the same medium buffer for 1 h at 4 C.
The cells may be scraped from the culture dishes and the resulting lysates clarified by centrifugation. SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) may be performed to separate the proteins. Western blotting and immunodetection may be performed by using anti-phosphoERK and anti-ERK antibodies. The bands may be quantified to determine the level of inhibition of ERK phosphorylation by the putative PCK3145 derivative. An inhibitory effect of VEGF-induced ERK phosphorylation (or VEGFR-induced ERK phosphorylation) by the putative PCK3145 derivative, analog or fragment means that the derivative, analog or fragment is biologically active.
In another example, a matrigel containing a putative PCK3145 derivative, fragment or analog with an angiogenesis-inducer is injected subcutaneously, to an animal. This plug is recovered after 7-21 days from the animal and examined histologically to determine the extent to which blood vessels have entered it. Quantification is performed as described above.
A biologically active PCK3145 derivative, fragment or analog is identified by the reduction in the number of blood vessels which have entered the matrigel plug or the extent to which blood vessels have entered it.
A derivative, fragment or analog causing a diminution in the formation or propagation of blood vessel (tubes, capillary-like structures) in an agiogenesis assay described herein is considered to be a biologically active derivative, fragment or analog.
A putative PCK3145 derivative, analog or fragment which is biologically active may also be identified in one of the assay described herein where an inhibitory effect on PDGF=induced ERK phosphorylation (or PDGFR-induced ERK phosphorylation) by the putative derivative, analog or fragment is observed or measured.
15 The biological activity of a desired polypeptide may also be determined, for example, by contacting a cell expressing a metalloproteinase (e.g., MMP-9, MMP-2) and/or pro-metalloproteinase (e.g., pro-MMP-9, pro-MMP-2) with a polypeptide of the present invention (a PSS94 family member (e.g.: original polypeptide, fragment, derivative, analogue, and/or any modified form of an original polypeptide, fragment, derivative or analogue) and, following 10 incubation of the polypeptide and cell, evaluating the levels (inside the cell or in the extracellular environment (supernatant or blood (plasma or serum))) of expression of the, metalloproteinase by western blot or the enzymatic activity of the metalloproteinase by zymography as described herein or by any other techniques known in the art to be representative of inetalloproteinase activity or expression (e.g., northern blot, PCR, 5 immunochemistry methods, etc.). A modification (e.g., reduction or in some cases an increase) of the level of expression or enzymatic activity of a metalloproteinase (and/or pro-metalloproteinase) will identify a biologically active polypeptide.
The biological activity of a desired polypeptide may further be determined using migration assays. U-87 cells are treated with a polypeptide of the present invention (e.g., any PCK3145 derivative, fragment, analog, such as for example, any one of or combinations of SEQ ID NOs.: 9 to 98). The treated cells are trypsinised, counted, and seeded on HA-coated filters inserted in modified Boyden Chambers as described herein or in the art. Cell migration is allowed to proceed for 2 hours at 37 C. Filters are then stained for cells that have migrated through the filter. A decreased basal U-87 cell migration observed in cells treated with a polypeptide of the present invention is indicative of a biologically active polypeptide (i.e., a biologically active PCK3145 derivative, fragment, analog).
Each putative derivative, fragment or analogue may be tested using this technique or any other techniques described herein or known in the art.
IN VIVO MMPs MEASUREMENTS
MMP-9 assay results Results of MMP-9 levels in patient's plasma, before and after one or more treatment cycle with PCK3145 derivative; SEQ ID NO.: 7 are illustrated in Table 2.
Normal values of healthy volunteers were not determined in this study but lizasa et al., has determined that the normal range of plasma MMP-9 concentrations is about 11.4 to 59.4 !5 ng/mI. Based on theses values, patients were sub-divided into two categories; those having normal value of MMP-9 (below 100pg/L) and those having an elevated level of (higher than 100Ng/L) at baseline (see column identified as Dl C1 in Table2).
In the normal value MMP-9 category (patients identified as E, F, G, H and I), there was no ;0 significant decrease in MMP-9 levels after one cycle of treatment (column identified D27C1) compared to baseline levels. For patients E and G, no decrease in MMP-9 levels was observed compared to baseline values even after 2 cycles of treatment (column identified D27C2). There was still no MMP-9 decrease even after 3 cycles of treatment for patient E
(D27C3) In the elevated MMP-9 category (patients identified as A, B, C and D), a significant decrease was observed for each patient after only one cycle of treatment (see column identified as D27C1). For example a decrease of up to 89 % in MMP-9 levels was observed for patient A
compared to baseline levels. For patient B, the decrease in MMP-9 was 41 %
after cycle 1.
For patients C and D the decrease at cycle 1 was 90 % and 34 % respectively.
This decrease was maintained for patients B and C who have received more treatment cycles (see columns identified as D27C2, D27C3 and D27C4). For example, at treatment cycle 2, patient B showed a reduction of 64 % of its baseline level of MMP-9.
A similar reduction was also measured for patient B at treatment cycle 3; i.e., a 65 %
reduction, and at treatment cycle 4; a 75 % reduction. In the case of patient C, a reduction of 76 % in MMP-9 levels was measured at cycle 2.
TABLE 2.
Elevated MMP-9: Baseline =100pg/L
Patient D1 C1 D27C1 D27C2 D27C3 D27C4 Maximum Reduction A 424 47.3 N.A. N.A. N.A. 89 %
B 156.5 91.6 55.6 54.5 39.4 75%
C 155 14.9 37.7 N.A. N.A. 90 %
D 130.2 85.2 N.A. N.A. 34%
Normal MMP-9: Baseline =100Ng/L
E 57.5 58 60.1 101.8 N.A.
F 53.2 73.1 N.A. N.A. N.A.
G 33.9 45.4 189.6 N.A.
H 57.0 44.0 65 I 22.1 18.8 N.A.=not applicable .5 Effect on MMP-9 secretion ,0 In order to support in vivo results described in Example 1, zymography assays and western blots were performed on cell lines incubated with a PCK3145 derivative (SEQ ID
NO.:7).
In the experiment presented in Fig. 1, 2.5x105 MatLyLu tumor cells (American Type Culture Collection No.: JHU-5)) were seeded in T-25 flasks containing RPMI with 10%
fetal bovine serum (FBS). After overnight incubation, the cells were washed once with serum free medium and treated with various concentrations of the PCK3145 derivative (500ug/ml and 1 mg/mi) in the presence of 50ug/ml collagen type-I in serum free RPMI for 72 hrs. Control cells received 50ug/ml collagen or only serum free medium.
The media were collected after 72 hours of exposure to the PCK3145 derivative and subjected to gelatin zymography. Zymography for MMP-2 and MMP-9 was performed in SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (10%) containing 0.1 %
gelatin (Invitrogen). Twenty-four microliters of culture media was mixed with non-reducing sample buffer and subjected to electrophoresis without boiling. After electrophoresis, gels were soaked for 30 minutes in 2.5% Triton X-100 solution with 2-3 washing steps.
The gels were then incubated for 18 hours at 379C in buffer containing 50 mM Tris/HCI, pH
7.6, 50 mM
NaCI, 10mM CaCI2 and 0.05% Brij-35. After incubation, the gels were stained with 0.2%
Coomassie blue and de-stained until clear proteolytic bands appeared. Gels were scanned with Microtek flatbed scanner (Scanmaker 5 software; Microtek lab, Redondo Beach, CA).
The band intensities were determined using the Image Quant software (version 5.0) from molecular Dynamics.
The MMP-9 and MMP-2 gelatinase zymography standard were purchased from Chemicon 10 (catalogue no. CC073). One nanogram of purified human pro-MMP-2 and pro-MMP-standards were used in every gel run.
Results of this experiment are illustrated in Fig.1 and indicate that PCK3145 derivative treatment of MatLyLu cells resulted in a dose-dependent reduction of MMP-9 secreted in the !5 cell culture media, as detected by zymography.
Western blot A separate western blot experiment was performed in which MatLyLu cells were treated with 100ug/ml, 500ug/ml and 1 mg/mI of the PCK3145 derivative for 72 hrs. At the end of the ,0 experiment, the media were collected and concentrated 5 times using Amicon centrifugal filter devices (3500 molecular weight cut-off).
Twenty five microliters samples were separated on SDS-PAGE gel under reducing conditions using pre-cast gels of 4-12% Bis-Tris (Invitrogen). Following electrophoresis, the proteins 5 were transferred on nitrocellulose membrane. Non-specific binding sites were blocked using 5 % skimmed milk in 10mM phosphate buffer saline (PBS) containing 0.05% Tween-20 for 1 hour at room temperature. The membrane was later incubated with a primary antibody (monoclonal, RDI-MMP-9abm-2A5) at a concentration of 1 ug/mI (in 10 mM PBS, containing 0.5% bovine serum albumin (BSA) and 0.05% Tween-20) for 3 hours at room temperature.
The membranes were washed three times in PBS (5 minutes each wash) to remove non-specific binding and they were incubated with the secondary antibody (Rabbit anti-mouse IgG
horseradish peroxidase-conjugated (Dako no. 0260)) at a dilution of 1:5000 for one hour.
Detection of specific MMP-9 protein was made by incubating the membrane in ECLT"' reagent (electro-chemoluminescence, Roche) and exposing to the X-ray film.
Results of this experiment are illustrated in Fig.2 and again indicate that treatment of MatLyLu cells PCK3145 derivative resulted in.a dose-dependent reduction of MMP-9 levels.
Effect on VEGF induced MMP-2 secretion Matrix metalloproteinases (MMPs) secreted by EC seem to play a key role in the processes of matrix remodeling and EC sprouting during angiogenesis. While proMMP-9 secretion is absent or at low levels in basal conditions, proMMP-2 secretion can however be increased by VEGF in HUVEC.
The effect of the PCK3145 derivative (SEQ ID NO.:7) on MMP extracellular levels was thus assessed by gelatin-zymography in the conditioned media of serum-starved HUVEC. After 16 hours of starvation, HUVEC were stimulated with VEGF in the presence or not of the PCK3145 derivative. A further 24 hours treatment shows that PCK3145 derivative effectively downregulated by approximately 35% the basal proMMP-2 levels in the extracellular media (Fig 3A, Fig. 3B). Most importantly, the effect of PCK3145 derivative (300 g/ml) was also observed on VEGF-induced proMMP-2 secretion as the inhibition was of approximately 50%.
When these experiments were performed in serum-free media, but in the presence of the MAPK inhibitor PD98059, VEGF-induced proMMP-2 extracellular levels were also significantly decreased. These results suggest that the effect of PCK3145 derivative towards MMP secretion is indeed regulated through a MAPK pathway in endothelial cells.
The effect of PCK3145 on MMP-9 secretion could not be observed in HUVEC
because only very low to undetectable levels of MMP-9 are secreted.
Phosphorylation of ERK-1/-2 pathway in endothelial cells VEGF is a strong activator of ERKs (Extracellular-signal-Regulated protein Kinases) 1 and 2 via VEGF receptor 2. In order to test the ability of the PCK3145 derivative in potentially antagonizing VEGF-mediated ERK phosphorylation, serum-starved quiescent endothelial cells (HUVEC) were incubated with vehicle (phosphate-buffered saline (PBS) pH
7.4) or PCK3145 derivative (300 ,ug/mI) for 24 h and then stimulated with VEGF, bFGF
(basic Fibroblast Growth Factor) or S1 P (sphingosine- 1 -phosphate). Cells were washed with PBS
containing NaF/Na3VO4 and incubated in the same medium buffer for 1 h at 4 C.
The cells were scraped from the culture dishes and the resulting lysates clarified by centrifugation.
Western blotting and immunodetection using anti-phosphoERK and anti-ERK
antibodies was then performed.
The results show a specific inhibitory effect of the PCK3145 derivative on ERK
phosphorylation induced by VEGF (Fig 4A, Fig. 4B) but-not that induced by bFGF
or S1P
(Fig 4A, Fig. 4B). This inhibitory effect was confirmed for two endothelial cells, HUVEC and BAEC (not shown). The total amount of ERK in each sample of cells was unaffected by the PCK3145 derivative (Fig 4A, Fig. 4B). Although, PCK3145 derivative also seemed, to stimulate ERK phosphorylation induced by S1 P in HUVEC (Fig 4A, Fig, 4B), that'result was found not statistically significant. Moreover, a dose-response to PCK3145 derivative was found to gradually inhibit the extent of ERK phosphorylation by VEGF (Fig 4C, Fig. 4D):' The effect of PCK3145 derivative was found comparable to that of PD98059, a documented pharmacological inhibitor of ERK phosphorylation. The lack of effect of a scrambled peptide ?5 (SEQ ID No.:99)"is demonstrated as a negative control (Fig 4E, Fig. 4F).
Finally, a time-course of PCK3145 derivative effect is shown at 3 and 24 hrs demonstrating the necessity of a long term action of PCK3145 derivative (Fig 4G, Fig. 4H).
~0 Effect on capillary-like structure formation by HUVEC
This three dimensional ECM model assay provides physiologically relevant environment for studies of cell morphology, biochemical function, and gene expression in endothelial cells (EC) that can be modulated for instance by tumor growth factors or hypoxic culture 5 conditions. Moreover, proteomic-based approaches to monitor levels of protein expression can also be achieved. When plated on Matrigel, EC have the ability to form capillary-like structures. The extent of capillary-like structures formation (density and size of structures) can be quantified by analysis of digitized images to determine the relative size and area covered by the tube-like network,. using an image analysis software (Un-Scan-it, Empix Imaging). HUVEC were trypsinised, counted and seeded on Matrigel. Adhesion to Matrigel was left to proceed for 30 minutes. Treatment with increasing concentrations of the PCK3145 derivative (0-300 g/ml) was then performed in serum-free media for 24 hours.
The extent of capillary-like structure formation was then assessed afterwards. The results show that the PCK3145 derivative negatively affects tubulogenesis (Fig 5A, Fig. 5B).
Cells were plated onto gelatin-coated filters inserted in modified Boyden chemotactic chambers. The effect of PCK3145 on basal migration and on VEGF-induced migration was monitored by the number of cells that had migrated comparatively to untreated control cells.
HUVEC were dislodged from the flasks by trypsinization, washed and resuspended in serum-free media. Cells were placed onto gelatin-coated filters inserted in chambers and incubated at 37 C, 5% CO2 for 30 min to allow adequate anchoring to the filters. The monolayers were then exposed to serum-free media containing PCK3145 (300 ,ug/mi) added within the upper and lower compartment of the chambers. After 2 h, VEGF (50 ng/ml) was added in the lower chamber as a chemoattractant. Cell migration was allowed to proceed for another 3 h. Filters were then fixed, stained, and the migrated cells quantified by microscopy as described in the Methods section. The results show that PCK3145 treatment had no significant effect on basal ?0 cell migration or on VEGF-induced cell migration (not shown) in this particular assay. The effect of. PCK on S1 P-induced HUVEC migration was also measured, but no inhibition was observed (not shown) in this particular assay.
?5 EXAMPLE 6 Phosphorylation of VEGF receptors in endothelial cells The multifunctionality of VEGF at the cellular level results from its ability to initiate a diverse, complex and integrated network of signaling pathways via its major receptor, VEGFR-2.
30 Thus, the inhibitory effect of the PCK3145 derivative on ERK
phosphorylation induced by VEGF was examined to verify whether it was a consequence of an inhibition of the phosphorylation of VEGFR-2. HUVEC were grown, serum-starved, pretreated with the PCK3145 derivative (300,ug/mI; 24 h), and stimulated with VEGF as described in Gingras et al. [Biochem J 348:273-280, (2000)]. After each treatment, equal amounts of protein were 35 immunoprecipitated with anti-VEGFR-2 polyclonal antibodies and analysed by Western blotting. Results of this experiment show that the PCK3145 derivative inhibited the phosphorylation of VEGFR-2 induced by VEGF in HUVEC (Fig 6A, Fig. 6B). This inhibitory effect of the PCK3145 derivative is also shown to be dose-dependent (Fig 6C, Fig. 6D), and could be to a certain extent compared to the action of PTK787, a known pharmacological inhibitor of the tyrosine kinase activity associated to the VEGFR-2. Finally, the lack. of effect of a scrambled peptide is shown (Fig 6E, Fig. 6F) and suggests the specificity of action of the PCK3145 derivative.
Phosphorylation of PDGF receptors in smooth muscle cells [0 The potential inhibitory action of the PCK3145 derivative towards the tyrosine kinase activity associated to the VEGFR-2 was also tested on the kinase activity associated to another receptor the PDGF receptor (PDGFR) in PASMC (pulmonary aortic smooth muscle cells).
Similar treatment of the PCK3145 derivative as for HUVEC was performed.
Interestingly, PCK3145 derivative leads to the inhibition of PDGFR phosphorylation induced.
by PDGF (Fig [5 7A, Fig. 7B); as well as of the PDGF-induced ERK phosphorylation (Fig 7C, Fig. 7D).
Intrinsic effect on ERK phosphorylation ?0 In order to investigate the potential intracellular pathways triggered by the PCK3145 derivative, a gene-reporter assay using the SEAP (Secreted Alkaline Phosphatase) Mercury Profiling Kit (CLONTECH) was performed in glioma cells (U-87). This assay enables the monitoring of transcription factors that are triggered by a particular experimental condition by assaying the alkaline phosphatase activity in the extracellular media. The ?5 derivative triggers significantly two pathways: the MAPK/JNK pathway (SRE) and the NFkB
pathway (Fig 8A). The MAPK pathway induction is extremely strong as compared to that of the NFkB pathway. The latter however potentially suggests the involvement of.
pro-apoptotic pathways that would be triggered by the PCK3145 derivative. Interestingly, the secretion of the constitutively expressed SEAP was found to be inhibited suggesting a potential effect of 30 the PCK3145 derivative on a more general constitutive secretion pathway.
The induction of the MAPK pathway by the PCK3145 derivative is further confirmed by the rapid and transient induction of ERK phosphorylation between 5-10 minutes (Fig 8B) and is shown to be dose-dependent (Fig 8C). Finally, the effects of the PCK3145 derivative were 35 also compared to those of a scrambled peptide. These results show that the scrambled peptide was unable to induce ERK phosphorylation comparable to that of the derivative (Fig 8D). Finally, these results also indicate that the MAPK
inhibitor PD98059 antagonized the induction of ERK phosphorylation by the PCK3145 derivative.
Effect on angiogenesis Matrigel containing the PCK3145 or its derivative (SEQ ID NO.:5 or SEQ ID
NO.:7) is injected subcutaneously to a rat. This solidified plug is recovered after 7-21 days in the animal and examined histologically to determine the extent to which blood vessels have entered the plugs.
In another assay, fertilized chick embryos are removed from their shell on day 3 or 4, and a methylcellulose disc containing PCK3145 (SEQ.ID NO.:5 or SEQ ID NO.:7) is implanted on the chorioallantoic membrane. The embryos are examined 48 hours later and the diameter of the avascular zone is measured.
The proangiogenic factor VEGF is secreted by many tumors in high concentrations, and suppression of the VEGF-VEGFR signalin.g pathway is an intensively explored avenue for suppression of tumor growth through the inhibition of angiogenesis. Although prostate cells of normal, benign, and of malignant phenotype have been shown to express VEGF, expression of the cognate receptors VEGFR-2 is generally believed to be restricted to EC.
In light of the results presented herein, two main lines of evidence suggest and support the pleiotropic molecular effects of PCK3145 in EC (PCK3145 is therefore a pleiotropic factor).
PCK3145 antagonizes the VEGFR-2 tyrosine kinase-associated activity as well as the subsequent intracellular transduction through the MAPK pathway. Moreover, inhibited capillary-like structure formation by EC as well as MMP secretion, two cellular pre-?5 requisite for angiogenesis to occur. The inhibitory effect on MMP is interesting since in genera, al correlation between the stage of tumor progression and level of MMP
expression has been observed. Collectively, these properties reflect PCK3145 antiangiogenic action on EC.
S0 Treatment of established human tumors might require not only prevention of further angiogenesis but also destruction of tumor blood vessels to reduce the already existing tumor mass. Although interference with VEGF-mediated signalling events is effective in preventing the early growth of neovessels (blocking early-stage angiogenesis), mature vessels from more established tumors are largely resistant to inhibitors directed against either VEGF or its 6 receptor VEGFR-2. These mature vessels are surrounded by periendothelial cells, such as pericytes and smooth muscle cells (SMC), and the contact between these cells stabilizes new blood vessels, promotes endothelial survival, and inhibits EC
proliferation. PDGF-B/PDGFR-f3 system is involved in vessel stabilization, and interference with this signalling system resulting in disruption of already established endothelial/periendothelial associations and vessel destabilization. Furthermore, the inhibition of both VEGF and PDGF
receptors, by either simultaneous exposure to receptor-specific receptor tyrosine kinase inhibitors or by an inhibitor with broad kinase specificity (SU6668), blocks further growth of end-stage and well-vascularized tumors, eliciting detachment of pericytes and disruption of tumor vascularity (blocking late-stage angiogenesis) (e.g., blocking late-stage angiogenesis).
As such PCK3145 may inhibit angiogenesis in highly vascularized tumors.
As PCK3145 as been found to interfere with both VEGFR and PDGFR signalling, may be used as a therapeutic agent in strategies devised either to interrupt or inhibit one or more of the pathogenic steps involved in the process of tumor neovascularization or to directly target and destroy the tumor vasculature and therefore blocking both the early- and late-stage angiogenesis. The inhibition of both receptors function by PCK3145 may confer an intrinsic advantage to the use of this peptide to inhibit angiogenesis.
?0 EXAMPLE 10 Effect on U-87 cell migration on hyaluronic acid Migration/invasion of cancer cells is a key event in tumor metastasis. In vitro, this process can be reconstituted by plating cells onto ECM-coated filters inserted in modified Boyden ?5 chemotactic chambers. The effect of the PCK3145 derivative can be monitored by the number of cells that had migrated comparatively to untreated control cells. In light of previous observations, the diminished migration onto hyaluronic acid (HA) matrice was confirmed. U-87 cells were treated with the PCK3145 derivative (300 ug/mI, 48 hrs), trypsinised, counted, and seeded on HA-coated filters inserted in modified Boyden Chambers. Cell migration was 30 allowed to proceed for 2 hours at 37 C. Filters were then stained for cells that have migrated through the filter. The results show that pretreatment with the PCK3145 derivative decreased basal U-87 cell migration by approximately 3-fold (Fig 9A). This result was performed for 3 more-times with new cell preparations.
Effect on U-87 cell adhesion to hyaluronic acid (HA) ECM recognition is a crucial event in the cell adhesion processes involved in tumor progression. This process is mediated and regulated through specialized cell surface receptors or integrins. While recent evidence suggests that a potential crosstalk between soluble MMP and cell surface integrins may regulate the cell's ability to recognize and adhere to its ECM environment, the PCK3145 derivative was tested in its ability to downregulate U-87 cell adhesion onto HA. U-87 cells were treated with the PCK3145 derivative (300 ug/mI, 48 hrs), trypsinised, counted, and seeded on wells coated with 10 ug/mI BSA
(bovine serum albumin) or HA. Cells were allowed to adhere for 3 hours. Three independent experiments were performed. Results of these experiments show that adhesion of cells treated with the PCK3145 derivative was significantly diminished on HA by 45-76% (Fig 9B).
Collectively, the inhibitory action of the PCK3145 derivative on ECM recognition and cell adhesion processes suggests that the expression of specific integrins or HA cell surface receptors such as those from the CD44 family could be targeted. Alternatively, such result also suggests that intracellular signalling regulating the activation states of cell surface integrins may be triggered by the PCK3145 derivative. One such potential intracellular protein is the GTPase RhoA, which is likely to mediate mechanisms regulating cytoskeletal morphogenesis.
Effect on CD44 cell surface shedding Decreased cell migration and adhesion on HA was observed when U-87 cells were pretreated with the PCK3145 derivative. This can be interpreted as either a potential ?5 downregulation of CD44 expression at the cell surface or by a potential cell surface shedding.
The latter hypothesis was tested by incubating serum-starve U-87 cells for 24 hours with the PCK3145 derivative (300 ug/mi), a concentration known to antagonize MMP
secretion. The conditioned media was then TCA-precipitated and Westernblotting an immunodetection for a 75 kDa immunoreactive protein using the anti-CD44 antibody was performed. An increased 10 CD44 cell surface shedding was demonstrated by the strong immunoreactive band observed in the cells which had been pre-treated with PCK3145.derivative (Fig. 10).
This effect is also shown in parallel with MT1-MMP-transfected cells. Such effect has been already reported by many groups and is established as one of the MT1-MMP-mediated functions in the regulation of the ECM adhesion. Interestingly, a slight increase in MT1-MMP expression in the cells 5 treated with the PCK3145 derivative was observed that may partially explain how PCK may lead to CD44 shedding. This induction has subsequently been reproduced below.
Altogether, these observations provide a rational for the diminished cell migration/adhesion. to HA.
Moreover, it is tempting to further suggest that this may also be a secondary regulation by the PCK3145 derivative of diminished cell surfacedocking of MMP-9 to CD44.
Effect on MT1-MMP and RhoA expression Specific manipulation of the GTPase Rho activity can be used to suppress or enhance the organizational behaviour of endothelial cells as well as it can restrict cancer cells proliferation. In particular, RhoA mediates cell contractility by organizing actin filaments which consequently regulates cell migration. Moreover, recent evidence suggested that RhoA/CD44/MMP-9 colocalized at common cell surface microdomains. Tests were carried out in order to determine whether the PCK3145 derivative affected RhoA gene and protein expression. U-87 cells were either treated with the PCK3145 derivative (300 ug/mI, 48 hrs).
Results of this experiment confirm that the PCK3145 derivative induced endogenous RhoA
protein expression in U-87 cells as assessed by Western blotting (Fig 11 A, Fig. 11C).
Finally, results show that RhoA protein expression induced by the PCK3145 derivative paralleled that of its gene expression as assessed by reverse transcription-polymerase chain reaction (RT-PCR) (Fig 11 D). Altogether, these results highlight the potential role of RhoA as being an intracellular mediator in the subsequent inhibitory activities of the derivative.
The overall effects of PSP94 family members described herein make them useful for treatment of several diseases in addition to the previously disclosed utility (inhibition of tumor 15 cell growth and skeletal metastasis).
For example, the effect of PSP94 family members on MMP-9 and MMP-2 makes them useful for reduction of cancer spreading and invasion of any type of cancer and not only for reduction of skeletal metastasis as disclosed and claimed in International application No.:
~0 PCT/CA02/01737. As such', PSP94 family member are able to prevent cancer (tumor) progression and metastasis as well as inhibiting angiogenesis.
The content of each publication, patent and patent application mentioned in the present application is incorporated herein by reference.
Although the present invention has been described in details herein and illustrated in the accompanying drawings, it is to be understood that the invention is not limited to the DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.
NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME
NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:
Claims (25)
1. A method of inhibiting angiogenesis in an individual in need thereof, the method comprising administering to the individual a compound selected from the group consisting of, a) SEQ ID NO.:5, b) a SEQ ID NO.:5 derivative able to reduce VEGF-induced VEGFR
phosphorylation in an in vitro assay, c) a SEQ ID NO.:5 fragment able to reduce VEGF-induced VEGFR
phosphorylation in an in vitro assay, d) a SEQ ID NO.:5 analog able to reduce VEGF-induced VEGFR
phosphorylation in an in vitro assay, and;
e) combination of any one of a) through d) thereof.
phosphorylation in an in vitro assay, c) a SEQ ID NO.:5 fragment able to reduce VEGF-induced VEGFR
phosphorylation in an in vitro assay, d) a SEQ ID NO.:5 analog able to reduce VEGF-induced VEGFR
phosphorylation in an in vitro assay, and;
e) combination of any one of a) through d) thereof.
2. The method of claim 1, wherein said compound further comprises a grouping for increasing the stability of said compound.
3. The method of claim 2, wherein said grouping is an acetylaminomethyl moiety attached to a sulfur atom of a cysteine.
4. The method of claim 1, wherein said compound is SEQ ID NO.:7.
5. The method of claim 1, wherein angiogenesis is cancer-associated angiogenesis.
6. The method of claim 1, wherein angiogenesis is metastasis-associated angiogenesis.
7. A method of treating a mammal having ocular neovascularization or inflammation, the method comprising administering to the mammal a compound selected from the group consisting of;
a) SEQ ID NO.:5, b) a SEQ ID NO.:5 derivative able to reduce VEGF-induced VEGFR
phosphorylation in an in vitro assay, c) a SEQ ID NO.:5 fragment able to reduce VEGF-induced VEGFR
phosphorylation in an in vitro assay, d) a SEQ ID NO.:5 analog able to reduce VEGF-induced VEGFR
phosphorylation in an in vitro assay, and;
e) combination of any one of a) through d) thereof.
a) SEQ ID NO.:5, b) a SEQ ID NO.:5 derivative able to reduce VEGF-induced VEGFR
phosphorylation in an in vitro assay, c) a SEQ ID NO.:5 fragment able to reduce VEGF-induced VEGFR
phosphorylation in an in vitro assay, d) a SEQ ID NO.:5 analog able to reduce VEGF-induced VEGFR
phosphorylation in an in vitro assay, and;
e) combination of any one of a) through d) thereof.
8. The method of claim 7, wherein said compound further comprises a grouping for increasing the stability of said compound.
9. The method of claim 8, wherein said grouping is an acetylaminomethyl moiety attached to a sulfur atom of a cysteine.
10. The method of claim 7, wherein said compound is SEQ ID NO.:7.
11. A pharmaceutical composition for treating angiogenesis, ocular neovascularization or inflammation, the composition comprising a) a compound selected from the group consisting of SEQ ID NO.:5, a SEQ ID
NO.:5 derivative able to reduce VEGF-induced VEGFR phosphorylation in an in vitro assay, a SEQ ID NO.:5 fragment able to reduce VEGF-induced VEGFR phosphorylation in an in vitro assay, a SEQ ID NO.:5 analog able to reduce VEGF-induced VEGFR phosphorylation in an in vitro assay and combination thereof, and;
b) a pharmaceutically acceptable carrier.
NO.:5 derivative able to reduce VEGF-induced VEGFR phosphorylation in an in vitro assay, a SEQ ID NO.:5 fragment able to reduce VEGF-induced VEGFR phosphorylation in an in vitro assay, a SEQ ID NO.:5 analog able to reduce VEGF-induced VEGFR phosphorylation in an in vitro assay and combination thereof, and;
b) a pharmaceutically acceptable carrier.
12. The pharmaceutical composition of claim 11, wherein said compound further comprises a grouping for increasing the stability of said compound.
13. The pharmaceutical composition of claim 12, wherein said grouping is an acetylaminomethyl moiety attached to a sulfur atom of a cysteine.
14. The pharmaceutical composition of claim 13, wherein said compound is SEQ
ID
NO.:7.
ID
NO.:7.
15. A method of preventing cancer progression in a mammal in need thereof, the method comprising administering to said mammal a compound selected from the group consisting of;
a) SEQ ID NO.:5, b) a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, c) a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, d) a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
e) combination of any one of a) through d) thereof.
a) SEQ ID NO.:5, b) a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, c) a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, d) a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
e) combination of any one of a) through d) thereof.
16. A method of preventing metastasis in a mammal in need thereof, the method comprising administering to said mammal a compound selected from the group consisting of;
a) SEQ ID NO.:5, b) a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, c) a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, d) a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
e) combination of any one of a) through d) thereof.
a) SEQ ID NO.:5, b) a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, c) a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, d) a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
e) combination of any one of a) through d) thereof.
17. A method of treating a patient having a metastatic cancer or metastasis other than skeletal metastasis, the method comprising administering to said patient a compound selected from the group consisting of a) SEQ ID NO.:5, b) a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, c) a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, d) a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
e) combination of any one of a) through d) thereof.
e) combination of any one of a) through d) thereof.
18. The method of claim 17, wherein said compound comprises the amino acid sequence defined in SEQ ID NO.:5.
19. The method of claim 26, wherein said compound comprises the amino acid sequence defined in SEQ ID NO.:7.
20. A pharmaceutical composition for preventing metastasis in a mammal, the pharmaceutical composition comprising a compound selected from the group consisting of;
a) SEQ ID NO.:5, b) a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, c) a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, d) a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
e) combination of any one of a) through d) thereof and:
a pharmaceutically acceptable carrier.
a) SEQ ID NO.:5, b) a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, c) a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, d) a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
e) combination of any one of a) through d) thereof and:
a pharmaceutically acceptable carrier.
21. A pharmaceutical composition for preventing cancer progression in a mammal, the pharmaceutical composition comprising a compound selected from the group consisting of;
a) SEQ ID NO.:5, b) a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, c) a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, d) a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
e) combination of any one of a) through d) thereof and:
a pharmaceutically acceptable carrier.
a) SEQ ID NO.:5, b) a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, c) a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, d) a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
e) combination of any one of a) through d) thereof and:
a pharmaceutically acceptable carrier.
22. A pharmaceutical composition for treating metastatic cancer or metastasis other than skeletal metastasis in a mammal, the pharmaceutical composition comprising a compound selected from the group consisting of;
a) SEQ ID NO.:5, b) a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, c) a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, d) a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
e) combination of any one of a) through d) thereof and:
a pharmaceutically acceptable carrier.
a) SEQ ID NO.:5, b) a SEQ ID NO.:5 derivative able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, c) a SEQ ID NO.:5 fragment able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, d) a SEQ ID NO.:5 analog able to reduce cell migration in an in vitro assay or able to reduce the level of expression of MMP-9 in an in vitro assay, and;
e) combination of any one of a) through d) thereof and:
a pharmaceutically acceptable carrier.
23. A compound able to inhibit angiogenesis, said compound consisting essentially of the amino acid sequence identified in SEQ ID NO.:5 and further comprising a stabilizing group covalently attached to an amino acid of said sequence.
24. The compound as defined in claim 23, wherein said stabilizing group is an acetylaminomethyl moiety attached to a sulfur atom of a cysteine.
25. The compound as defined in claim 23, wherein said compound has the composition defined in SEQ ID NO.:7
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/857,358 | 2004-06-01 | ||
US10/857,358 US20050026833A1 (en) | 2001-11-08 | 2004-06-01 | PSP-94: use for treatment of hypercalcemia and bone metastasis |
US10/948,229 | 2004-09-24 | ||
US10/948,229 US20050096273A1 (en) | 2003-09-26 | 2004-09-24 | Regulation of matrix metalloproteinases by PSP94 family members |
US11/004,273 US20050148514A1 (en) | 2003-09-26 | 2004-12-02 | Method and composition for treatment of angiogenesis |
US11/004,273 | 2004-12-02 | ||
US11/004,270 | 2004-12-02 | ||
US11/004,270 US20050147601A1 (en) | 2003-09-26 | 2004-12-02 | Regulation of cell migration and adhesion |
PCT/CA2005/000430 WO2005118623A1 (en) | 2004-06-01 | 2005-03-21 | Method and composition for treating angiogenesis and for preventing cancer progression and metastasis comprising a prostate secretory protein (psp94) family member |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2567901A1 true CA2567901A1 (en) | 2005-12-15 |
Family
ID=35462882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002567901A Abandoned CA2567901A1 (en) | 2004-06-01 | 2005-03-21 | Method and composition for treating angiogenesis and for preventing cancer progression and metastasis comprising a prostate secretory protein (psp94) family member |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1765852A4 (en) |
JP (1) | JP2008501645A (en) |
AU (1) | AU2005250059A1 (en) |
CA (1) | CA2567901A1 (en) |
WO (1) | WO2005118623A1 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2355334A1 (en) * | 2000-10-16 | 2002-04-16 | Procyon Biopharma Inc. | Pharmaceutical preparations and methods for inhibiting tumors |
CA2361736A1 (en) * | 2001-11-08 | 2003-05-08 | Unknown | Psp 94: use for treatment of hypercalcemia and bone metastasis |
CA2441695A1 (en) * | 2003-09-26 | 2005-03-26 | Unknown | Regulation of matrix metalloproteinases by psp94 family members |
-
2005
- 2005-03-21 EP EP05714663A patent/EP1765852A4/en not_active Withdrawn
- 2005-03-21 WO PCT/CA2005/000430 patent/WO2005118623A1/en active Application Filing
- 2005-03-21 JP JP2007513628A patent/JP2008501645A/en not_active Withdrawn
- 2005-03-21 AU AU2005250059A patent/AU2005250059A1/en not_active Abandoned
- 2005-03-21 CA CA002567901A patent/CA2567901A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1765852A1 (en) | 2007-03-28 |
WO2005118623A1 (en) | 2005-12-15 |
AU2005250059A1 (en) | 2005-12-15 |
JP2008501645A (en) | 2008-01-24 |
EP1765852A4 (en) | 2008-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5824655A (en) | Anti-transforming growth factor-β gene therapy | |
US7482004B2 (en) | Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage | |
US6960559B1 (en) | Neurite growth regulatory factors | |
AU680932B2 (en) | Neurite growth regulatory factors | |
Ryan et al. | Oncostatin M binds to extracellular matrix in a bioactive conformation: implications for inflammation and metastasis | |
WO2000032631A2 (en) | Proteins that bind angiogenesis-inhibiting proteins, compositions and methods of use thereof | |
JPH0780780B2 (en) | Inhibition of transforming growth factor-beta to prevent extracellular matrix accumulation | |
AU2015359043B2 (en) | Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors | |
JPH05503070A (en) | A method for inhibiting lymphocyte adhesion to vascular endothelium using a novel extracellular matrix receptor/ligand interaction | |
Bergmann et al. | PAR-type thrombin receptors in renal carcinoma cells: PAR1-mediated EGFR activation promotes cell migration | |
WO2006041205A1 (en) | Angiogenesis promoter | |
EP1395278A2 (en) | Ocular tear growth factor-like protein | |
Schaffner-Reckinger et al. | The actin-bundling protein L-plastin—A double-edged sword: Beneficial for the immune response, maleficent in cancer | |
JP2007509042A (en) | Methods for altering hematopoietic progenitor cell adhesion, differentiation and migration | |
AU765126B2 (en) | Invasion-inducing agents and invasion-inhibitors for use in wound healing and cancer | |
US20080200393A1 (en) | Method and Composition For Treating Angiogenesis and For Preventing Cancer Progression and Metastasis Comprising a Prostate Secretory Protein (Psp94) Family Member | |
CA2567901A1 (en) | Method and composition for treating angiogenesis and for preventing cancer progression and metastasis comprising a prostate secretory protein (psp94) family member | |
US20080182777A1 (en) | Regulation of cell migration and adhesion | |
US20050148514A1 (en) | Method and composition for treatment of angiogenesis | |
US8080252B2 (en) | Compounds and methods of modulating angiogenesis | |
WO2008011513A2 (en) | Compounds and methods of modulating angiogenesis | |
Giblin | Investigating cell lineage specific biosynthesis of tenascin-C during inflammation | |
Yu | Purification and Functional Characterization of Recombinant Human ADAM8 protease | |
Wheaton et al. | Articles in PresS. Am J Physiol Lung Cell Mol Physiol (April 22, 2016). doi: 10.1152/ajplung. 00424.2015 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |